<!DOCTYPE html>
<!-- Created by pdf2htmlEX (https://github.com/pdf2htmlEX/pdf2htmlEX) -->
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta charset="utf-8"/>

<meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1"/>
<style type="text/css">
/*! 
 * Base CSS for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/pdf2htmlEX/pdf2htmlEX/blob/master/share/LICENSE
 */#sidebar{position:absolute;top:0;left:0;bottom:0;width:250px;padding:0;margin:0;overflow:auto}#page-container{position:absolute;top:0;left:0;margin:0;padding:0;border:0}@media screen{#sidebar.opened+#page-container{left:250px}#page-container{bottom:0;right:0;overflow:auto}.loading-indicator{display:none}.loading-indicator.active{display:block;position:absolute;width:64px;height:64px;top:50%;left:50%;margin-top:-32px;margin-left:-32px}.loading-indicator img{position:absolute;top:0;left:0;bottom:0;right:0}}@media print{@page{margin:0}html{margin:0}body{margin:0;-webkit-print-color-adjust:exact}#sidebar{display:none}#page-container{width:auto;height:auto;overflow:visible;background-color:transparent}.d{display:none}}.pf{position:relative;background-color:white;overflow:hidden;margin:0;border:0}.pc{position:absolute;border:0;padding:0;margin:0;top:0;left:0;width:100%;height:100%;overflow:hidden;display:block;transform-origin:0 0;-ms-transform-origin:0 0;-webkit-transform-origin:0 0}.pc.opened{display:block}.bf{position:absolute;border:0;margin:0;top:0;bottom:0;width:100%;height:100%;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}.bi{position:absolute;border:0;margin:0;-ms-user-select:none;-moz-user-select:none;-webkit-user-select:none;user-select:none}@media print{.pf{margin:0;box-shadow:none;page-break-after:always;page-break-inside:avoid}@-moz-document url-prefix(){.pf{overflow:visible;border:1px solid #fff}.pc{overflow:visible}}}.c{position:absolute;border:0;padding:0;margin:0;overflow:hidden;display:block}.t{position:absolute;white-space:pre;font-size:1px;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%;unicode-bidi:bidi-override;-moz-font-feature-settings:"liga" 0}.t:after{content:''}.t:before{content:'';display:inline-block}.t span{position:relative;unicode-bidi:bidi-override}._{display:inline-block;color:transparent;z-index:-1}::selection{background:rgba(255,255,0,1.0)}::-moz-selection{background:rgba(255,255,0,1.0)}.pi{display:none}.d{position:absolute;transform-origin:0 100%;-ms-transform-origin:0 100%;-webkit-transform-origin:0 100%}.it{border:0;background-color:rgba(255,255,255,0.0)}.ir:hover{cursor:pointer}</style>
<style type="text/css">
/*! 
 * Fancy styles for pdf2htmlEX
 * Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> 
 * https://github.com/pdf2htmlEX/pdf2htmlEX/blob/master/share/LICENSE
 */@keyframes fadein{from{opacity:0}to{opacity:1}}@-webkit-keyframes fadein{from{opacity:0}to{opacity:1}}@keyframes swing{0{transform:rotate(0)}10%{transform:rotate(0)}90%{transform:rotate(720deg)}100%{transform:rotate(720deg)}}@-webkit-keyframes swing{0{-webkit-transform:rotate(0)}10%{-webkit-transform:rotate(0)}90%{-webkit-transform:rotate(720deg)}100%{-webkit-transform:rotate(720deg)}}@media screen{#sidebar{background-color:#2f3236;background-image:url("data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHdpZHRoPSI0IiBoZWlnaHQ9IjQiPgo8cmVjdCB3aWR0aD0iNCIgaGVpZ2h0PSI0IiBmaWxsPSIjNDAzYzNmIj48L3JlY3Q+CjxwYXRoIGQ9Ik0wIDBMNCA0Wk00IDBMMCA0WiIgc3Ryb2tlLXdpZHRoPSIxIiBzdHJva2U9IiMxZTI5MmQiPjwvcGF0aD4KPC9zdmc+")}#outline{font-family:Georgia,Times,"Times New Roman",serif;font-size:13px;margin:2em 1em}#outline ul{padding:0}#outline li{list-style-type:none;margin:1em 0}#outline li>ul{margin-left:1em}#outline a,#outline a:visited,#outline a:hover,#outline a:active{line-height:1.2;color:#e8e8e8;text-overflow:ellipsis;white-space:nowrap;text-decoration:none;display:block;overflow:hidden;outline:0}#outline a:hover{color:#0cf}#page-container{background-color:#ffffff;-webkit-transition:left 500ms;transition:left 500ms}.pf{margin:13px auto;box-shadow:1px 1px 3px 1px #cccccc;border-collapse:separate}.pc.opened{-webkit-animation:fadein 100ms;animation:fadein 100ms}.loading-indicator.active{-webkit-animation:swing 1.5s ease-in-out .01s infinite alternate none;animation:swing 1.5s ease-in-out .01s infinite alternate none}.checked{background:no-repeat url(data:image/png;base64,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)}}</style>
<style type="text/css">
.ff0{font-family:sans-serif;visibility:hidden;}
@font-face{font-family:ff1;src:url('data:application/font-woff;base64,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')format("woff");}.ff1{font-family:ff1;line-height:0.959000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff2;src:url('data:application/font-woff;base64,d09GRgABAAAAAA6IAA0AAAAAFHQAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAAObAAAABoAAAAc22AvXEdERUYAAA5MAAAAHgAAAB4AKQAtT1MvMgAAAaQAAABCAAAAVlWhXoBjbWFwAAACeAAAANIAAAHEr3iudWdhc3AAAA5EAAAACAAAAAj//wADZ2x5ZgAAA5wAAAfWAAAKIK34AxJoZWFkAAABMAAAAC8AAAA2We+ju2hoZWEAAAFgAAAAIQAAACQFUwHjaG10eAAAAegAAACQAAAAnD/pBDJsb2NhAAADTAAAAFAAAABQLJwvEm1heHAAAAGEAAAAHgAAACAAbgA+bmFtZQAAC3QAAAJxAAAFQG3Fx/Zwb3N0AAAN6AAAAFoAAABwA+oEenicY2BkAAPxlUEm8fw2Xxm4mV+A+DWqGxpg9P+T/6WY9jLtAXI5GJhAogA22gvnAHicY2BkYGDa818KSD75f/J/FNNehhQGPgZkoA4Aq6YHOAAAAHicY2BkYGBQZ7BmYGUAASYgZmQAiTmA+QwADIwArQAAeJxjYGRcyziBgZWBgamLaQ+DMEMPiP6/j/EBgyEjE1CUgZWZAQYYGZBAQJprCpBSYKgEqpcCqtzD8AymBgBYRwzKAAB4nB2LMQ4BURRFz/3dRGQKMUYkQ+Lze8lIlKK2CY0lTG0H9qGZSqXQ0it1KpWCRuF73OTkJue960rmWLQ0MsNTyscTb3AJtZEaU5fEqz4EtyXwsK4JOtJzLbzOTOy20IWhNuTaM1ZKoV18mWtzoGM/+a/djcxcYVuvO03NGGlFQ92/76vCuzUDVfH5BR/8IEB4nM2Pu04CQRiFv4FdYHcRd0FX5SIrt1BaGGtIbGysfAFCLIgNoSG8Dr3oE1j5JjzI8M8wyeIbcJL//Nc5JwMUOUYbhcGvdMr2HlvJKbFMSmQ888Ir78xZsGTNRmvZZ4yZyvyNGR98sjJzvTdS+s/yj/7WO/1lVa94FH5iQg4P31Ull8suVwgIiaSqUhO+lIhJqNOwWih5odyxKggV+A91/Jy18Z2DUa8E+U0YibzgwlBNTOKkfqrREKfr9Ob2jmar3bnvkj30+oMhI84CB8YiGzUAAAAAACgAKAAoACgARABgAG4AfgCmANYA8gEgAUwBWgF0AZwBygH8AhACPgJiAooCrgMCAyYDQANaA2gDngPCA+oEJAREBHYEnATABNYE+AUQeJxlVX1sW1cVv/ea+sWxGyd5SZwv27Gf48/YcfzsZ8dO/JkPJ2ni1PZzEuezWUqbNN3YYO26IKFt7YqAsQoQGqo2pkqtkDsKNEUFqa0WbdLK6FY2uqrAKqHSsv4BSIyxaUV+5rznrGnBlt/ze/ee3znnd37nXLQNxRAiPnIByZAcKZAKqRFiaww1MtpAa2qwQYlr6Bj+5F5BeO1yQfguzhYuF8iFYh/+NioJ10pYKH6ASrhDIKiE4IORr9SMx8g6qoIHVk5V4fo6DePCPi+Hde5of7MtbLeHniLrqVd77o7/7OjY+3M/+A9sLf2m1Ixule0ohvOHwcLC6sBaTm2Z/fVhK9EfQufQPayA+BFNMf57qn+osILnpbWfw+UAYMIaljE0PrCa30/Wi6PwSlpXlz7DN0kBaeCBYijJG2O0+BtYD+fzmhkjReOb6jdb8ssvPr6Q0MeS/ZOjMU17LylkC9tWJlaOsKmuyX4uWoEnAI8gDvA+ALwapBU9ajjW0yBBmiH9CKZFSHl9nQiPX3mT6IJDky/OZBd8tlNx1hbKeW2BSVIQbhHN7NjS8cd2dT3b+y+h38FNhjyRRcAv3QTUO+QMopAS/tGMhaEYrJGxMrxwJGu7np/GzuavFbzkTDF9/To585RwFzciyN4Cu/8JcakQjVqBJyksSgzNgWlKSlaJN3N+fumx5bkXvrV67UxLVyBx3rRnjN+VIIVdO/LOrudzy2TmjYBrRbgtlHqDoRTkDNhkGbC3oyZAlgGKVDsXYWTgRwNOqghzYyg9M2/WWzg+3/G7XTvfW85ZM9+ZJZPFz3Um7d5I397u1uJPSGH/1LH+gwsBqTaAi+4ArlhXqN2dhbkFUijm4I20Rk7BP4VUV7G0LKbJqYUu4acD/IIL84PiVvyxUAV0VuJPxdq0wN53wKZKrDZEpiNiZA7RmNpMfe1Jx1DCrOnMB9PWubNt8VisN0IKtbaUXx+P2IQ/k6m7w12uCJJqbYILwAOjLRKemKmcatBjxuLCD8Ayh9fWfIGRmL756cUxu6/TZJ87q3PzQ2uk4GZzvVM1dKB0YsIr/J5M/WnA84iUuwd0dB5EahB1WdaMTvaQNl0yUBTrwee3B6L+mLsv4d43n85UzcWNCXeiz314MkJemjUFOnVBXyjbNbi/aynmdBjCXCjr2bks+UhA/E6In5K0D+EyfuJUvZ6dy76uIgW+eJqITUQQA7FcwldhLrRIbPstZT2HCeuR0eYqsqnnSxG+ggQj4RwzcCgVzrX3Lbpoj6WxB28IES+J7B0O7M6xwjqWyTuGY61cvw1iaCx9jL8J2PUItVObbQJMUvfbBO+u7IlN7zvxTJtT2WbIfzXeHVpKt31l/vGXK0aoJ0aiyXItzIBzEnBqxNo+gNRAGeSAYmHFxsOHVX1pfs9afnS2SrirTgYjJy/YrENP7vQcXHz0h88uZWf/5gyU54KulMC/BP7pLW7YMP4iMgrrldPJTDKpHKRWd3f1qJyOcJLCGyPFdwg7sv9IfbYpkwIcWenfMAsv4g3QigsFJSyx70TKNssJYfp90nD0SxFrvGajXOJT5jVbxNkpcXtRMaFbruU9bDLJ7k3xjz5jN3ksOxf7M84BzsVY3apuh7svFnB48Ubc4TrYUVFF02q6pilgCyTjnmgLqW5vbnEqzdM79vzY6omOs1HhR3XGSoWpvkmrh3yBf/waaKFW7DVpalGQNCcOQLi/7SA7xoM+hYN3yLWtwTEbD50oXCWTU33Cu9hvd+0TPgRjqAOwjzbIN6BnleWu5TwNdXKj2Xs6wkfMVq3WqhXlgDcuacUHiWsYUPgtMJcsNH6W0jAWiqGv9JILq+9+uHq1LTsP3nLkjWt/v31bdAM2op8rW7PhygK/NRsaIJCL+DLSi+eBlMv/JcSJRYT7aRUZHWNCFemcL6yy8XaqqTWcsvHW6njTCGPlo3hjjEy4/LszaeEmtnR49gp/wa3L3Z1w2yjrBC7r4Kv2vq8H3ZxVkuRozFvpyNqotsbgqC0LmafI5GpMuIN1vs4l4ZaEA7ME9HsC9KuUTqK6Lf1uq7t/FMnxibV8Kr82s2Na+IPTyI042rlhrPz6yyvzB17Zd9YXPzQT6Huu3A/bQXdvERY6tl2MjPOXDyJx3AG1MI+N0nmkkX0B/l51g7q2fnxFH14dCOj4cZqplX2JM2h6XLbpxRFfK2GfUBDZwbwzn2ZvkECVvVnemGs++QvhV4dGBoclLsATHgYuqiUupG6pF8NWY4b+9XZi7Wyja1uaDD6G4YEGnnS3UwtqT6woUQD2SuAgARwY4aH+oZln/t+hlxgNNjPtXl97qsced6uzXJPB5PWaRqN9+NWpUEtdjcloCRl7hpuM6URrQ52FsXQbg4OiNsCHlmglvcN5L84GvzQt/GKHg/awVpF3UHV6o3ub2xkNKzpTlemabDW01ad2Q0umbpDD1fGZGTFefelzfA6Cr31gKvppViaB0vhcNFtJUv3ufqUdhNWm8WZsovSHSWY0g63CDZ/9EWwScUwwX48DDiXhyFiapfHxj+xfzobIMbDg8NsgN22Zo7bSZ+Qo7FWX9zKb+8UvOfqRNUhessxmOPI9e4B8X7I1C38E+/exS/xJGKVPQBsAjCoQUkBpyg6PCZfyT0/wPeQFvFGcwhifEn6LfQj9F3UJUB4AAHicrVPNThsxEJ5kF6qqEseq3OZYCRJtVgIBN5TykwMCZQGJ47LrBEOyjmwHNe/SZ+iD9Nhj1VfoK1T9PDFRf9RKlUi09ueZz/PNjG0i2qCP1KLl71vra8Qt2mx/j7hNL5K3ESe0k3yIOKXNdD3iNXqV7kW8Dvt7MFvpSwT6IrsCblHe/hRxmzaSNxEndJ9kEaeUJ58jXqPXKUe8Tnn6jvpkaEYLsqRpTHfkialH+/hntL3CvZ/wnuAc/gwj0yHViHFLCrhAJIcYiqaYmQbUUAWvhUYYS/HV1JV9E/yZhitlJyuFWYH7uGKegLHkFojQCE/LWOLzErcWzRL4ATZDI4yXiBqyOsO6weeR3Uws/d9y0sJgrBRy0bEGKxkErUZ0ltGukAXTRaylkY6FrGpR/DOXc+QyQoxKdj8xg3+Bedm3f+lWYvHgL9cmZmKB72kuJ+fADwpPlTj0jfpmtrB6fOe5t7+fbYexJ+PeNudZlvNhbW4VFwvn1dTxoKmMnRlbelV3+XAy4WHY7HionLKPwXiiYS3KxrF2XLK3Za2mpX1gM+LLO8VnpjF+MVPcj5G0adiqsYaCVTXrhj1oVwVfQKXxXDY1X66inI9GulJinJYLRm6/7q2U9SVmgyCW7+dWu1pXQcSh3IJu6BT3Z0BHtLW6M083pkBvaurAGzo5kW5RcXM6HBxthbJCVYWvOwNfTjRcQzmROZjhHGmoxvNJCXAs/fUyWzCUvIUu3gLTgdzQ/81iuS+8pw7t4svlXe1AyjT+2Nix4ryb8QH/NVv48qyz28mzfOe5+3AtN82tXkhPaqVrZV043F43e2bFH7oTEBIAAAB4nG3JOw6CUAAAwRFLKSgstIfY2IgBL2AMfiKoUdRwTe9GJ+8AbDLVivj3wU9urFUwEZmaiSXmFpZSWThrG1uF0s7eQeXo5Oziqta4uXt4emm9fXx1A4dGDGMAAAAAAAH//wACAAEAAAAMAAAAFgAAAAIAAQADACYAAQAEAAAAAgAAAAB4nGNgYGBkAILHIueiQXSN6oYGGA0APvoFxAAA')format("woff");}.ff2{font-family:ff2;line-height:0.930000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff3;src:url('data:application/font-woff;base64,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')format("woff");}.ff3{font-family:ff3;line-height:0.930000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff4;src:url('data:application/font-woff;base64,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')format("woff");}.ff4{font-family:ff4;line-height:0.934000;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff5;src:url('data:application/font-woff;base64,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')format("woff");}.ff5{font-family:ff5;line-height:0.666504;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff6;src:url('data:application/font-woff;base64,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')format("woff");}.ff6{font-family:ff6;line-height:0.910023;font-style:normal;font-weight:normal;visibility:visible;}
@font-face{font-family:ff7;src:url('data:application/font-woff;base64,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')format("woff");}.ff7{font-family:ff7;line-height:0.690400;font-style:normal;font-weight:normal;visibility:visible;}
.m0{transform:matrix(0.300000,0.000000,0.000000,0.300000,0,0);-ms-transform:matrix(0.300000,0.000000,0.000000,0.300000,0,0);-webkit-transform:matrix(0.300000,0.000000,0.000000,0.300000,0,0);}
.m1{transform:matrix(1.200000,0.000000,0.000000,1.200000,0,0);-ms-transform:matrix(1.200000,0.000000,0.000000,1.200000,0,0);-webkit-transform:matrix(1.200000,0.000000,0.000000,1.200000,0,0);}
.v0{vertical-align:0.000000px;}
.ls11{letter-spacing:-2.200000px;}
.lsa{letter-spacing:-1.092000px;}
.lsc{letter-spacing:-0.800000px;}
.ls1{letter-spacing:-0.600000px;}
.lsd{letter-spacing:-0.520000px;}
.ls12{letter-spacing:-0.400000px;}
.lsb{letter-spacing:-0.390000px;}
.ls13{letter-spacing:-0.260000px;}
.ls8{letter-spacing:-0.200000px;}
.ls3{letter-spacing:-0.160000px;}
.ls9{letter-spacing:-0.130000px;}
.ls0{letter-spacing:0.000000px;}
.lsf{letter-spacing:0.130000px;}
.lse{letter-spacing:0.200000px;}
.ls15{letter-spacing:0.252000px;}
.ls5{letter-spacing:0.260000px;}
.ls19{letter-spacing:0.288000px;}
.ls18{letter-spacing:0.360000px;}
.ls10{letter-spacing:0.390000px;}
.ls4{letter-spacing:0.400000px;}
.ls14{letter-spacing:0.540000px;}
.ls7{letter-spacing:0.600000px;}
.ls16{letter-spacing:0.720000px;}
.ls17{letter-spacing:0.936000px;}
.ls2{letter-spacing:0.950000px;}
.ls6{letter-spacing:1.000000px;}
.sc_{text-shadow:none;}
.sc0{text-shadow:-0.015em 0 transparent,0 0.015em transparent,0.015em 0 transparent,0 -0.015em  transparent;}
@media screen and (-webkit-min-device-pixel-ratio:0){
.sc_{-webkit-text-stroke:0px transparent;}
.sc0{-webkit-text-stroke:0.015em transparent;text-shadow:none;}
}
.ws10a{word-spacing:-4.040000px;}
.ws73{word-spacing:-3.720000px;}
.ws160{word-spacing:-3.708000px;}
.ws10d{word-spacing:-3.000000px;}
.wsd6{word-spacing:-2.880000px;}
.wsee{word-spacing:-2.720000px;}
.wsb6{word-spacing:-2.680000px;}
.ws101{word-spacing:-2.560000px;}
.ws65{word-spacing:-2.480000px;}
.ws100{word-spacing:-2.200000px;}
.ws70{word-spacing:-2.120000px;}
.ws2a{word-spacing:-2.040000px;}
.ws1a{word-spacing:-1.960000px;}
.wse6{word-spacing:-1.920000px;}
.wsbb{word-spacing:-1.880000px;}
.ws1b{word-spacing:-1.840000px;}
.wsb8{word-spacing:-1.800000px;}
.ws6c{word-spacing:-1.760000px;}
.ws67{word-spacing:-1.680000px;}
.ws8c{word-spacing:-1.640000px;}
.ws83{word-spacing:-1.600000px;}
.wsbc{word-spacing:-1.560000px;}
.ws135{word-spacing:-1.548000px;}
.ws74{word-spacing:-1.520000px;}
.ws6{word-spacing:-1.480000px;}
.ws167{word-spacing:-1.476000px;}
.ws9e{word-spacing:-1.440000px;}
.ws96{word-spacing:-1.400000px;}
.wsd8{word-spacing:-1.320000px;}
.ws11b{word-spacing:-1.296000px;}
.wsae{word-spacing:-1.280000px;}
.ws150{word-spacing:-1.260000px;}
.wsc3{word-spacing:-1.240000px;}
.ws41{word-spacing:-1.200000px;}
.ws131{word-spacing:-1.188000px;}
.wse{word-spacing:-1.160000px;}
.ws16a{word-spacing:-1.152000px;}
.ws16e{word-spacing:-1.080000px;}
.ws30{word-spacing:-1.040000px;}
.ws87{word-spacing:-1.000000px;}
.ws14a{word-spacing:-0.972000px;}
.ws34{word-spacing:-0.960000px;}
.ws1d{word-spacing:-0.950000px;}
.ws15f{word-spacing:-0.936000px;}
.ws3d{word-spacing:-0.880000px;}
.ws7d{word-spacing:-0.840000px;}
.ws129{word-spacing:-0.828000px;}
.wsac{word-spacing:-0.800000px;}
.ws144{word-spacing:-0.756000px;}
.ws5{word-spacing:-0.720000px;}
.ws113{word-spacing:-0.648000px;}
.ws16{word-spacing:-0.600000px;}
.ws136{word-spacing:-0.576000px;}
.ws8a{word-spacing:-0.560000px;}
.ws112{word-spacing:-0.540000px;}
.ws98{word-spacing:-0.520000px;}
.wsc{word-spacing:-0.440000px;}
.ws29{word-spacing:-0.400000px;}
.wsdf{word-spacing:-0.390000px;}
.wsbe{word-spacing:-0.360000px;}
.ws72{word-spacing:-0.320000px;}
.ws170{word-spacing:-0.288000px;}
.ws9d{word-spacing:-0.280000px;}
.ws36{word-spacing:-0.260000px;}
.ws128{word-spacing:-0.252000px;}
.ws10e{word-spacing:-0.240000px;}
.wsc5{word-spacing:-0.200000px;}
.ws7c{word-spacing:-0.160000px;}
.wsb2{word-spacing:-0.130000px;}
.wsf9{word-spacing:-0.120000px;}
.ws23{word-spacing:-0.080000px;}
.ws12c{word-spacing:-0.072000px;}
.ws9{word-spacing:-0.040000px;}
.ws0{word-spacing:0.000000px;}
.ws4d{word-spacing:0.040000px;}
.ws62{word-spacing:0.080000px;}
.ws88{word-spacing:0.120000px;}
.ws54{word-spacing:0.130000px;}
.ws1e{word-spacing:0.160000px;}
.ws130{word-spacing:0.180000px;}
.ws3f{word-spacing:0.200000px;}
.wsb3{word-spacing:0.240000px;}
.ws105{word-spacing:0.260000px;}
.wse7{word-spacing:0.280000px;}
.ws12b{word-spacing:0.288000px;}
.ws31{word-spacing:0.320000px;}
.ws107{word-spacing:0.360000px;}
.ws82{word-spacing:0.390000px;}
.ws6f{word-spacing:0.400000px;}
.ws116{word-spacing:0.432000px;}
.ws2{word-spacing:0.480000px;}
.ws161{word-spacing:0.504000px;}
.wsab{word-spacing:0.520000px;}
.ws3{word-spacing:0.600000px;}
.ws56{word-spacing:0.640000px;}
.ws138{word-spacing:0.648000px;}
.ws45{word-spacing:0.680000px;}
.ws86{word-spacing:0.720000px;}
.ws79{word-spacing:0.760000px;}
.ws114{word-spacing:0.792000px;}
.wsa4{word-spacing:0.800000px;}
.wse0{word-spacing:0.840000px;}
.ws133{word-spacing:0.864000px;}
.ws97{word-spacing:0.880000px;}
.ws16d{word-spacing:0.900000px;}
.ws108{word-spacing:0.920000px;}
.ws132{word-spacing:0.936000px;}
.wsbf{word-spacing:0.960000px;}
.ws33{word-spacing:1.000000px;}
.ws14b{word-spacing:1.008000px;}
.ws4{word-spacing:1.040000px;}
.ws8e{word-spacing:1.080000px;}
.ws63{word-spacing:1.092000px;}
.ws64{word-spacing:1.120000px;}
.ws84{word-spacing:1.160000px;}
.ws9f{word-spacing:1.280000px;}
.ws35{word-spacing:1.320000px;}
.ws78{word-spacing:1.360000px;}
.ws13d{word-spacing:1.368000px;}
.ws68{word-spacing:1.400000px;}
.ws5a{word-spacing:1.440000px;}
.ws5b{word-spacing:1.480000px;}
.ws157{word-spacing:1.512000px;}
.wsb{word-spacing:1.520000px;}
.ws57{word-spacing:1.600000px;}
.ws3e{word-spacing:1.640000px;}
.ws146{word-spacing:1.656000px;}
.wsbd{word-spacing:1.680000px;}
.ws3b{word-spacing:1.720000px;}
.wsdc{word-spacing:1.760000px;}
.ws13b{word-spacing:1.764000px;}
.ws2d{word-spacing:1.800000px;}
.ws14f{word-spacing:1.836000px;}
.ws12{word-spacing:1.840000px;}
.wsa8{word-spacing:1.880000px;}
.ws102{word-spacing:1.920000px;}
.ws119{word-spacing:1.944000px;}
.ws48{word-spacing:1.960000px;}
.ws40{word-spacing:2.000000px;}
.ws151{word-spacing:2.016000px;}
.ws9a{word-spacing:2.040000px;}
.ws15{word-spacing:2.080000px;}
.ws10{word-spacing:2.120000px;}
.ws22{word-spacing:2.160000px;}
.ws158{word-spacing:2.196000px;}
.ws10f{word-spacing:2.200000px;}
.ws12f{word-spacing:2.232000px;}
.wsa1{word-spacing:2.240000px;}
.ws152{word-spacing:2.268000px;}
.wsf{word-spacing:2.280000px;}
.ws13f{word-spacing:2.304000px;}
.wsfd{word-spacing:2.320000px;}
.wse9{word-spacing:2.360000px;}
.ws5c{word-spacing:2.440000px;}
.ws168{word-spacing:2.448000px;}
.ws9c{word-spacing:2.480000px;}
.ws8{word-spacing:2.520000px;}
.ws4a{word-spacing:2.560000px;}
.wsff{word-spacing:2.600000px;}
.ws47{word-spacing:2.640000px;}
.wsa{word-spacing:2.680000px;}
.ws38{word-spacing:2.720000px;}
.ws126{word-spacing:2.772000px;}
.ws49{word-spacing:2.800000px;}
.ws122{word-spacing:2.808000px;}
.wsdb{word-spacing:2.880000px;}
.ws19{word-spacing:2.920000px;}
.wsd7{word-spacing:2.960000px;}
.wsa2{word-spacing:3.000000px;}
.ws143{word-spacing:3.024000px;}
.ws28{word-spacing:3.040000px;}
.wseb{word-spacing:3.080000px;}
.ws90{word-spacing:3.120000px;}
.wsfb{word-spacing:3.160000px;}
.wsd{word-spacing:3.240000px;}
.ws15d{word-spacing:3.276000px;}
.ws43{word-spacing:3.280000px;}
.ws24{word-spacing:3.320000px;}
.ws26{word-spacing:3.360000px;}
.wsc1{word-spacing:3.400000px;}
.ws154{word-spacing:3.420000px;}
.ws127{word-spacing:3.492000px;}
.ws27{word-spacing:3.520000px;}
.wsd5{word-spacing:3.560000px;}
.wsef{word-spacing:3.600000px;}
.ws2b{word-spacing:3.640000px;}
.ws164{word-spacing:3.672000px;}
.ws21{word-spacing:3.680000px;}
.wsa5{word-spacing:3.720000px;}
.wsc2{word-spacing:3.760000px;}
.ws12d{word-spacing:3.852000px;}
.ws25{word-spacing:3.880000px;}
.ws94{word-spacing:3.960000px;}
.ws110{word-spacing:4.000000px;}
.ws66{word-spacing:4.040000px;}
.ws1c{word-spacing:4.080000px;}
.ws165{word-spacing:4.104000px;}
.ws8d{word-spacing:4.160000px;}
.ws120{word-spacing:4.176000px;}
.ws103{word-spacing:4.200000px;}
.wscd{word-spacing:4.280000px;}
.ws95{word-spacing:4.320000px;}
.wsf6{word-spacing:4.360000px;}
.ws42{word-spacing:4.440000px;}
.ws4b{word-spacing:4.480000px;}
.ws14{word-spacing:4.520000px;}
.ws20{word-spacing:4.560000px;}
.ws92{word-spacing:4.600000px;}
.wse5{word-spacing:4.640000px;}
.wsf0{word-spacing:4.680000px;}
.ws37{word-spacing:4.800000px;}
.ws3a{word-spacing:4.960000px;}
.ws13{word-spacing:5.000000px;}
.ws1{word-spacing:5.080000px;}
.wsb4{word-spacing:5.240000px;}
.ws13c{word-spacing:5.256000px;}
.ws2f{word-spacing:5.280000px;}
.ws166{word-spacing:5.292000px;}
.ws13a{word-spacing:5.328000px;}
.wsa6{word-spacing:5.360000px;}
.wsb1{word-spacing:5.440000px;}
.wsb7{word-spacing:5.480000px;}
.wsd2{word-spacing:5.520000px;}
.ws9b{word-spacing:5.560000px;}
.wsca{word-spacing:5.600000px;}
.ws58{word-spacing:5.640000px;}
.ws52{word-spacing:5.720000px;}
.ws7f{word-spacing:5.760000px;}
.ws169{word-spacing:5.868000px;}
.ws85{word-spacing:5.920000px;}
.ws139{word-spacing:5.940000px;}
.ws59{word-spacing:6.000000px;}
.wsb9{word-spacing:6.120000px;}
.ws134{word-spacing:6.156000px;}
.wsda{word-spacing:6.160000px;}
.wsc0{word-spacing:6.240000px;}
.ws16c{word-spacing:6.264000px;}
.wsba{word-spacing:6.280000px;}
.ws15c{word-spacing:6.372000px;}
.ws13e{word-spacing:6.444000px;}
.ws93{word-spacing:6.560000px;}
.ws6d{word-spacing:6.600000px;}
.ws15a{word-spacing:6.696000px;}
.wsf5{word-spacing:6.760000px;}
.ws145{word-spacing:6.768000px;}
.ws1f{word-spacing:6.800000px;}
.ws156{word-spacing:6.804000px;}
.wse4{word-spacing:6.840000px;}
.ws123{word-spacing:6.876000px;}
.wscf{word-spacing:6.880000px;}
.wsc6{word-spacing:7.040000px;}
.ws141{word-spacing:7.056000px;}
.wsc8{word-spacing:7.280000px;}
.ws7e{word-spacing:7.320000px;}
.ws8b{word-spacing:7.360000px;}
.wsad{word-spacing:7.400000px;}
.ws111{word-spacing:7.440000px;}
.ws14d{word-spacing:7.452000px;}
.ws89{word-spacing:7.480000px;}
.wse1{word-spacing:7.560000px;}
.ws12a{word-spacing:7.596000px;}
.wsa9{word-spacing:7.600000px;}
.ws11c{word-spacing:7.668000px;}
.ws76{word-spacing:7.760000px;}
.ws117{word-spacing:7.776000px;}
.wsde{word-spacing:7.800000px;}
.wsf4{word-spacing:7.840000px;}
.ws69{word-spacing:7.960000px;}
.ws153{word-spacing:8.028000px;}
.wse3{word-spacing:8.080000px;}
.ws115{word-spacing:8.136000px;}
.ws7b{word-spacing:8.200000px;}
.ws14e{word-spacing:8.244000px;}
.ws5d{word-spacing:8.280000px;}
.wsdd{word-spacing:8.400000px;}
.ws4c{word-spacing:8.480000px;}
.ws99{word-spacing:8.520000px;}
.ws11e{word-spacing:8.532000px;}
.ws61{word-spacing:8.560000px;}
.ws10c{word-spacing:8.600000px;}
.wsf7{word-spacing:8.640000px;}
.ws140{word-spacing:8.712000px;}
.wsa0{word-spacing:8.720000px;}
.ws159{word-spacing:8.748000px;}
.wsaa{word-spacing:8.760000px;}
.ws2c{word-spacing:8.800000px;}
.ws10b{word-spacing:8.840000px;}
.wsf3{word-spacing:8.880000px;}
.wsc7{word-spacing:8.960000px;}
.ws162{word-spacing:9.000000px;}
.ws91{word-spacing:9.040000px;}
.ws39{word-spacing:9.160000px;}
.ws142{word-spacing:9.180000px;}
.ws16b{word-spacing:9.288000px;}
.ws4e{word-spacing:9.320000px;}
.wscc{word-spacing:9.360000px;}
.wsd3{word-spacing:9.440000px;}
.wsd4{word-spacing:9.520000px;}
.wsd9{word-spacing:9.600000px;}
.wsd1{word-spacing:9.640000px;}
.ws46{word-spacing:9.680000px;}
.wsc4{word-spacing:9.760000px;}
.ws55{word-spacing:9.880000px;}
.ws75{word-spacing:9.920000px;}
.ws80{word-spacing:10.000000px;}
.wsf2{word-spacing:10.040000px;}
.ws124{word-spacing:10.152000px;}
.ws109{word-spacing:10.200000px;}
.wsd0{word-spacing:10.240000px;}
.wsfa{word-spacing:10.280000px;}
.wsce{word-spacing:10.320000px;}
.ws60{word-spacing:10.480000px;}
.wsfe{word-spacing:10.680000px;}
.ws81{word-spacing:10.840000px;}
.wsfc{word-spacing:10.920000px;}
.ws17{word-spacing:10.960000px;}
.ws11d{word-spacing:11.016000px;}
.ws3c{word-spacing:11.040000px;}
.wsec{word-spacing:11.120000px;}
.ws104{word-spacing:11.320000px;}
.ws50{word-spacing:11.360000px;}
.ws147{word-spacing:11.736000px;}
.ws6a{word-spacing:11.840000px;}
.ws53{word-spacing:12.080000px;}
.wsa7{word-spacing:12.120000px;}
.wsb5{word-spacing:12.240000px;}
.ws106{word-spacing:12.440000px;}
.wse2{word-spacing:12.680000px;}
.wscb{word-spacing:12.960000px;}
.ws163{word-spacing:13.176000px;}
.ws155{word-spacing:13.320000px;}
.ws149{word-spacing:13.356000px;}
.wsc9{word-spacing:13.360000px;}
.wsa3{word-spacing:13.840000px;}
.ws148{word-spacing:13.896000px;}
.ws11a{word-spacing:13.932000px;}
.ws77{word-spacing:14.040000px;}
.ws7{word-spacing:14.160000px;}
.wsf8{word-spacing:14.320000px;}
.ws18{word-spacing:14.360000px;}
.ws8f{word-spacing:14.520000px;}
.ws11f{word-spacing:14.688000px;}
.ws16f{word-spacing:14.796000px;}
.ws2e{word-spacing:14.840000px;}
.ws118{word-spacing:15.012000px;}
.ws125{word-spacing:15.048000px;}
.wse8{word-spacing:15.160000px;}
.ws121{word-spacing:15.192000px;}
.ws15e{word-spacing:16.200000px;}
.ws14c{word-spacing:16.704000px;}
.ws6b{word-spacing:17.200000px;}
.ws51{word-spacing:17.320000px;}
.ws12e{word-spacing:17.388000px;}
.wsf1{word-spacing:17.760000px;}
.ws71{word-spacing:18.000000px;}
.wsea{word-spacing:18.120000px;}
.ws7a{word-spacing:18.840000px;}
.ws32{word-spacing:19.120000px;}
.wsb0{word-spacing:19.160000px;}
.wsed{word-spacing:19.480000px;}
.ws5f{word-spacing:20.440000px;}
.ws11{word-spacing:20.720000px;}
.ws5e{word-spacing:22.000000px;}
.ws15b{word-spacing:23.004000px;}
.ws6e{word-spacing:26.320000px;}
.ws137{word-spacing:28.116000px;}
.wsaf{word-spacing:29.560000px;}
.ws44{word-spacing:33.160000px;}
.ws4f{word-spacing:41.160000px;}
._17{margin-left:-32.004000px;}
._14{margin-left:-25.704000px;}
._c{margin-left:-22.800000px;}
._13{margin-left:-20.736000px;}
._19{margin-left:-18.360000px;}
._16{margin-left:-17.244000px;}
._d{margin-left:-15.040000px;}
._e{margin-left:-12.600000px;}
._b{margin-left:-10.520000px;}
._0{margin-left:-7.784000px;}
._15{margin-left:-6.696000px;}
._a{margin-left:-5.680000px;}
._3{margin-left:-4.240000px;}
._2{margin-left:-3.120000px;}
._1{margin-left:-1.520000px;}
._4{width:1.120000px;}
._5{width:2.160000px;}
._12{width:4.068000px;}
._11{width:5.508000px;}
._9{width:6.800000px;}
._8{width:7.992000px;}
._f{width:9.540000px;}
._10{width:10.548000px;}
._18{width:14.104000px;}
._7{width:1387.040000px;}
._6{width:1732.080000px;}
.fc2{color:transparent;}
.fc1{color:rgb(0,0,0);}
.fc0{color:rgb(255,255,255);}
.fs6{font-size:4.000000px;}
.fs7{font-size:20.800000px;}
.fsc{font-size:23.400000px;}
.fs0{font-size:24.000000px;}
.fs4{font-size:26.000000px;}
.fs1{font-size:28.000000px;}
.fsa{font-size:31.200000px;}
.fs8{font-size:32.000000px;}
.fsb{font-size:36.000000px;}
.fs5{font-size:38.000000px;}
.fs2{font-size:40.000000px;}
.fs3{font-size:48.000000px;}
.fs9{font-size:72.000000px;}
.y0{bottom:0.000000px;}
.y1f{bottom:83.779320px;}
.y3c{bottom:83.801640px;}
.y1a5{bottom:83.821320px;}
.y168{bottom:83.854920px;}
.ye0{bottom:84.912120px;}
.y116{bottom:85.062240px;}
.y8e{bottom:85.284120px;}
.y12d{bottom:85.296120px;}
.yac{bottom:90.684120px;}
.y3b{bottom:95.801640px;}
.y1a4{bottom:97.018920px;}
.y167{bottom:97.052520px;}
.y1e{bottom:98.179320px;}
.y12c{bottom:98.493720px;}
.ydf{bottom:99.312120px;}
.y115{bottom:99.462240px;}
.y8c{bottom:99.684120px;}
.y8d{bottom:105.084120px;}
.y3a{bottom:107.801640px;}
.y1a3{bottom:110.216520px;}
.y166{bottom:110.250120px;}
.y12b{bottom:111.691320px;}
.y1c{bottom:112.579320px;}
.yde{bottom:113.712120px;}
.y114{bottom:113.862240px;}
.y8b{bottom:114.084120px;}
.y1d{bottom:117.979320px;}
.y39{bottom:119.801640px;}
.y11c{bottom:121.284120px;}
.y1a2{bottom:123.414120px;}
.y165{bottom:123.447720px;}
.y12a{bottom:124.888920px;}
.y1b{bottom:126.979320px;}
.ydd{bottom:128.112120px;}
.y8a{bottom:128.484120px;}
.y113{bottom:128.502240px;}
.y1a1{bottom:136.611720px;}
.y164{bottom:136.645320px;}
.y129{bottom:138.086520px;}
.y38{bottom:139.001640px;}
.y1a{bottom:141.379320px;}
.ydc{bottom:142.512120px;}
.y89{bottom:142.884120px;}
.y112{bottom:143.142240px;}
.y37{bottom:143.321640px;}
.yab{bottom:148.284120px;}
.y1a0{bottom:149.809320px;}
.y163{bottom:149.842920px;}
.y36{bottom:151.001520px;}
.y128{bottom:151.284120px;}
.yaa{bottom:151.884120px;}
.y35{bottom:155.321520px;}
.y19{bottom:155.779320px;}
.ydb{bottom:156.912120px;}
.y88{bottom:157.284120px;}
.y111{bottom:157.782240px;}
.y34{bottom:163.001520px;}
.y19f{bottom:163.006920px;}
.y162{bottom:163.040520px;}
.y33{bottom:167.321520px;}
.y127{bottom:169.284120px;}
.y18{bottom:170.179320px;}
.yda{bottom:171.312120px;}
.y87{bottom:171.684120px;}
.y110{bottom:172.422240px;}
.y32{bottom:175.001520px;}
.y19e{bottom:176.204520px;}
.y161{bottom:176.238120px;}
.ya9{bottom:177.084120px;}
.y117{bottom:178.884120px;}
.y31{bottom:179.321520px;}
.y17{bottom:184.579320px;}
.yd9{bottom:185.712120px;}
.ya7{bottom:186.084120px;}
.y10f{bottom:187.062240px;}
.y19d{bottom:189.402120px;}
.y160{bottom:189.435720px;}
.ya8{bottom:191.484120px;}
.y86{bottom:193.284120px;}
.y126{bottom:195.686520px;}
.y16{bottom:198.979320px;}
.yd8{bottom:200.112120px;}
.ya6{bottom:200.484120px;}
.y10e{bottom:201.702240px;}
.y19c{bottom:202.599720px;}
.y15f{bottom:202.633320px;}
.y2d{bottom:207.684120px;}
.y125{bottom:208.884120px;}
.ya5{bottom:209.484120px;}
.y15{bottom:213.379320px;}
.yd7{bottom:214.512120px;}
.ya4{bottom:214.884120px;}
.y19b{bottom:215.797320px;}
.y15e{bottom:215.830920px;}
.y10d{bottom:216.342240px;}
.y2c{bottom:222.084120px;}
.y124{bottom:226.884120px;}
.y14{bottom:227.779320px;}
.yd6{bottom:228.912120px;}
.y19a{bottom:228.994920px;}
.y15d{bottom:229.028520px;}
.y85{bottom:229.284120px;}
.y10c{bottom:230.982240px;}
.y2b{bottom:236.484120px;}
.y13{bottom:242.179320px;}
.y199{bottom:242.192520px;}
.y15c{bottom:242.226120px;}
.yd5{bottom:243.312120px;}
.y84{bottom:243.684120px;}
.y10b{bottom:245.622240px;}
.ya3{bottom:249.084120px;}
.y2a{bottom:250.884120px;}
.y198{bottom:255.390120px;}
.y15b{bottom:255.423720px;}
.y123{bottom:255.686520px;}
.y12{bottom:256.579320px;}
.yd4{bottom:257.712120px;}
.y83{bottom:258.084120px;}
.y10a{bottom:260.262240px;}
.ya2{bottom:263.484120px;}
.y28{bottom:265.284120px;}
.y197{bottom:268.587720px;}
.y15a{bottom:268.621320px;}
.y122{bottom:268.884120px;}
.y29{bottom:270.684120px;}
.y10{bottom:270.979320px;}
.yd3{bottom:272.112120px;}
.y81{bottom:272.484120px;}
.y109{bottom:274.902240px;}
.y11{bottom:276.379320px;}
.y82{bottom:277.884120px;}
.y27{bottom:279.684120px;}
.y196{bottom:281.785320px;}
.y159{bottom:281.818920px;}
.yf{bottom:285.379320px;}
.yd2{bottom:286.512120px;}
.y7f{bottom:286.884120px;}
.y108{bottom:289.542240px;}
.y80{bottom:292.284120px;}
.y26{bottom:294.084120px;}
.y195{bottom:294.982920px;}
.y158{bottom:295.016520px;}
.yd{bottom:299.779320px;}
.yd1{bottom:300.912120px;}
.y7e{bottom:301.284120px;}
.yc9{bottom:301.524120px;}
.y107{bottom:304.182240px;}
.ye{bottom:305.179320px;}
.y194{bottom:308.180520px;}
.y157{bottom:308.214120px;}
.y25{bottom:308.484120px;}
.yc{bottom:314.179320px;}
.yd0{bottom:315.312120px;}
.y7d{bottom:315.684120px;}
.yc8{bottom:316.164120px;}
.y106{bottom:318.822240px;}
.ya1{bottom:321.084120px;}
.y193{bottom:321.378120px;}
.y156{bottom:321.411720px;}
.y24{bottom:322.884120px;}
.yb{bottom:328.579320px;}
.ycf{bottom:329.712120px;}
.y7c{bottom:330.084120px;}
.yc7{bottom:330.804120px;}
.y105{bottom:333.462240px;}
.y192{bottom:334.575720px;}
.y155{bottom:334.609320px;}
.y11e{bottom:335.484120px;}
.y21{bottom:337.279320px;}
.y23{bottom:337.284120px;}
.y22{bottom:342.684120px;}
.yce{bottom:344.112120px;}
.y7b{bottom:344.484120px;}
.yc6{bottom:345.444120px;}
.y191{bottom:347.773320px;}
.y154{bottom:347.806920px;}
.y104{bottom:348.102240px;}
.ya{bottom:350.179320px;}
.y20{bottom:351.679320px;}
.ycd{bottom:358.512120px;}
.y7a{bottom:358.884120px;}
.yc5{bottom:360.084120px;}
.y190{bottom:360.970920px;}
.y153{bottom:361.004520px;}
.y103{bottom:362.742240px;}
.ya0{bottom:364.284120px;}
.ycc{bottom:372.912120px;}
.y79{bottom:373.284120px;}
.y18f{bottom:374.168520px;}
.y152{bottom:374.202120px;}
.yc4{bottom:374.724120px;}
.y102{bottom:377.382240px;}
.y121{bottom:378.684120px;}
.ycb{bottom:387.312120px;}
.y18e{bottom:387.366120px;}
.y151{bottom:387.399720px;}
.y78{bottom:387.684120px;}
.yc2{bottom:389.124120px;}
.y56{bottom:390.856920px;}
.y101{bottom:392.022240px;}
.yc3{bottom:394.524120px;}
.y18d{bottom:400.563720px;}
.y150{bottom:400.597320px;}
.yca{bottom:401.712120px;}
.y77{bottom:402.084120px;}
.y55{bottom:405.256920px;}
.y100{bottom:406.662240px;}
.y9f{bottom:407.484120px;}
.y11d{bottom:409.284120px;}
.yc1{bottom:410.724120px;}
.y18c{bottom:413.761320px;}
.y14f{bottom:413.794920px;}
.y76{bottom:416.484120px;}
.yff{bottom:421.302240px;}
.y11b{bottom:421.884120px;}
.y18b{bottom:426.958920px;}
.y14e{bottom:426.992520px;}
.y75{bottom:430.884120px;}
.ye7{bottom:432.837360px;}
.yfe{bottom:435.942240px;}
.y54{bottom:440.068920px;}
.y18a{bottom:440.156520px;}
.y14d{bottom:440.190120px;}
.ye6{bottom:444.232560px;}
.y74{bottom:445.284120px;}
.yc0{bottom:446.724000px;}
.yfd{bottom:450.582240px;}
.y9e{bottom:450.684120px;}
.y189{bottom:453.354120px;}
.y14c{bottom:453.387720px;}
.y53{bottom:454.468920px;}
.ye4{bottom:455.621760px;}
.y73{bottom:459.684120px;}
.ye5{bottom:460.492560px;}
.ybf{bottom:461.364000px;}
.yf2{bottom:465.084120px;}
.yfc{bottom:465.222240px;}
.y188{bottom:466.551720px;}
.y14b{bottom:466.585320px;}
.ye3{bottom:468.225360px;}
.y52{bottom:468.868920px;}
.y72{bottom:474.084120px;}
.ybe{bottom:476.004000px;}
.yf1{bottom:479.484120px;}
.y187{bottom:479.749320px;}
.y14a{bottom:479.782920px;}
.yfb{bottom:479.862240px;}
.ye2{bottom:480.828960px;}
.y9d{bottom:481.284120px;}
.y51{bottom:483.268920px;}
.y71{bottom:488.484120px;}
.ybd{bottom:490.644000px;}
.y186{bottom:492.946920px;}
.y149{bottom:492.980520px;}
.ye1{bottom:493.432560px;}
.yfa{bottom:494.502240px;}
.y50{bottom:497.668920px;}
.y70{bottom:502.884120px;}
.ybc{bottom:505.284000px;}
.y185{bottom:506.144520px;}
.y148{bottom:506.178120px;}
.yf9{bottom:509.142240px;}
.yf7{bottom:509.148120px;}
.y4f{bottom:512.068920px;}
.yf8{bottom:514.542240px;}
.y9b{bottom:517.284120px;}
.y184{bottom:519.342120px;}
.y147{bottom:519.375720px;}
.ybb{bottom:519.924000px;}
.y9c{bottom:522.684120px;}
.yf6{bottom:523.788120px;}
.y6f{bottom:524.484120px;}
.y4e{bottom:526.468920px;}
.y9a{bottom:531.684120px;}
.y183{bottom:532.539720px;}
.y146{bottom:532.573320px;}
.yba{bottom:534.564000px;}
.yf5{bottom:538.428120px;}
.y4d{bottom:540.868920px;}
.y182{bottom:545.737320px;}
.y145{bottom:545.770920px;}
.y99{bottom:546.084120px;}
.yb9{bottom:549.204000px;}
.yf0{bottom:551.484120px;}
.yf4{bottom:553.068120px;}
.yef{bottom:555.084120px;}
.y4c{bottom:555.268920px;}
.y181{bottom:558.934920px;}
.y144{bottom:558.968520px;}
.y6e{bottom:560.484120px;}
.yb8{bottom:563.844000px;}
.y98{bottom:565.884120px;}
.yf3{bottom:567.708120px;}
.y4b{bottom:569.668920px;}
.y180{bottom:572.132520px;}
.y143{bottom:572.166120px;}
.y6d{bottom:574.884120px;}
.yb7{bottom:578.484000px;}
.y11a{bottom:580.284120px;}
.y4a{bottom:584.068920px;}
.y17f{bottom:585.330120px;}
.y142{bottom:585.363720px;}
.y6c{bottom:589.284120px;}
.yb6{bottom:593.124000px;}
.y119{bottom:596.484120px;}
.y49{bottom:598.468920px;}
.y17e{bottom:598.527720px;}
.y141{bottom:598.561320px;}
.yeb{bottom:603.220680px;}
.y6b{bottom:603.684120px;}
.yb5{bottom:607.764000px;}
.yec{bottom:608.091480px;}
.y97{bottom:609.084120px;}
.y17d{bottom:611.725320px;}
.y140{bottom:611.758920px;}
.y48{bottom:612.868920px;}
.yea{bottom:615.824280px;}
.y6a{bottom:618.084120px;}
.yb4{bottom:622.404000px;}
.yb2{bottom:622.404120px;}
.y17c{bottom:624.922920px;}
.y13f{bottom:624.956520px;}
.yee{bottom:625.284120px;}
.y47{bottom:627.268920px;}
.yb3{bottom:627.804000px;}
.ye9{bottom:628.427880px;}
.y69{bottom:632.484120px;}
.yb1{bottom:637.044120px;}
.y17b{bottom:638.120520px;}
.y13e{bottom:638.154120px;}
.ye8{bottom:641.031480px;}
.y46{bottom:641.668920px;}
.y68{bottom:646.884120px;}
.y17a{bottom:651.318120px;}
.y13d{bottom:651.351720px;}
.y45{bottom:656.068920px;}
.yb0{bottom:658.879320px;}
.y67{bottom:661.284120px;}
.y179{bottom:664.515720px;}
.y13c{bottom:664.549320px;}
.y177{bottom:664.689720px;}
.y96{bottom:666.684120px;}
.y178{bottom:669.375600px;}
.y65{bottom:675.684120px;}
.y13b{bottom:677.746920px;}
.y176{bottom:677.887320px;}
.y66{bottom:681.084120px;}
.yaf{bottom:682.884120px;}
.y64{bottom:690.084120px;}
.y13a{bottom:690.944520px;}
.y175{bottom:691.084920px;}
.y95{bottom:695.484120px;}
.y94{bottom:699.084120px;}
.y139{bottom:704.142120px;}
.y174{bottom:704.282520px;}
.y63{bottom:704.484120px;}
.y118{bottom:709.884120px;}
.y42{bottom:713.664120px;}
.y44{bottom:713.668920px;}
.y138{bottom:717.339720px;}
.y1b0{bottom:717.361320px;}
.y173{bottom:717.480120px;}
.y62{bottom:718.884120px;}
.y43{bottom:720.148920px;}
.y40{bottom:730.468920px;}
.y137{bottom:730.537320px;}
.y1af{bottom:730.558920px;}
.y172{bottom:730.677720px;}
.y61{bottom:733.284120px;}
.y41{bottom:736.948920px;}
.y136{bottom:743.734920px;}
.y1ae{bottom:743.756520px;}
.y171{bottom:743.875320px;}
.y60{bottom:747.684120px;}
.y120{bottom:753.084120px;}
.y93{bottom:756.684120px;}
.y135{bottom:756.932520px;}
.y1ad{bottom:756.954120px;}
.y170{bottom:757.072920px;}
.y5f{bottom:762.084120px;}
.yed{bottom:767.484120px;}
.y134{bottom:770.130120px;}
.y1ac{bottom:770.151720px;}
.y16f{bottom:770.270520px;}
.yae{bottom:771.084120px;}
.y5e{bottom:776.484120px;}
.y92{bottom:781.884120px;}
.y133{bottom:783.327720px;}
.y1ab{bottom:783.349320px;}
.y16e{bottom:783.468120px;}
.y3f{bottom:790.473720px;}
.y5d{bottom:790.884120px;}
.yad{bottom:796.284120px;}
.y132{bottom:796.525320px;}
.y1aa{bottom:796.546920px;}
.y16d{bottom:796.665720px;}
.y8{bottom:798.885720px;}
.y5c{bottom:805.284120px;}
.y7{bottom:809.083320px;}
.y1{bottom:809.549400px;}
.y131{bottom:809.722920px;}
.y1a9{bottom:809.744520px;}
.y16c{bottom:809.863320px;}
.y3e{bottom:814.471320px;}
.y6{bottom:819.280920px;}
.y5b{bottom:819.684120px;}
.y130{bottom:822.920520px;}
.y1a8{bottom:822.942120px;}
.y16b{bottom:823.060920px;}
.y11f{bottom:825.084120px;}
.y91{bottom:828.684120px;}
.y5{bottom:829.478520px;}
.y5a{bottom:834.084120px;}
.y12f{bottom:836.118120px;}
.y1a7{bottom:836.139720px;}
.y16a{bottom:836.258520px;}
.y3d{bottom:838.468920px;}
.y90{bottom:839.484120px;}
.y4{bottom:839.676120px;}
.y8f{bottom:843.084120px;}
.y58{bottom:848.484120px;}
.y12e{bottom:849.315720px;}
.y1a6{bottom:849.337320px;}
.y169{bottom:849.456120px;}
.y3{bottom:849.873720px;}
.y59{bottom:853.884120px;}
.y2{bottom:860.071320px;}
.y57{bottom:881.016120px;}
.y9{bottom:883.416120px;}
.y30{bottom:926.935200px;}
.y2f{bottom:928.135200px;}
.y2e{bottom:928.135800px;}
.h8{height:2.872000px;}
.h9{height:15.163200px;}
.h12{height:16.801200px;}
.h10{height:17.058600px;}
.h1{height:17.496000px;}
.h6{height:18.668000px;}
.h2{height:20.412000px;}
.hd{height:21.840000px;}
.hb{height:22.400000px;}
.ha{height:23.328000px;}
.h7{height:25.692171px;}
.h11{height:25.848000px;}
.hf{height:26.244000px;}
.h3{height:28.000000px;}
.h5{height:28.720000px;}
.he{height:29.160000px;}
.h4{height:33.600000px;}
.hc{height:50.400000px;}
.h0{height:939.600000px;}
.w0{width:723.600000px;}
.x0{left:0.000000px;}
.xe{left:10.080000px;}
.xf{left:48.342000px;}
.x2{left:57.600000px;}
.x8{left:72.000000px;}
.x18{left:75.600000px;}
.x5{left:77.100120px;}
.x6{left:80.883120px;}
.x5f{left:85.235880px;}
.x1b{left:89.999400px;}
.x3{left:91.823640px;}
.x4{left:95.606640px;}
.x19{left:128.579400px;}
.x1a{left:132.479400px;}
.x4c{left:135.655440px;}
.x4d{left:143.377440px;}
.x60{left:157.832640px;}
.x55{left:159.153720px;}
.x56{left:165.339120px;}
.x6b{left:174.155400px;}
.x15{left:175.534440px;}
.x16{left:180.701040px;}
.x20{left:182.934000px;}
.x47{left:190.188720px;}
.x53{left:200.103960px;}
.x48{left:202.129560px;}
.x54{left:203.847960px;}
.x21{left:206.334000px;}
.x4e{left:216.194880px;}
.x1c{left:221.531880px;}
.x4f{left:222.614160px;}
.x70{left:229.849920px;}
.x1d{left:231.515880px;}
.x49{left:232.591080px;}
.x57{left:234.629160px;}
.x4b{left:238.441800px;}
.x1e{left:242.644680px;}
.x4a{left:245.905440px;}
.x71{left:248.047200px;}
.x1f{left:256.941960px;}
.x58{left:278.042400px;}
.x45{left:279.413160px;}
.x59{left:285.920400px;}
.x46{left:287.135160px;}
.x5a{left:312.120240px;}
.x7{left:316.821600px;}
.x5b{left:319.998240px;}
.x22{left:327.390480px;}
.x6c{left:335.333880px;}
.x5c{left:339.874680px;}
.x6d{left:343.133880px;}
.x5d{left:346.449960px;}
.x72{left:349.972080px;}
.x6e{left:352.200000px;}
.x6f{left:360.000000px;}
.x9{left:363.600000px;}
.x10{left:366.720000px;}
.x50{left:378.002160px;}
.x67{left:379.211880px;}
.x23{left:381.594480px;}
.x76{left:382.798800px;}
.x11{left:386.852400px;}
.x12{left:392.018880px;}
.x44{left:396.000000px;}
.x26{left:397.032000px;}
.x27{left:400.893000px;}
.x66{left:410.459520px;}
.x2f{left:414.839520px;}
.x68{left:417.251400px;}
.x30{left:418.700520px;}
.x17{left:421.135080px;}
.x2e{left:424.022520px;}
.x51{left:435.300120px;}
.x39{left:449.240760px;}
.x77{left:451.632120px;}
.x78{left:456.314400px;}
.x2a{left:460.985760px;}
.x2b{left:464.846760px;}
.x3a{left:466.790760px;}
.x24{left:484.686840px;}
.x25{left:488.547840px;}
.x3b{left:490.841880px;}
.x41{left:494.387400px;}
.x42{left:502.187400px;}
.x3c{left:508.391880px;}
.x43{left:509.603160px;}
.x75{left:516.570600px;}
.x1{left:518.760000px;}
.x35{left:526.052760px;}
.x33{left:533.172600px;}
.x34{left:540.606120px;}
.x69{left:548.712360px;}
.x2c{left:550.088160px;}
.x61{left:551.553720px;}
.x2d{left:553.949160px;}
.x6a{left:556.512360px;}
.x37{left:559.050960px;}
.x38{left:566.850960px;}
.x62{left:569.688720px;}
.x74{left:571.523040px;}
.x13{left:572.750640px;}
.x5e{left:575.103480px;}
.x14{left:577.917240px;}
.x73{left:585.906240px;}
.x63{left:590.654640px;}
.x64{left:594.671640px;}
.x3d{left:598.401960px;}
.xa{left:602.934840px;}
.xb{left:606.834840px;}
.x52{left:619.845120px;}
.x31{left:632.212440px;}
.x28{left:639.039720px;}
.x65{left:640.161000px;}
.x29{left:642.900840px;}
.xc{left:644.100000px;}
.x32{left:645.706440px;}
.xd{left:648.000000px;}
.x3f{left:649.946160px;}
.x3e{left:658.200000px;}
.x40{left:662.004000px;}
.x36{left:666.000000px;}
@media print{
.v0{vertical-align:0.000000pt;}
.ls11{letter-spacing:-2.444444pt;}
.lsa{letter-spacing:-1.213333pt;}
.lsc{letter-spacing:-0.888889pt;}
.ls1{letter-spacing:-0.666667pt;}
.lsd{letter-spacing:-0.577778pt;}
.ls12{letter-spacing:-0.444444pt;}
.lsb{letter-spacing:-0.433333pt;}
.ls13{letter-spacing:-0.288889pt;}
.ls8{letter-spacing:-0.222222pt;}
.ls3{letter-spacing:-0.177778pt;}
.ls9{letter-spacing:-0.144444pt;}
.ls0{letter-spacing:0.000000pt;}
.lsf{letter-spacing:0.144444pt;}
.lse{letter-spacing:0.222222pt;}
.ls15{letter-spacing:0.280000pt;}
.ls5{letter-spacing:0.288889pt;}
.ls19{letter-spacing:0.320000pt;}
.ls18{letter-spacing:0.400000pt;}
.ls10{letter-spacing:0.433333pt;}
.ls4{letter-spacing:0.444444pt;}
.ls14{letter-spacing:0.600000pt;}
.ls7{letter-spacing:0.666667pt;}
.ls16{letter-spacing:0.800000pt;}
.ls17{letter-spacing:1.040000pt;}
.ls2{letter-spacing:1.055556pt;}
.ls6{letter-spacing:1.111111pt;}
.ws10a{word-spacing:-4.488889pt;}
.ws73{word-spacing:-4.133333pt;}
.ws160{word-spacing:-4.120000pt;}
.ws10d{word-spacing:-3.333333pt;}
.wsd6{word-spacing:-3.200000pt;}
.wsee{word-spacing:-3.022222pt;}
.wsb6{word-spacing:-2.977778pt;}
.ws101{word-spacing:-2.844444pt;}
.ws65{word-spacing:-2.755556pt;}
.ws100{word-spacing:-2.444444pt;}
.ws70{word-spacing:-2.355556pt;}
.ws2a{word-spacing:-2.266667pt;}
.ws1a{word-spacing:-2.177778pt;}
.wse6{word-spacing:-2.133333pt;}
.wsbb{word-spacing:-2.088889pt;}
.ws1b{word-spacing:-2.044444pt;}
.wsb8{word-spacing:-2.000000pt;}
.ws6c{word-spacing:-1.955556pt;}
.ws67{word-spacing:-1.866667pt;}
.ws8c{word-spacing:-1.822222pt;}
.ws83{word-spacing:-1.777778pt;}
.wsbc{word-spacing:-1.733333pt;}
.ws135{word-spacing:-1.720000pt;}
.ws74{word-spacing:-1.688889pt;}
.ws6{word-spacing:-1.644444pt;}
.ws167{word-spacing:-1.640000pt;}
.ws9e{word-spacing:-1.600000pt;}
.ws96{word-spacing:-1.555556pt;}
.wsd8{word-spacing:-1.466667pt;}
.ws11b{word-spacing:-1.440000pt;}
.wsae{word-spacing:-1.422222pt;}
.ws150{word-spacing:-1.400000pt;}
.wsc3{word-spacing:-1.377778pt;}
.ws41{word-spacing:-1.333333pt;}
.ws131{word-spacing:-1.320000pt;}
.wse{word-spacing:-1.288889pt;}
.ws16a{word-spacing:-1.280000pt;}
.ws16e{word-spacing:-1.200000pt;}
.ws30{word-spacing:-1.155556pt;}
.ws87{word-spacing:-1.111111pt;}
.ws14a{word-spacing:-1.080000pt;}
.ws34{word-spacing:-1.066667pt;}
.ws1d{word-spacing:-1.055556pt;}
.ws15f{word-spacing:-1.040000pt;}
.ws3d{word-spacing:-0.977778pt;}
.ws7d{word-spacing:-0.933333pt;}
.ws129{word-spacing:-0.920000pt;}
.wsac{word-spacing:-0.888889pt;}
.ws144{word-spacing:-0.840000pt;}
.ws5{word-spacing:-0.800000pt;}
.ws113{word-spacing:-0.720000pt;}
.ws16{word-spacing:-0.666667pt;}
.ws136{word-spacing:-0.640000pt;}
.ws8a{word-spacing:-0.622222pt;}
.ws112{word-spacing:-0.600000pt;}
.ws98{word-spacing:-0.577778pt;}
.wsc{word-spacing:-0.488889pt;}
.ws29{word-spacing:-0.444444pt;}
.wsdf{word-spacing:-0.433333pt;}
.wsbe{word-spacing:-0.400000pt;}
.ws72{word-spacing:-0.355556pt;}
.ws170{word-spacing:-0.320000pt;}
.ws9d{word-spacing:-0.311111pt;}
.ws36{word-spacing:-0.288889pt;}
.ws128{word-spacing:-0.280000pt;}
.ws10e{word-spacing:-0.266667pt;}
.wsc5{word-spacing:-0.222222pt;}
.ws7c{word-spacing:-0.177778pt;}
.wsb2{word-spacing:-0.144444pt;}
.wsf9{word-spacing:-0.133333pt;}
.ws23{word-spacing:-0.088889pt;}
.ws12c{word-spacing:-0.080000pt;}
.ws9{word-spacing:-0.044444pt;}
.ws0{word-spacing:0.000000pt;}
.ws4d{word-spacing:0.044444pt;}
.ws62{word-spacing:0.088889pt;}
.ws88{word-spacing:0.133333pt;}
.ws54{word-spacing:0.144444pt;}
.ws1e{word-spacing:0.177778pt;}
.ws130{word-spacing:0.200000pt;}
.ws3f{word-spacing:0.222222pt;}
.wsb3{word-spacing:0.266667pt;}
.ws105{word-spacing:0.288889pt;}
.wse7{word-spacing:0.311111pt;}
.ws12b{word-spacing:0.320000pt;}
.ws31{word-spacing:0.355556pt;}
.ws107{word-spacing:0.400000pt;}
.ws82{word-spacing:0.433333pt;}
.ws6f{word-spacing:0.444444pt;}
.ws116{word-spacing:0.480000pt;}
.ws2{word-spacing:0.533333pt;}
.ws161{word-spacing:0.560000pt;}
.wsab{word-spacing:0.577778pt;}
.ws3{word-spacing:0.666667pt;}
.ws56{word-spacing:0.711111pt;}
.ws138{word-spacing:0.720000pt;}
.ws45{word-spacing:0.755556pt;}
.ws86{word-spacing:0.800000pt;}
.ws79{word-spacing:0.844444pt;}
.ws114{word-spacing:0.880000pt;}
.wsa4{word-spacing:0.888889pt;}
.wse0{word-spacing:0.933333pt;}
.ws133{word-spacing:0.960000pt;}
.ws97{word-spacing:0.977778pt;}
.ws16d{word-spacing:1.000000pt;}
.ws108{word-spacing:1.022222pt;}
.ws132{word-spacing:1.040000pt;}
.wsbf{word-spacing:1.066667pt;}
.ws33{word-spacing:1.111111pt;}
.ws14b{word-spacing:1.120000pt;}
.ws4{word-spacing:1.155556pt;}
.ws8e{word-spacing:1.200000pt;}
.ws63{word-spacing:1.213333pt;}
.ws64{word-spacing:1.244444pt;}
.ws84{word-spacing:1.288889pt;}
.ws9f{word-spacing:1.422222pt;}
.ws35{word-spacing:1.466667pt;}
.ws78{word-spacing:1.511111pt;}
.ws13d{word-spacing:1.520000pt;}
.ws68{word-spacing:1.555556pt;}
.ws5a{word-spacing:1.600000pt;}
.ws5b{word-spacing:1.644444pt;}
.ws157{word-spacing:1.680000pt;}
.wsb{word-spacing:1.688889pt;}
.ws57{word-spacing:1.777778pt;}
.ws3e{word-spacing:1.822222pt;}
.ws146{word-spacing:1.840000pt;}
.wsbd{word-spacing:1.866667pt;}
.ws3b{word-spacing:1.911111pt;}
.wsdc{word-spacing:1.955556pt;}
.ws13b{word-spacing:1.960000pt;}
.ws2d{word-spacing:2.000000pt;}
.ws14f{word-spacing:2.040000pt;}
.ws12{word-spacing:2.044444pt;}
.wsa8{word-spacing:2.088889pt;}
.ws102{word-spacing:2.133333pt;}
.ws119{word-spacing:2.160000pt;}
.ws48{word-spacing:2.177778pt;}
.ws40{word-spacing:2.222222pt;}
.ws151{word-spacing:2.240000pt;}
.ws9a{word-spacing:2.266667pt;}
.ws15{word-spacing:2.311111pt;}
.ws10{word-spacing:2.355556pt;}
.ws22{word-spacing:2.400000pt;}
.ws158{word-spacing:2.440000pt;}
.ws10f{word-spacing:2.444444pt;}
.ws12f{word-spacing:2.480000pt;}
.wsa1{word-spacing:2.488889pt;}
.ws152{word-spacing:2.520000pt;}
.wsf{word-spacing:2.533333pt;}
.ws13f{word-spacing:2.560000pt;}
.wsfd{word-spacing:2.577778pt;}
.wse9{word-spacing:2.622222pt;}
.ws5c{word-spacing:2.711111pt;}
.ws168{word-spacing:2.720000pt;}
.ws9c{word-spacing:2.755556pt;}
.ws8{word-spacing:2.800000pt;}
.ws4a{word-spacing:2.844444pt;}
.wsff{word-spacing:2.888889pt;}
.ws47{word-spacing:2.933333pt;}
.wsa{word-spacing:2.977778pt;}
.ws38{word-spacing:3.022222pt;}
.ws126{word-spacing:3.080000pt;}
.ws49{word-spacing:3.111111pt;}
.ws122{word-spacing:3.120000pt;}
.wsdb{word-spacing:3.200000pt;}
.ws19{word-spacing:3.244444pt;}
.wsd7{word-spacing:3.288889pt;}
.wsa2{word-spacing:3.333333pt;}
.ws143{word-spacing:3.360000pt;}
.ws28{word-spacing:3.377778pt;}
.wseb{word-spacing:3.422222pt;}
.ws90{word-spacing:3.466667pt;}
.wsfb{word-spacing:3.511111pt;}
.wsd{word-spacing:3.600000pt;}
.ws15d{word-spacing:3.640000pt;}
.ws43{word-spacing:3.644444pt;}
.ws24{word-spacing:3.688889pt;}
.ws26{word-spacing:3.733333pt;}
.wsc1{word-spacing:3.777778pt;}
.ws154{word-spacing:3.800000pt;}
.ws127{word-spacing:3.880000pt;}
.ws27{word-spacing:3.911111pt;}
.wsd5{word-spacing:3.955556pt;}
.wsef{word-spacing:4.000000pt;}
.ws2b{word-spacing:4.044444pt;}
.ws164{word-spacing:4.080000pt;}
.ws21{word-spacing:4.088889pt;}
.wsa5{word-spacing:4.133333pt;}
.wsc2{word-spacing:4.177778pt;}
.ws12d{word-spacing:4.280000pt;}
.ws25{word-spacing:4.311111pt;}
.ws94{word-spacing:4.400000pt;}
.ws110{word-spacing:4.444444pt;}
.ws66{word-spacing:4.488889pt;}
.ws1c{word-spacing:4.533333pt;}
.ws165{word-spacing:4.560000pt;}
.ws8d{word-spacing:4.622222pt;}
.ws120{word-spacing:4.640000pt;}
.ws103{word-spacing:4.666667pt;}
.wscd{word-spacing:4.755556pt;}
.ws95{word-spacing:4.800000pt;}
.wsf6{word-spacing:4.844444pt;}
.ws42{word-spacing:4.933333pt;}
.ws4b{word-spacing:4.977778pt;}
.ws14{word-spacing:5.022222pt;}
.ws20{word-spacing:5.066667pt;}
.ws92{word-spacing:5.111111pt;}
.wse5{word-spacing:5.155556pt;}
.wsf0{word-spacing:5.200000pt;}
.ws37{word-spacing:5.333333pt;}
.ws3a{word-spacing:5.511111pt;}
.ws13{word-spacing:5.555556pt;}
.ws1{word-spacing:5.644444pt;}
.wsb4{word-spacing:5.822222pt;}
.ws13c{word-spacing:5.840000pt;}
.ws2f{word-spacing:5.866667pt;}
.ws166{word-spacing:5.880000pt;}
.ws13a{word-spacing:5.920000pt;}
.wsa6{word-spacing:5.955556pt;}
.wsb1{word-spacing:6.044444pt;}
.wsb7{word-spacing:6.088889pt;}
.wsd2{word-spacing:6.133333pt;}
.ws9b{word-spacing:6.177778pt;}
.wsca{word-spacing:6.222222pt;}
.ws58{word-spacing:6.266667pt;}
.ws52{word-spacing:6.355556pt;}
.ws7f{word-spacing:6.400000pt;}
.ws169{word-spacing:6.520000pt;}
.ws85{word-spacing:6.577778pt;}
.ws139{word-spacing:6.600000pt;}
.ws59{word-spacing:6.666667pt;}
.wsb9{word-spacing:6.800000pt;}
.ws134{word-spacing:6.840000pt;}
.wsda{word-spacing:6.844444pt;}
.wsc0{word-spacing:6.933333pt;}
.ws16c{word-spacing:6.960000pt;}
.wsba{word-spacing:6.977778pt;}
.ws15c{word-spacing:7.080000pt;}
.ws13e{word-spacing:7.160000pt;}
.ws93{word-spacing:7.288889pt;}
.ws6d{word-spacing:7.333333pt;}
.ws15a{word-spacing:7.440000pt;}
.wsf5{word-spacing:7.511111pt;}
.ws145{word-spacing:7.520000pt;}
.ws1f{word-spacing:7.555556pt;}
.ws156{word-spacing:7.560000pt;}
.wse4{word-spacing:7.600000pt;}
.ws123{word-spacing:7.640000pt;}
.wscf{word-spacing:7.644444pt;}
.wsc6{word-spacing:7.822222pt;}
.ws141{word-spacing:7.840000pt;}
.wsc8{word-spacing:8.088889pt;}
.ws7e{word-spacing:8.133333pt;}
.ws8b{word-spacing:8.177778pt;}
.wsad{word-spacing:8.222222pt;}
.ws111{word-spacing:8.266667pt;}
.ws14d{word-spacing:8.280000pt;}
.ws89{word-spacing:8.311111pt;}
.wse1{word-spacing:8.400000pt;}
.ws12a{word-spacing:8.440000pt;}
.wsa9{word-spacing:8.444444pt;}
.ws11c{word-spacing:8.520000pt;}
.ws76{word-spacing:8.622222pt;}
.ws117{word-spacing:8.640000pt;}
.wsde{word-spacing:8.666667pt;}
.wsf4{word-spacing:8.711111pt;}
.ws69{word-spacing:8.844444pt;}
.ws153{word-spacing:8.920000pt;}
.wse3{word-spacing:8.977778pt;}
.ws115{word-spacing:9.040000pt;}
.ws7b{word-spacing:9.111111pt;}
.ws14e{word-spacing:9.160000pt;}
.ws5d{word-spacing:9.200000pt;}
.wsdd{word-spacing:9.333333pt;}
.ws4c{word-spacing:9.422222pt;}
.ws99{word-spacing:9.466667pt;}
.ws11e{word-spacing:9.480000pt;}
.ws61{word-spacing:9.511111pt;}
.ws10c{word-spacing:9.555556pt;}
.wsf7{word-spacing:9.600000pt;}
.ws140{word-spacing:9.680000pt;}
.wsa0{word-spacing:9.688889pt;}
.ws159{word-spacing:9.720000pt;}
.wsaa{word-spacing:9.733333pt;}
.ws2c{word-spacing:9.777778pt;}
.ws10b{word-spacing:9.822222pt;}
.wsf3{word-spacing:9.866667pt;}
.wsc7{word-spacing:9.955556pt;}
.ws162{word-spacing:10.000000pt;}
.ws91{word-spacing:10.044444pt;}
.ws39{word-spacing:10.177778pt;}
.ws142{word-spacing:10.200000pt;}
.ws16b{word-spacing:10.320000pt;}
.ws4e{word-spacing:10.355556pt;}
.wscc{word-spacing:10.400000pt;}
.wsd3{word-spacing:10.488889pt;}
.wsd4{word-spacing:10.577778pt;}
.wsd9{word-spacing:10.666667pt;}
.wsd1{word-spacing:10.711111pt;}
.ws46{word-spacing:10.755556pt;}
.wsc4{word-spacing:10.844444pt;}
.ws55{word-spacing:10.977778pt;}
.ws75{word-spacing:11.022222pt;}
.ws80{word-spacing:11.111111pt;}
.wsf2{word-spacing:11.155556pt;}
.ws124{word-spacing:11.280000pt;}
.ws109{word-spacing:11.333333pt;}
.wsd0{word-spacing:11.377778pt;}
.wsfa{word-spacing:11.422222pt;}
.wsce{word-spacing:11.466667pt;}
.ws60{word-spacing:11.644444pt;}
.wsfe{word-spacing:11.866667pt;}
.ws81{word-spacing:12.044444pt;}
.wsfc{word-spacing:12.133333pt;}
.ws17{word-spacing:12.177778pt;}
.ws11d{word-spacing:12.240000pt;}
.ws3c{word-spacing:12.266667pt;}
.wsec{word-spacing:12.355556pt;}
.ws104{word-spacing:12.577778pt;}
.ws50{word-spacing:12.622222pt;}
.ws147{word-spacing:13.040000pt;}
.ws6a{word-spacing:13.155556pt;}
.ws53{word-spacing:13.422222pt;}
.wsa7{word-spacing:13.466667pt;}
.wsb5{word-spacing:13.600000pt;}
.ws106{word-spacing:13.822222pt;}
.wse2{word-spacing:14.088889pt;}
.wscb{word-spacing:14.400000pt;}
.ws163{word-spacing:14.640000pt;}
.ws155{word-spacing:14.800000pt;}
.ws149{word-spacing:14.840000pt;}
.wsc9{word-spacing:14.844444pt;}
.wsa3{word-spacing:15.377778pt;}
.ws148{word-spacing:15.440000pt;}
.ws11a{word-spacing:15.480000pt;}
.ws77{word-spacing:15.600000pt;}
.ws7{word-spacing:15.733333pt;}
.wsf8{word-spacing:15.911111pt;}
.ws18{word-spacing:15.955556pt;}
.ws8f{word-spacing:16.133333pt;}
.ws11f{word-spacing:16.320000pt;}
.ws16f{word-spacing:16.440000pt;}
.ws2e{word-spacing:16.488889pt;}
.ws118{word-spacing:16.680000pt;}
.ws125{word-spacing:16.720000pt;}
.wse8{word-spacing:16.844444pt;}
.ws121{word-spacing:16.880000pt;}
.ws15e{word-spacing:18.000000pt;}
.ws14c{word-spacing:18.560000pt;}
.ws6b{word-spacing:19.111111pt;}
.ws51{word-spacing:19.244444pt;}
.ws12e{word-spacing:19.320000pt;}
.wsf1{word-spacing:19.733333pt;}
.ws71{word-spacing:20.000000pt;}
.wsea{word-spacing:20.133333pt;}
.ws7a{word-spacing:20.933333pt;}
.ws32{word-spacing:21.244444pt;}
.wsb0{word-spacing:21.288889pt;}
.wsed{word-spacing:21.644444pt;}
.ws5f{word-spacing:22.711111pt;}
.ws11{word-spacing:23.022222pt;}
.ws5e{word-spacing:24.444444pt;}
.ws15b{word-spacing:25.560000pt;}
.ws6e{word-spacing:29.244444pt;}
.ws137{word-spacing:31.240000pt;}
.wsaf{word-spacing:32.844444pt;}
.ws44{word-spacing:36.844444pt;}
.ws4f{word-spacing:45.733333pt;}
._17{margin-left:-35.560000pt;}
._14{margin-left:-28.560000pt;}
._c{margin-left:-25.333333pt;}
._13{margin-left:-23.040000pt;}
._19{margin-left:-20.400000pt;}
._16{margin-left:-19.160000pt;}
._d{margin-left:-16.711111pt;}
._e{margin-left:-14.000000pt;}
._b{margin-left:-11.688889pt;}
._0{margin-left:-8.648889pt;}
._15{margin-left:-7.440000pt;}
._a{margin-left:-6.311111pt;}
._3{margin-left:-4.711111pt;}
._2{margin-left:-3.466667pt;}
._1{margin-left:-1.688889pt;}
._4{width:1.244444pt;}
._5{width:2.400000pt;}
._12{width:4.520000pt;}
._11{width:6.120000pt;}
._9{width:7.555556pt;}
._8{width:8.880000pt;}
._f{width:10.600000pt;}
._10{width:11.720000pt;}
._18{width:15.671111pt;}
._7{width:1541.155556pt;}
._6{width:1924.533333pt;}
.fs6{font-size:4.444444pt;}
.fs7{font-size:23.111111pt;}
.fsc{font-size:26.000000pt;}
.fs0{font-size:26.666667pt;}
.fs4{font-size:28.888889pt;}
.fs1{font-size:31.111111pt;}
.fsa{font-size:34.666667pt;}
.fs8{font-size:35.555556pt;}
.fsb{font-size:40.000000pt;}
.fs5{font-size:42.222222pt;}
.fs2{font-size:44.444444pt;}
.fs3{font-size:53.333333pt;}
.fs9{font-size:80.000000pt;}
.y0{bottom:0.000000pt;}
.y1f{bottom:93.088133pt;}
.y3c{bottom:93.112933pt;}
.y1a5{bottom:93.134800pt;}
.y168{bottom:93.172133pt;}
.ye0{bottom:94.346800pt;}
.y116{bottom:94.513600pt;}
.y8e{bottom:94.760133pt;}
.y12d{bottom:94.773467pt;}
.yac{bottom:100.760133pt;}
.y3b{bottom:106.446267pt;}
.y1a4{bottom:107.798800pt;}
.y167{bottom:107.836133pt;}
.y1e{bottom:109.088133pt;}
.y12c{bottom:109.437467pt;}
.ydf{bottom:110.346800pt;}
.y115{bottom:110.513600pt;}
.y8c{bottom:110.760133pt;}
.y8d{bottom:116.760133pt;}
.y3a{bottom:119.779600pt;}
.y1a3{bottom:122.462800pt;}
.y166{bottom:122.500133pt;}
.y12b{bottom:124.101467pt;}
.y1c{bottom:125.088133pt;}
.yde{bottom:126.346800pt;}
.y114{bottom:126.513600pt;}
.y8b{bottom:126.760133pt;}
.y1d{bottom:131.088133pt;}
.y39{bottom:133.112933pt;}
.y11c{bottom:134.760133pt;}
.y1a2{bottom:137.126800pt;}
.y165{bottom:137.164133pt;}
.y12a{bottom:138.765467pt;}
.y1b{bottom:141.088133pt;}
.ydd{bottom:142.346800pt;}
.y8a{bottom:142.760133pt;}
.y113{bottom:142.780267pt;}
.y1a1{bottom:151.790800pt;}
.y164{bottom:151.828133pt;}
.y129{bottom:153.429467pt;}
.y38{bottom:154.446267pt;}
.y1a{bottom:157.088133pt;}
.ydc{bottom:158.346800pt;}
.y89{bottom:158.760133pt;}
.y112{bottom:159.046933pt;}
.y37{bottom:159.246267pt;}
.yab{bottom:164.760133pt;}
.y1a0{bottom:166.454800pt;}
.y163{bottom:166.492133pt;}
.y36{bottom:167.779467pt;}
.y128{bottom:168.093467pt;}
.yaa{bottom:168.760133pt;}
.y35{bottom:172.579467pt;}
.y19{bottom:173.088133pt;}
.ydb{bottom:174.346800pt;}
.y88{bottom:174.760133pt;}
.y111{bottom:175.313600pt;}
.y34{bottom:181.112800pt;}
.y19f{bottom:181.118800pt;}
.y162{bottom:181.156133pt;}
.y33{bottom:185.912800pt;}
.y127{bottom:188.093467pt;}
.y18{bottom:189.088133pt;}
.yda{bottom:190.346800pt;}
.y87{bottom:190.760133pt;}
.y110{bottom:191.580267pt;}
.y32{bottom:194.446133pt;}
.y19e{bottom:195.782800pt;}
.y161{bottom:195.820133pt;}
.ya9{bottom:196.760133pt;}
.y117{bottom:198.760133pt;}
.y31{bottom:199.246133pt;}
.y17{bottom:205.088133pt;}
.yd9{bottom:206.346800pt;}
.ya7{bottom:206.760133pt;}
.y10f{bottom:207.846933pt;}
.y19d{bottom:210.446800pt;}
.y160{bottom:210.484133pt;}
.ya8{bottom:212.760133pt;}
.y86{bottom:214.760133pt;}
.y126{bottom:217.429467pt;}
.y16{bottom:221.088133pt;}
.yd8{bottom:222.346800pt;}
.ya6{bottom:222.760133pt;}
.y10e{bottom:224.113600pt;}
.y19c{bottom:225.110800pt;}
.y15f{bottom:225.148133pt;}
.y2d{bottom:230.760133pt;}
.y125{bottom:232.093467pt;}
.ya5{bottom:232.760133pt;}
.y15{bottom:237.088133pt;}
.yd7{bottom:238.346800pt;}
.ya4{bottom:238.760133pt;}
.y19b{bottom:239.774800pt;}
.y15e{bottom:239.812133pt;}
.y10d{bottom:240.380267pt;}
.y2c{bottom:246.760133pt;}
.y124{bottom:252.093467pt;}
.y14{bottom:253.088133pt;}
.yd6{bottom:254.346800pt;}
.y19a{bottom:254.438800pt;}
.y15d{bottom:254.476133pt;}
.y85{bottom:254.760133pt;}
.y10c{bottom:256.646933pt;}
.y2b{bottom:262.760133pt;}
.y13{bottom:269.088133pt;}
.y199{bottom:269.102800pt;}
.y15c{bottom:269.140133pt;}
.yd5{bottom:270.346800pt;}
.y84{bottom:270.760133pt;}
.y10b{bottom:272.913600pt;}
.ya3{bottom:276.760133pt;}
.y2a{bottom:278.760133pt;}
.y198{bottom:283.766800pt;}
.y15b{bottom:283.804133pt;}
.y123{bottom:284.096133pt;}
.y12{bottom:285.088133pt;}
.yd4{bottom:286.346800pt;}
.y83{bottom:286.760133pt;}
.y10a{bottom:289.180267pt;}
.ya2{bottom:292.760133pt;}
.y28{bottom:294.760133pt;}
.y197{bottom:298.430800pt;}
.y15a{bottom:298.468133pt;}
.y122{bottom:298.760133pt;}
.y29{bottom:300.760133pt;}
.y10{bottom:301.088133pt;}
.yd3{bottom:302.346800pt;}
.y81{bottom:302.760133pt;}
.y109{bottom:305.446933pt;}
.y11{bottom:307.088133pt;}
.y82{bottom:308.760133pt;}
.y27{bottom:310.760133pt;}
.y196{bottom:313.094800pt;}
.y159{bottom:313.132133pt;}
.yf{bottom:317.088133pt;}
.yd2{bottom:318.346800pt;}
.y7f{bottom:318.760133pt;}
.y108{bottom:321.713600pt;}
.y80{bottom:324.760133pt;}
.y26{bottom:326.760133pt;}
.y195{bottom:327.758800pt;}
.y158{bottom:327.796133pt;}
.yd{bottom:333.088133pt;}
.yd1{bottom:334.346800pt;}
.y7e{bottom:334.760133pt;}
.yc9{bottom:335.026800pt;}
.y107{bottom:337.980267pt;}
.ye{bottom:339.088133pt;}
.y194{bottom:342.422800pt;}
.y157{bottom:342.460133pt;}
.y25{bottom:342.760133pt;}
.yc{bottom:349.088133pt;}
.yd0{bottom:350.346800pt;}
.y7d{bottom:350.760133pt;}
.yc8{bottom:351.293467pt;}
.y106{bottom:354.246933pt;}
.ya1{bottom:356.760133pt;}
.y193{bottom:357.086800pt;}
.y156{bottom:357.124133pt;}
.y24{bottom:358.760133pt;}
.yb{bottom:365.088133pt;}
.ycf{bottom:366.346800pt;}
.y7c{bottom:366.760133pt;}
.yc7{bottom:367.560133pt;}
.y105{bottom:370.513600pt;}
.y192{bottom:371.750800pt;}
.y155{bottom:371.788133pt;}
.y11e{bottom:372.760133pt;}
.y21{bottom:374.754800pt;}
.y23{bottom:374.760133pt;}
.y22{bottom:380.760133pt;}
.yce{bottom:382.346800pt;}
.y7b{bottom:382.760133pt;}
.yc6{bottom:383.826800pt;}
.y191{bottom:386.414800pt;}
.y154{bottom:386.452133pt;}
.y104{bottom:386.780267pt;}
.ya{bottom:389.088133pt;}
.y20{bottom:390.754800pt;}
.ycd{bottom:398.346800pt;}
.y7a{bottom:398.760133pt;}
.yc5{bottom:400.093467pt;}
.y190{bottom:401.078800pt;}
.y153{bottom:401.116133pt;}
.y103{bottom:403.046933pt;}
.ya0{bottom:404.760133pt;}
.ycc{bottom:414.346800pt;}
.y79{bottom:414.760133pt;}
.y18f{bottom:415.742800pt;}
.y152{bottom:415.780133pt;}
.yc4{bottom:416.360133pt;}
.y102{bottom:419.313600pt;}
.y121{bottom:420.760133pt;}
.ycb{bottom:430.346800pt;}
.y18e{bottom:430.406800pt;}
.y151{bottom:430.444133pt;}
.y78{bottom:430.760133pt;}
.yc2{bottom:432.360133pt;}
.y56{bottom:434.285467pt;}
.y101{bottom:435.580267pt;}
.yc3{bottom:438.360133pt;}
.y18d{bottom:445.070800pt;}
.y150{bottom:445.108133pt;}
.yca{bottom:446.346800pt;}
.y77{bottom:446.760133pt;}
.y55{bottom:450.285467pt;}
.y100{bottom:451.846933pt;}
.y9f{bottom:452.760133pt;}
.y11d{bottom:454.760133pt;}
.yc1{bottom:456.360133pt;}
.y18c{bottom:459.734800pt;}
.y14f{bottom:459.772133pt;}
.y76{bottom:462.760133pt;}
.yff{bottom:468.113600pt;}
.y11b{bottom:468.760133pt;}
.y18b{bottom:474.398800pt;}
.y14e{bottom:474.436133pt;}
.y75{bottom:478.760133pt;}
.ye7{bottom:480.930400pt;}
.yfe{bottom:484.380267pt;}
.y54{bottom:488.965467pt;}
.y18a{bottom:489.062800pt;}
.y14d{bottom:489.100133pt;}
.ye6{bottom:493.591733pt;}
.y74{bottom:494.760133pt;}
.yc0{bottom:496.360000pt;}
.yfd{bottom:500.646933pt;}
.y9e{bottom:500.760133pt;}
.y189{bottom:503.726800pt;}
.y14c{bottom:503.764133pt;}
.y53{bottom:504.965467pt;}
.ye4{bottom:506.246400pt;}
.y73{bottom:510.760133pt;}
.ye5{bottom:511.658400pt;}
.ybf{bottom:512.626667pt;}
.yf2{bottom:516.760133pt;}
.yfc{bottom:516.913600pt;}
.y188{bottom:518.390800pt;}
.y14b{bottom:518.428133pt;}
.ye3{bottom:520.250400pt;}
.y52{bottom:520.965467pt;}
.y72{bottom:526.760133pt;}
.ybe{bottom:528.893333pt;}
.yf1{bottom:532.760133pt;}
.y187{bottom:533.054800pt;}
.y14a{bottom:533.092133pt;}
.yfb{bottom:533.180267pt;}
.ye2{bottom:534.254400pt;}
.y9d{bottom:534.760133pt;}
.y51{bottom:536.965467pt;}
.y71{bottom:542.760133pt;}
.ybd{bottom:545.160000pt;}
.y186{bottom:547.718800pt;}
.y149{bottom:547.756133pt;}
.ye1{bottom:548.258400pt;}
.yfa{bottom:549.446933pt;}
.y50{bottom:552.965467pt;}
.y70{bottom:558.760133pt;}
.ybc{bottom:561.426667pt;}
.y185{bottom:562.382800pt;}
.y148{bottom:562.420133pt;}
.yf9{bottom:565.713600pt;}
.yf7{bottom:565.720133pt;}
.y4f{bottom:568.965467pt;}
.yf8{bottom:571.713600pt;}
.y9b{bottom:574.760133pt;}
.y184{bottom:577.046800pt;}
.y147{bottom:577.084133pt;}
.ybb{bottom:577.693333pt;}
.y9c{bottom:580.760133pt;}
.yf6{bottom:581.986800pt;}
.y6f{bottom:582.760133pt;}
.y4e{bottom:584.965467pt;}
.y9a{bottom:590.760133pt;}
.y183{bottom:591.710800pt;}
.y146{bottom:591.748133pt;}
.yba{bottom:593.960000pt;}
.yf5{bottom:598.253467pt;}
.y4d{bottom:600.965467pt;}
.y182{bottom:606.374800pt;}
.y145{bottom:606.412133pt;}
.y99{bottom:606.760133pt;}
.yb9{bottom:610.226667pt;}
.yf0{bottom:612.760133pt;}
.yf4{bottom:614.520133pt;}
.yef{bottom:616.760133pt;}
.y4c{bottom:616.965467pt;}
.y181{bottom:621.038800pt;}
.y144{bottom:621.076133pt;}
.y6e{bottom:622.760133pt;}
.yb8{bottom:626.493333pt;}
.y98{bottom:628.760133pt;}
.yf3{bottom:630.786800pt;}
.y4b{bottom:632.965467pt;}
.y180{bottom:635.702800pt;}
.y143{bottom:635.740133pt;}
.y6d{bottom:638.760133pt;}
.yb7{bottom:642.760000pt;}
.y11a{bottom:644.760133pt;}
.y4a{bottom:648.965467pt;}
.y17f{bottom:650.366800pt;}
.y142{bottom:650.404133pt;}
.y6c{bottom:654.760133pt;}
.yb6{bottom:659.026667pt;}
.y119{bottom:662.760133pt;}
.y49{bottom:664.965467pt;}
.y17e{bottom:665.030800pt;}
.y141{bottom:665.068133pt;}
.yeb{bottom:670.245200pt;}
.y6b{bottom:670.760133pt;}
.yb5{bottom:675.293333pt;}
.yec{bottom:675.657200pt;}
.y97{bottom:676.760133pt;}
.y17d{bottom:679.694800pt;}
.y140{bottom:679.732133pt;}
.y48{bottom:680.965467pt;}
.yea{bottom:684.249200pt;}
.y6a{bottom:686.760133pt;}
.yb4{bottom:691.560000pt;}
.yb2{bottom:691.560133pt;}
.y17c{bottom:694.358800pt;}
.y13f{bottom:694.396133pt;}
.yee{bottom:694.760133pt;}
.y47{bottom:696.965467pt;}
.yb3{bottom:697.560000pt;}
.ye9{bottom:698.253200pt;}
.y69{bottom:702.760133pt;}
.yb1{bottom:707.826800pt;}
.y17b{bottom:709.022800pt;}
.y13e{bottom:709.060133pt;}
.ye8{bottom:712.257200pt;}
.y46{bottom:712.965467pt;}
.y68{bottom:718.760133pt;}
.y17a{bottom:723.686800pt;}
.y13d{bottom:723.724133pt;}
.y45{bottom:728.965467pt;}
.yb0{bottom:732.088133pt;}
.y67{bottom:734.760133pt;}
.y179{bottom:738.350800pt;}
.y13c{bottom:738.388133pt;}
.y177{bottom:738.544133pt;}
.y96{bottom:740.760133pt;}
.y178{bottom:743.750667pt;}
.y65{bottom:750.760133pt;}
.y13b{bottom:753.052133pt;}
.y176{bottom:753.208133pt;}
.y66{bottom:756.760133pt;}
.yaf{bottom:758.760133pt;}
.y64{bottom:766.760133pt;}
.y13a{bottom:767.716133pt;}
.y175{bottom:767.872133pt;}
.y95{bottom:772.760133pt;}
.y94{bottom:776.760133pt;}
.y139{bottom:782.380133pt;}
.y174{bottom:782.536133pt;}
.y63{bottom:782.760133pt;}
.y118{bottom:788.760133pt;}
.y42{bottom:792.960133pt;}
.y44{bottom:792.965467pt;}
.y138{bottom:797.044133pt;}
.y1b0{bottom:797.068133pt;}
.y173{bottom:797.200133pt;}
.y62{bottom:798.760133pt;}
.y43{bottom:800.165467pt;}
.y40{bottom:811.632133pt;}
.y137{bottom:811.708133pt;}
.y1af{bottom:811.732133pt;}
.y172{bottom:811.864133pt;}
.y61{bottom:814.760133pt;}
.y41{bottom:818.832133pt;}
.y136{bottom:826.372133pt;}
.y1ae{bottom:826.396133pt;}
.y171{bottom:826.528133pt;}
.y60{bottom:830.760133pt;}
.y120{bottom:836.760133pt;}
.y93{bottom:840.760133pt;}
.y135{bottom:841.036133pt;}
.y1ad{bottom:841.060133pt;}
.y170{bottom:841.192133pt;}
.y5f{bottom:846.760133pt;}
.yed{bottom:852.760133pt;}
.y134{bottom:855.700133pt;}
.y1ac{bottom:855.724133pt;}
.y16f{bottom:855.856133pt;}
.yae{bottom:856.760133pt;}
.y5e{bottom:862.760133pt;}
.y92{bottom:868.760133pt;}
.y133{bottom:870.364133pt;}
.y1ab{bottom:870.388133pt;}
.y16e{bottom:870.520133pt;}
.y3f{bottom:878.304133pt;}
.y5d{bottom:878.760133pt;}
.yad{bottom:884.760133pt;}
.y132{bottom:885.028133pt;}
.y1aa{bottom:885.052133pt;}
.y16d{bottom:885.184133pt;}
.y8{bottom:887.650800pt;}
.y5c{bottom:894.760133pt;}
.y7{bottom:898.981467pt;}
.y1{bottom:899.499333pt;}
.y131{bottom:899.692133pt;}
.y1a9{bottom:899.716133pt;}
.y16c{bottom:899.848133pt;}
.y3e{bottom:904.968133pt;}
.y6{bottom:910.312133pt;}
.y5b{bottom:910.760133pt;}
.y130{bottom:914.356133pt;}
.y1a8{bottom:914.380133pt;}
.y16b{bottom:914.512133pt;}
.y11f{bottom:916.760133pt;}
.y91{bottom:920.760133pt;}
.y5{bottom:921.642800pt;}
.y5a{bottom:926.760133pt;}
.y12f{bottom:929.020133pt;}
.y1a7{bottom:929.044133pt;}
.y16a{bottom:929.176133pt;}
.y3d{bottom:931.632133pt;}
.y90{bottom:932.760133pt;}
.y4{bottom:932.973467pt;}
.y8f{bottom:936.760133pt;}
.y58{bottom:942.760133pt;}
.y12e{bottom:943.684133pt;}
.y1a6{bottom:943.708133pt;}
.y169{bottom:943.840133pt;}
.y3{bottom:944.304133pt;}
.y59{bottom:948.760133pt;}
.y2{bottom:955.634800pt;}
.y57{bottom:978.906800pt;}
.y9{bottom:981.573467pt;}
.y30{bottom:1029.928000pt;}
.y2f{bottom:1031.261333pt;}
.y2e{bottom:1031.262000pt;}
.h8{height:3.191111pt;}
.h9{height:16.848000pt;}
.h12{height:18.668000pt;}
.h10{height:18.954000pt;}
.h1{height:19.440000pt;}
.h6{height:20.742222pt;}
.h2{height:22.680000pt;}
.hd{height:24.266667pt;}
.hb{height:24.888889pt;}
.ha{height:25.920000pt;}
.h7{height:28.546856pt;}
.h11{height:28.720000pt;}
.hf{height:29.160000pt;}
.h3{height:31.111111pt;}
.h5{height:31.911111pt;}
.he{height:32.400000pt;}
.h4{height:37.333333pt;}
.hc{height:56.000000pt;}
.h0{height:1044.000000pt;}
.w0{width:804.000000pt;}
.x0{left:0.000000pt;}
.xe{left:11.200000pt;}
.xf{left:53.713333pt;}
.x2{left:64.000000pt;}
.x8{left:80.000000pt;}
.x18{left:84.000000pt;}
.x5{left:85.666800pt;}
.x6{left:89.870133pt;}
.x5f{left:94.706533pt;}
.x1b{left:99.999333pt;}
.x3{left:102.026267pt;}
.x4{left:106.229600pt;}
.x19{left:142.866000pt;}
.x1a{left:147.199333pt;}
.x4c{left:150.728267pt;}
.x4d{left:159.308267pt;}
.x60{left:175.369600pt;}
.x55{left:176.837467pt;}
.x56{left:183.710133pt;}
.x6b{left:193.506000pt;}
.x15{left:195.038267pt;}
.x16{left:200.778933pt;}
.x20{left:203.260000pt;}
.x47{left:211.320800pt;}
.x53{left:222.337733pt;}
.x48{left:224.588400pt;}
.x54{left:226.497733pt;}
.x21{left:229.260000pt;}
.x4e{left:240.216533pt;}
.x1c{left:246.146533pt;}
.x4f{left:247.349067pt;}
.x70{left:255.388800pt;}
.x1d{left:257.239867pt;}
.x49{left:258.434533pt;}
.x57{left:260.699067pt;}
.x4b{left:264.935333pt;}
.x1e{left:269.605200pt;}
.x4a{left:273.228267pt;}
.x71{left:275.608000pt;}
.x1f{left:285.491067pt;}
.x58{left:308.936000pt;}
.x45{left:310.459067pt;}
.x59{left:317.689333pt;}
.x46{left:319.039067pt;}
.x5a{left:346.800267pt;}
.x7{left:352.024000pt;}
.x5b{left:355.553600pt;}
.x22{left:363.767200pt;}
.x6c{left:372.593200pt;}
.x5c{left:377.638533pt;}
.x6d{left:381.259867pt;}
.x5d{left:384.944400pt;}
.x72{left:388.857867pt;}
.x6e{left:391.333333pt;}
.x6f{left:400.000000pt;}
.x9{left:404.000000pt;}
.x10{left:407.466667pt;}
.x50{left:420.002400pt;}
.x67{left:421.346533pt;}
.x23{left:423.993867pt;}
.x76{left:425.332000pt;}
.x11{left:429.836000pt;}
.x12{left:435.576533pt;}
.x44{left:440.000000pt;}
.x26{left:441.146667pt;}
.x27{left:445.436667pt;}
.x66{left:456.066133pt;}
.x2f{left:460.932800pt;}
.x68{left:463.612667pt;}
.x30{left:465.222800pt;}
.x17{left:467.927867pt;}
.x2e{left:471.136133pt;}
.x51{left:483.666800pt;}
.x39{left:499.156400pt;}
.x77{left:501.813467pt;}
.x78{left:507.016000pt;}
.x2a{left:512.206400pt;}
.x2b{left:516.496400pt;}
.x3a{left:518.656400pt;}
.x24{left:538.540933pt;}
.x25{left:542.830933pt;}
.x3b{left:545.379867pt;}
.x41{left:549.319333pt;}
.x42{left:557.986000pt;}
.x3c{left:564.879867pt;}
.x43{left:566.225733pt;}
.x75{left:573.967333pt;}
.x1{left:576.400000pt;}
.x35{left:584.503067pt;}
.x33{left:592.414000pt;}
.x34{left:600.673467pt;}
.x69{left:609.680400pt;}
.x2c{left:611.209067pt;}
.x61{left:612.837467pt;}
.x2d{left:615.499067pt;}
.x6a{left:618.347067pt;}
.x37{left:621.167733pt;}
.x38{left:629.834400pt;}
.x62{left:632.987467pt;}
.x74{left:635.025600pt;}
.x13{left:636.389600pt;}
.x5e{left:639.003867pt;}
.x14{left:642.130267pt;}
.x73{left:651.006933pt;}
.x63{left:656.282933pt;}
.x64{left:660.746267pt;}
.x3d{left:664.891067pt;}
.xa{left:669.927600pt;}
.xb{left:674.260933pt;}
.x52{left:688.716800pt;}
.x31{left:702.458267pt;}
.x28{left:710.044133pt;}
.x65{left:711.290000pt;}
.x29{left:714.334267pt;}
.xc{left:715.666667pt;}
.x32{left:717.451600pt;}
.xd{left:720.000000pt;}
.x3f{left:722.162400pt;}
.x3e{left:731.333333pt;}
.x40{left:735.560000pt;}
.x36{left:740.000000pt;}
}
</style>
<script>
/*
 Copyright 2012 Mozilla Foundation 
 Copyright 2013 Lu Wang <coolwanglu@gmail.com>
 Apachine License Version 2.0 
*/
(function(){function b(a,b,e,f){var c=(a.className||"").split(/\s+/g);""===c[0]&&c.shift();var d=c.indexOf(b);0>d&&e&&c.push(b);0<=d&&f&&c.splice(d,1);a.className=c.join(" ");return 0<=d}if(!("classList"in document.createElement("div"))){var e={add:function(a){b(this.element,a,!0,!1)},contains:function(a){return b(this.element,a,!1,!1)},remove:function(a){b(this.element,a,!1,!0)},toggle:function(a){b(this.element,a,!0,!0)}};Object.defineProperty(HTMLElement.prototype,"classList",{get:function(){if(this._classList)return this._classList;
var a=Object.create(e,{element:{value:this,writable:!1,enumerable:!0}});Object.defineProperty(this,"_classList",{value:a,writable:!1,enumerable:!1});return a},enumerable:!0})}})();
</script>
<script>
(function(){/*
 pdf2htmlEX.js: Core UI functions for pdf2htmlEX 
 Copyright 2012,2013 Lu Wang <coolwanglu@gmail.com> and other contributors 
 https://github.com/pdf2htmlEX/pdf2htmlEX/blob/master/share/LICENSE 
*/
var pdf2htmlEX=window.pdf2htmlEX=window.pdf2htmlEX||{},CSS_CLASS_NAMES={page_frame:"pf",page_content_box:"pc",page_data:"pi",background_image:"bi",link:"l",input_radio:"ir",__dummy__:"no comma"},DEFAULT_CONFIG={container_id:"page-container",sidebar_id:"sidebar",outline_id:"outline",loading_indicator_cls:"loading-indicator",preload_pages:3,render_timeout:100,scale_step:0.9,key_handler:!0,hashchange_handler:!0,view_history_handler:!0,__dummy__:"no comma"},EPS=1E-6;
function invert(a){var b=a[0]*a[3]-a[1]*a[2];return[a[3]/b,-a[1]/b,-a[2]/b,a[0]/b,(a[2]*a[5]-a[3]*a[4])/b,(a[1]*a[4]-a[0]*a[5])/b]}function transform(a,b){return[a[0]*b[0]+a[2]*b[1]+a[4],a[1]*b[0]+a[3]*b[1]+a[5]]}function get_page_number(a){return parseInt(a.getAttribute("data-page-no"),16)}function disable_dragstart(a){for(var b=0,c=a.length;b<c;++b)a[b].addEventListener("dragstart",function(){return!1},!1)}
function clone_and_extend_objs(a){for(var b={},c=0,e=arguments.length;c<e;++c){var h=arguments[c],d;for(d in h)h.hasOwnProperty(d)&&(b[d]=h[d])}return b}
function Page(a){if(a){this.shown=this.loaded=!1;this.page=a;this.num=get_page_number(a);this.original_height=a.clientHeight;this.original_width=a.clientWidth;var b=a.getElementsByClassName(CSS_CLASS_NAMES.page_content_box)[0];b&&(this.content_box=b,this.original_scale=this.cur_scale=this.original_height/b.clientHeight,this.page_data=JSON.parse(a.getElementsByClassName(CSS_CLASS_NAMES.page_data)[0].getAttribute("data-data")),this.ctm=this.page_data.ctm,this.ictm=invert(this.ctm),this.loaded=!0)}}
Page.prototype={hide:function(){this.loaded&&this.shown&&(this.content_box.classList.remove("opened"),this.shown=!1)},show:function(){this.loaded&&!this.shown&&(this.content_box.classList.add("opened"),this.shown=!0)},rescale:function(a){this.cur_scale=0===a?this.original_scale:a;this.loaded&&(a=this.content_box.style,a.msTransform=a.webkitTransform=a.transform="scale("+this.cur_scale.toFixed(3)+")");a=this.page.style;a.height=this.original_height*this.cur_scale+"px";a.width=this.original_width*this.cur_scale+
"px"},view_position:function(){var a=this.page,b=a.parentNode;return[b.scrollLeft-a.offsetLeft-a.clientLeft,b.scrollTop-a.offsetTop-a.clientTop]},height:function(){return this.page.clientHeight},width:function(){return this.page.clientWidth}};function Viewer(a){this.config=clone_and_extend_objs(DEFAULT_CONFIG,0<arguments.length?a:{});this.pages_loading=[];this.init_before_loading_content();var b=this;document.addEventListener("DOMContentLoaded",function(){b.init_after_loading_content()},!1)}
Viewer.prototype={scale:1,cur_page_idx:0,first_page_idx:0,init_before_loading_content:function(){this.pre_hide_pages()},initialize_radio_button:function(){for(var a=document.getElementsByClassName(CSS_CLASS_NAMES.input_radio),b=0;b<a.length;b++)a[b].addEventListener("click",function(){this.classList.toggle("checked")})},init_after_loading_content:function(){this.sidebar=document.getElementById(this.config.sidebar_id);this.outline=document.getElementById(this.config.outline_id);this.container=document.getElementById(this.config.container_id);
this.loading_indicator=document.getElementsByClassName(this.config.loading_indicator_cls)[0];for(var a=!0,b=this.outline.childNodes,c=0,e=b.length;c<e;++c)if("ul"===b[c].nodeName.toLowerCase()){a=!1;break}a||this.sidebar.classList.add("opened");this.find_pages();if(0!=this.pages.length){disable_dragstart(document.getElementsByClassName(CSS_CLASS_NAMES.background_image));this.config.key_handler&&this.register_key_handler();var h=this;this.config.hashchange_handler&&window.addEventListener("hashchange",
function(a){h.navigate_to_dest(document.location.hash.substring(1))},!1);this.config.view_history_handler&&window.addEventListener("popstate",function(a){a.state&&h.navigate_to_dest(a.state)},!1);this.container.addEventListener("scroll",function(){h.update_page_idx();h.schedule_render(!0)},!1);[this.outline].concat(Array.from(this.container.querySelectorAll("a.l"))).forEach(function(a){a.addEventListener("click",h.link_handler.bind(h),!1)});this.initialize_radio_button();this.render()}},find_pages:function(){for(var a=
[],b={},c=this.container.childNodes,e=0,h=c.length;e<h;++e){var d=c[e];d.nodeType===Node.ELEMENT_NODE&&d.classList.contains(CSS_CLASS_NAMES.page_frame)&&(d=new Page(d),a.push(d),b[d.num]=a.length-1)}this.pages=a;this.page_map=b},load_page:function(a,b,c){var e=this.pages;if(!(a>=e.length||(e=e[a],e.loaded||this.pages_loading[a]))){var e=e.page,h=e.getAttribute("data-page-url");if(h){this.pages_loading[a]=!0;var d=e.getElementsByClassName(this.config.loading_indicator_cls)[0];"undefined"===typeof d&&
(d=this.loading_indicator.cloneNode(!0),d.classList.add("active"),e.appendChild(d));var f=this,g=new XMLHttpRequest;g.open("GET",h,!0);g.onload=function(){if(200===g.status||0===g.status){var b=document.createElement("div");b.innerHTML=g.responseText;for(var d=null,b=b.childNodes,e=0,h=b.length;e<h;++e){var p=b[e];if(p.nodeType===Node.ELEMENT_NODE&&p.classList.contains(CSS_CLASS_NAMES.page_frame)){d=p;break}}b=f.pages[a];f.container.replaceChild(d,b.page);b=new Page(d);f.pages[a]=b;b.hide();b.rescale(f.scale);
disable_dragstart(d.getElementsByClassName(CSS_CLASS_NAMES.background_image));f.schedule_render(!1);c&&c(b)}delete f.pages_loading[a]};g.send(null)}void 0===b&&(b=this.config.preload_pages);0<--b&&(f=this,setTimeout(function(){f.load_page(a+1,b)},0))}},pre_hide_pages:function(){var a="@media screen{."+CSS_CLASS_NAMES.page_content_box+"{display:none;}}",b=document.createElement("style");b.styleSheet?b.styleSheet.cssText=a:b.appendChild(document.createTextNode(a));document.head.appendChild(b)},render:function(){for(var a=
this.container,b=a.scrollTop,c=a.clientHeight,a=b-c,b=b+c+c,c=this.pages,e=0,h=c.length;e<h;++e){var d=c[e],f=d.page,g=f.offsetTop+f.clientTop,f=g+f.clientHeight;g<=b&&f>=a?d.loaded?d.show():this.load_page(e):d.hide()}},update_page_idx:function(){var a=this.pages,b=a.length;if(!(2>b)){for(var c=this.container,e=c.scrollTop,c=e+c.clientHeight,h=-1,d=b,f=d-h;1<f;){var g=h+Math.floor(f/2),f=a[g].page;f.offsetTop+f.clientTop+f.clientHeight>=e?d=g:h=g;f=d-h}this.first_page_idx=d;for(var g=h=this.cur_page_idx,
k=0;d<b;++d){var f=a[d].page,l=f.offsetTop+f.clientTop,f=f.clientHeight;if(l>c)break;f=(Math.min(c,l+f)-Math.max(e,l))/f;if(d===h&&Math.abs(f-1)<=EPS){g=h;break}f>k&&(k=f,g=d)}this.cur_page_idx=g}},schedule_render:function(a){if(void 0!==this.render_timer){if(!a)return;clearTimeout(this.render_timer)}var b=this;this.render_timer=setTimeout(function(){delete b.render_timer;b.render()},this.config.render_timeout)},register_key_handler:function(){var a=this;window.addEventListener("DOMMouseScroll",function(b){if(b.ctrlKey){b.preventDefault();
var c=a.container,e=c.getBoundingClientRect(),c=[b.clientX-e.left-c.clientLeft,b.clientY-e.top-c.clientTop];a.rescale(Math.pow(a.config.scale_step,b.detail),!0,c)}},!1);window.addEventListener("keydown",function(b){var c=!1,e=b.ctrlKey||b.metaKey,h=b.altKey;switch(b.keyCode){case 61:case 107:case 187:e&&(a.rescale(1/a.config.scale_step,!0),c=!0);break;case 173:case 109:case 189:e&&(a.rescale(a.config.scale_step,!0),c=!0);break;case 48:e&&(a.rescale(0,!1),c=!0);break;case 33:h?a.scroll_to(a.cur_page_idx-
1):a.container.scrollTop-=a.container.clientHeight;c=!0;break;case 34:h?a.scroll_to(a.cur_page_idx+1):a.container.scrollTop+=a.container.clientHeight;c=!0;break;case 35:a.container.scrollTop=a.container.scrollHeight;c=!0;break;case 36:a.container.scrollTop=0,c=!0}c&&b.preventDefault()},!1)},rescale:function(a,b,c){var e=this.scale;this.scale=a=0===a?1:b?e*a:a;c||(c=[0,0]);b=this.container;c[0]+=b.scrollLeft;c[1]+=b.scrollTop;for(var h=this.pages,d=h.length,f=this.first_page_idx;f<d;++f){var g=h[f].page;
if(g.offsetTop+g.clientTop>=c[1])break}g=f-1;0>g&&(g=0);var g=h[g].page,k=g.clientWidth,f=g.clientHeight,l=g.offsetLeft+g.clientLeft,m=c[0]-l;0>m?m=0:m>k&&(m=k);k=g.offsetTop+g.clientTop;c=c[1]-k;0>c?c=0:c>f&&(c=f);for(f=0;f<d;++f)h[f].rescale(a);b.scrollLeft+=m/e*a+g.offsetLeft+g.clientLeft-m-l;b.scrollTop+=c/e*a+g.offsetTop+g.clientTop-c-k;this.schedule_render(!0)},fit_width:function(){var a=this.cur_page_idx;this.rescale(this.container.clientWidth/this.pages[a].width(),!0);this.scroll_to(a)},fit_height:function(){var a=
this.cur_page_idx;this.rescale(this.container.clientHeight/this.pages[a].height(),!0);this.scroll_to(a)},get_containing_page:function(a){for(;a;){if(a.nodeType===Node.ELEMENT_NODE&&a.classList.contains(CSS_CLASS_NAMES.page_frame)){a=get_page_number(a);var b=this.page_map;return a in b?this.pages[b[a]]:null}a=a.parentNode}return null},link_handler:function(a){var b=a.target,c=b.getAttribute("data-dest-detail");c||(b=a.currentTarget,c=b.getAttribute("data-dest-detail"));if(c){if(this.config.view_history_handler)try{var e=
this.get_current_view_hash();window.history.replaceState(e,"","#"+e);window.history.pushState(c,"","#"+c)}catch(h){}this.navigate_to_dest(c,this.get_containing_page(b));a.preventDefault()}},navigate_to_dest:function(a,b){try{var c=JSON.parse(a)}catch(e){return}if(c instanceof Array){var h=c[0],d=this.page_map;if(h in d){for(var f=d[h],h=this.pages[f],d=2,g=c.length;d<g;++d){var k=c[d];if(null!==k&&"number"!==typeof k)return}for(;6>c.length;)c.push(null);var g=b||this.pages[this.cur_page_idx],d=g.view_position(),
d=transform(g.ictm,[d[0],g.height()-d[1]]),g=this.scale,l=[0,0],m=!0,k=!1,n=this.scale;switch(c[1]){case "XYZ":l=[null===c[2]?d[0]:c[2]*n,null===c[3]?d[1]:c[3]*n];g=c[4];if(null===g||0===g)g=this.scale;k=!0;break;case "Fit":case "FitB":l=[0,0];k=!0;break;case "FitH":case "FitBH":l=[0,null===c[2]?d[1]:c[2]*n];k=!0;break;case "FitV":case "FitBV":l=[null===c[2]?d[0]:c[2]*n,0];k=!0;break;case "FitR":l=[c[2]*n,c[5]*n],m=!1,k=!0}if(k){this.rescale(g,!1);var p=this,c=function(a){l=transform(a.ctm,l);m&&
(l[1]=a.height()-l[1]);p.scroll_to(f,l)};h.loaded?c(h):(this.load_page(f,void 0,c),this.scroll_to(f))}}}},scroll_to:function(a,b){var c=this.pages;if(!(0>a||a>=c.length)){c=c[a].view_position();void 0===b&&(b=[0,0]);var e=this.container;e.scrollLeft+=b[0]-c[0];e.scrollTop+=b[1]-c[1]}},get_current_view_hash:function(){var a=[],b=this.pages[this.cur_page_idx];a.push(b.num);a.push("XYZ");var c=b.view_position(),c=transform(b.ictm,[c[0],b.height()-c[1]]);a.push(c[0]/this.scale);a.push(c[1]/this.scale);
a.push(this.scale);return JSON.stringify(a)}};pdf2htmlEX.Viewer=Viewer;})();
</script>
<script>
try{
pdf2htmlEX.defaultViewer = new pdf2htmlEX.Viewer({});
}catch(e){}
</script>
<title></title>
</head>
<body>
<div id="sidebar">
<div id="outline">
</div>
</div>
<div id="page-container">
<div id="pf1" class="pf w0 h0" data-page-no="1"><div class="pc pc1 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x1 h1 y1 ff1 fs0 fc0 sc0 ls0 ws0"><span class="fc2 sc0">https://doi.org/10.1177/1060028017697424</span></div><div class="t m0 x1 h2 y2 ff1 fs1 fc1 sc0 ls0 ws0">Annals of Pharmacotherapy</div><div class="t m0 x1 h2 y3 ff1 fs1 fc1 sc0 ls0 ws0">2017, Vol. 51(6) 488 <span class="_ _0"></span>–495</div><div class="t m0 x1 h2 y4 ff1 fs1 fc1 sc0 ls0 ws0">© The Author(s) 2017</div><div class="t m0 x1 h2 y5 ff1 fs1 fc1 sc0 ls0 ws0">Reprints and permissions: </div><div class="t m0 x1 h2 y6 ff1 fs1 fc1 sc0 ls0 ws0">sagepub.com/journalsPermissions.nav</div><div class="t m0 x1 h2 y7 ff1 fs1 fc1 sc0 ls0 ws0">DOI: 10.1177/1060028017697424</div><div class="t m0 x1 h2 y8 ff1 fs1 fc1 sc0 ls0 ws0">journals.sagepub.com/home/aop</div><div class="t m0 x2 h3 y9 ff2 fs2 fc1 sc0 ls0 ws0">Review Article-New Drug Approval</div><div class="t m0 x2 h4 ya ff3 fs3 fc1 sc0 ls0 ws0">Introduction</div><div class="t m0 x2 h5 yb ff4 fs2 fc1 sc0 ls1 ws1">Pulmonary hypertension (PH) is defined as a mean pulmo<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 yc ff4 fs2 fc1 sc0 ls1 ws2">nary arterial pressure <span class="ff5 ls0 ws0">≥</span>25 mm Hg during right heart catheter<span class="_ _1"></span><span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 yd ff4 fs2 fc1 sc0 ls1 ws3">ization.</div><div class="t m0 x3 h6 ye ff4 fs4 fc1 sc0 ls0 ws0">1</div><div class="t m0 x4 h5 yd ff4 fs2 fc1 sc0 ls1 ws4"> The most recent <span class="_ _1"></span>W<span class="_ _2"></span>orld Health Organization (WHO) </div><div class="t m0 x2 h5 yf ff4 fs2 fc1 sc0 ls1 ws5">clinical classification divides PH into 5 groups based on etiol<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y10 ff4 fs2 fc1 sc0 ls1 ws3">ogy<span class="_ _2"></span>.</div><div class="t m0 x5 h6 y11 ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x6 h5 y10 ff4 fs2 fc1 sc0 ls1 ws6"> WHO Group I is referred to as pulmonary arterial hyper<span class="_ _1"></span><span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y12 ff4 fs2 fc1 sc0 ls1 ws7">tension (P<span class="_ _2"></span>AH). Patients with P<span class="_ _3"></span>AH are further classified </div><div class="t m0 x2 h5 y13 ff4 fs2 fc1 sc0 ls1 ws8">according to a modified WHO functional classification (FC) </div><div class="t m0 x2 h5 y14 ff4 fs2 fc1 sc0 ls1 ws9">system. Class I is patients with PH but without resulting limi<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y15 ff4 fs2 fc1 sc0 ls1 wsa">tation of physical activity<span class="_ _2"></span>. Class II is patients comfortable at<span class="_ _4"></span> </div><div class="t m0 x2 h5 y16 ff4 fs2 fc1 sc0 ls1 wsb">rest but with slight limitation of physical activity<span class="_ _2"></span>. Class III is<span class="_ _4"></span> </div><div class="t m0 x2 h5 y17 ff4 fs2 fc1 sc0 ls1 wsc">patients, again comfortable at rest, but with marked limitation </div><div class="t m0 x2 h5 y18 ff4 fs2 fc1 sc0 ls1 wsd">of physical activity<span class="_ _2"></span>. Class IV is patients with marked symp<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y19 ff4 fs2 fc1 sc0 ls1 wse">toms at rest and unable to carry out any physical activity with<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y1a ff4 fs2 fc1 sc0 ls1 wsf">out symptoms as well as those with syncope. Understanding </div><div class="t m0 x2 h5 y1b ff4 fs2 fc1 sc0 ls1 ws10">these FCs is key in P<span class="_ _3"></span>AH management because improvement<span class="_ _4"></span> </div><div class="t m0 x2 h5 y1c ff4 fs2 fc1 sc0 ls1 ws0">from FC IV/III to II has resulted in improved prognosis.</div><div class="t m0 x7 h6 y1d ff4 fs4 fc1 sc0 ls0 ws0">3</div><div class="t m0 x8 h5 y1e ff4 fs2 fc1 sc0 ls0 ws11">Advanced therapy<span class="_ _2"></span>, or P<span class="_ _2"></span>AH-specific therapy<span class="_ _2"></span>, often </div><div class="t m0 x2 h5 y1f ff4 fs2 fc1 sc0 ls0 ws12">referred to as <span class="ff6">pulmonary vasodilator therapy</span> is directed at </div><div class="t m0 x9 h5 y20 ff4 fs2 fc1 sc0 ls0 wsd">the biochemical pathways involved in the pathogenesis of </div><div class="t m0 x9 h5 y21 ff4 fs2 fc1 sc0 ls0 ws13">PH, rather than the underlying cause of the PH.</div><div class="t m0 xa h6 y22 ff4 fs4 fc1 sc0 ls0 ws0">4</div><div class="t m0 xb h5 y23 ff4 fs2 fc1 sc0 ls0 ws13"> Current </div><div class="t m0 x9 h5 y24 ff4 fs2 fc1 sc0 ls0 ws14">therapeutic options include prostacyclin pathway agonists </div><div class="t m0 x9 h5 y25 ff4 fs2 fc1 sc0 ls0 ws15">(epoprostenol, treprostinil, and iloprost), endothelin recep<span class="ws0">-</span></div><div class="t m0 x9 h5 y26 ff4 fs2 fc1 sc0 ls0 ws16">tor antagonists (ERAs; ambrisentan, bosentan, macitentan), </div><div class="t m0 x9 h5 y27 ff4 fs2 fc1 sc0 ls0 ws17">phosphodiesterase type 5 (PDE-5) inhibitors (sildenafil, </div><div class="t m0 x9 h5 y28 ff4 fs2 fc1 sc0 ls0 ws18">tadalafil), and guanylate cyclase stimulant (riociguat).</div><div class="t m0 xc h6 y29 ff4 fs4 fc1 sc0 ls0 ws0">5</div><div class="t m0 xd h5 y28 ff4 fs2 fc1 sc0 ls0 ws0"> </div><div class="t m0 x9 h5 y2a ff4 fs2 fc1 sc0 ls0 ws19">Patients with persistent PH with WHO functional class II, </div><div class="t m0 x9 h5 y2b ff4 fs2 fc1 sc0 ls0 ws1a">III, or IV are considered for advanced therapy after diagnos<span class="ws0">-</span></div><div class="t m0 x9 h5 y2c ff4 fs2 fc1 sc0 ls0 ws1b">tic right heart catheterization with vasoreactivity testing and </div><div class="t m0 x9 h5 y2d ff4 fs2 fc1 sc0 ls0 ws1c">extensive investigations for the etiology of PH have been </div><div class="t m0 xe h7 y2e ff7 fs5 fc0 sc0 ls2 ws1d">697424<span class="ff1 fs6 ls3 ws1e">AO<span class="fc2 sc0">P</span></span></div><div class="t m0 xf h8 y2f ff4 fs6 fc0 sc0 ls0 ws0">X<span class="fc2 sc0">X</span>X10.1177/1060028017697424Annals of Pharmacotherapy<span class="ff3">Baker et al</span></div><div class="t m0 xe h8 y30 ff6 fs6 fc0 sc0 ls0 ws0">review-articl<span class="fc2 sc0">e</span><span class="ff4">2017</span></div><div class="t m0 x9 h9 y31 ff1 fs7 fc1 sc0 ls0 ws0">1</div><div class="t m0 x10 ha y32 ff1 fs8 fc1 sc0 ls0 ws0">University of Connecticut, Storrs, CT, USA</div><div class="t m0 x9 h9 y33 ff1 fs7 fc1 sc0 ls0 ws0">2</div><div class="t m0 x10 ha y34 ff1 fs8 fc1 sc0 ls0 ws0">Center for Advanced Heart Failure and Transplant, Hartford, CT, USA</div><div class="t m0 x9 h9 y35 ff1 fs7 fc1 sc0 ls0 ws0">3</div><div class="t m0 x10 ha y36 ff1 fs8 fc1 sc0 ls0 ws0">University of Connecticut/Hartford Hospital, CT, USA</div><div class="t m0 x9 h9 y37 ff1 fs7 fc1 sc0 ls0 ws0">4</div><div class="t m0 x10 ha y38 ff1 fs8 fc1 sc0 ls0 ws0">University of Connecticut School of Medicine, Hartford, CT, USA</div><div class="t m0 x9 hb y39 ff3 fs8 fc1 sc0 ls0 ws0">Corresponding Author:</div><div class="t m0 x9 ha y3a ff1 fs8 fc1 sc0 ls0 ws0">William L. Baker, University of Connecticut, School of Pharmacy, 69 N </div><div class="t m0 x9 ha y3b ff1 fs8 fc1 sc0 ls0 ws0">Eagleville Rd, Unit 3092, Storrs, CT 06269, USA. </div><div class="t m0 x9 ha y3c ff1 fs8 fc1 sc0 ls0 ws0">Email: william.baker_jr@uconn.edu</div><div class="t m0 x2 hc y3d ff3 fs9 fc1 sc0 ls0 ws0">Selexipag, an Oral Prostacyclin-</div><div class="t m0 x2 hc y3e ff3 fs9 fc1 sc0 ls0 ws0">Receptor Agonist for Pulmonary Arterial </div><div class="t m0 x2 hc y3f ff3 fs9 fc1 sc0 ls0 ws0">Hypertension</div><div class="t m0 x2 h4 y40 ff3 fs3 fc1 sc0 ls0 ws0">William L. Baker, PharmD, FCCP, FACC, FAHA</div><div class="t m0 x11 hd y41 ff3 fsa fc1 sc0 ls0 ws0">1</div><div class="t m0 x12 h4 y40 ff3 fs3 fc1 sc0 ls0 ws0">, Konstadina Darsaklis, MD</div><div class="t m0 x13 hd y41 ff3 fsa fc1 sc0 ls0 ws0">2</div><div class="t m0 x14 h4 y40 ff3 fs3 fc1 sc0 ls0 ws0">, </div><div class="t m0 x2 h4 y42 ff3 fs3 fc1 sc0 ls0 ws0">Aditi Singhvi, MD</div><div class="t m0 x15 hd y43 ff3 fsa fc1 sc0 ls0 ws0">3</div><div class="t m0 x16 h4 y44 ff3 fs3 fc1 sc0 ls0 ws0">, and Edward L. Salerno, MD, FCCP</div><div class="t m0 x17 hd y43 ff3 fsa fc1 sc0 ls0 ws0">4</div><div class="t m0 x2 h3 y45 ff3 fs2 fc1 sc0 ls0 ws0">Abstract</div><div class="t m0 x2 he y46 ff3 fs2 fc1 sc0 ls0 ws0">Objective:<span class="ff1 ws1f"> To evaluate the data supporting the approval of selexipag and discuss its potential place in therapy for </span></div><div class="t m0 x2 he y47 ff1 fs2 fc1 sc0 ls0 wsa">managing pulmonary arterial hypertension (PAH). <span class="ff3">Data Sources:</span> A systematic review of the literature for all relevant </div><div class="t m0 x2 he y48 ff1 fs2 fc1 sc0 ls0 ws20">articles was performed through January 16, 2017, using MEDLINE and SCOPUS. A manual search of references from </div><div class="t m0 x2 he y49 ff1 fs2 fc1 sc0 ls0 ws21">reports of clinical trials, review articles, and recent conference abstracts was performed to identify additional relevant </div><div class="t m0 x2 he y4a ff1 fs2 fc1 sc0 ls0 ws0">studies. <span class="_ _5"></span><span class="ff3 ws22">Study Selection and Data Extraction:<span class="ff1"> Eligible citations included in vitro or in vivo evaluations of selexipag, </span></span></div><div class="t m0 x2 he y4b ff1 fs2 fc1 sc0 ls0 ws23">with no restrictions on patient population or indication. Data related to the patient populations and outcomes of interest </div><div class="t m0 x2 he y4c ff1 fs2 fc1 sc0 ls0 ws24">were extracted from each citation. <span class="ff3">Data Synthesis:</span> Single phase II and phase III trials have been published evaluating </div><div class="t m0 x2 he y4d ff1 fs2 fc1 sc0 ls0 ws25">selexipag in patients with PAH. In 43 patients, the phase II trial showed that selexipag significantly reduced pulmonary </div><div class="t m0 x2 he y4e ff1 fs2 fc1 sc0 ls0 ws26">vascular resistance by 30% versus placebo (<span class="ff2 ws0">P</span> = 0.0045) and improved 6-minute walk distance by 24 m (<span class="ff2 ws0">P</span> &lt; 0.05). The </div><div class="t m0 x2 he y4f ff1 fs2 fc1 sc0 ls0 ws27">larger phase III trial enrolled 1156 patients with PAH, showing that selexipag lowered the incidence of death or PAH-</div><div class="t m0 x2 he y50 ff1 fs2 fc1 sc0 ls0 ws28">related complications by 40% versus placebo (<span class="ff2 ws0">P</span> &lt; 0.001). Selexipag also improved 6-minute walk distance and lowered </div><div class="t m0 x2 he y51 ff1 fs2 fc1 sc0 ls0 ws1a">hospitalization risk. Common adverse events included headache, diarrhea, nausea, and jaw pain. <span class="ff3 ws0">Conclusions:</span> The specific </div><div class="t m0 x2 he y52 ff1 fs2 fc1 sc0 ls0 ws29">role of selexipag for managing PAH patients is unclear because of its modest efficacy, lack of mortality reduction, and cost </div><div class="t m0 x2 he y53 ff1 fs2 fc1 sc0 ls0 ws2a">similar to intravenous prostacyclins. Additional clinical trials exploring combination therapy as well as its role in other types </div><div class="t m0 x2 he y54 ff1 fs2 fc1 sc0 ls0 ws0">of pulmonary hypertension are needed.</div><div class="t m0 x2 h3 y55 ff3 fs2 fc1 sc0 ls0 ws0">Keywords</div><div class="t m0 x2 he y56 ff1 fs2 fc1 sc0 ls0 ws0">selexipag, prostacyclin-receptor agonist, pulmonary arterial hypertension</div><a class="l" href="https://us.sagepub.com/en-us/journals-permissions"><div class="d m1" style="border-style:none;position:absolute;left:518.760000px;bottom:817.171200px;width:105.432000px;height:8.127000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="https://journals.sagepub.com/home/aop"><div class="d m1" style="border-style:none;position:absolute;left:518.760000px;bottom:796.771200px;width:90.705000px;height:8.127000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="mailto:william.baker_jr@uconn.edu"><div class="d m1" style="border-style:none;position:absolute;left:388.876800px;bottom:81.401520px;width:92.926000px;height:9.288000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf2" class="pf w0 h0" data-page-no="2"><div class="pc pc2 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x18 he y57 ff2 fs2 fc1 sc0 ls0 ws0">Baker et al <span class="_ _6"> </span><span class="ff1">489</span></div><div class="t m0 x18 h5 y58 ff4 fs2 fc1 sc0 ls0 ws0">performed.</div><div class="t m0 x19 h6 y59 ff4 fs4 fc1 sc0 ls0 ws0">5</div><div class="t m0 x1a h5 y58 ff4 fs2 fc1 sc0 ls0 ws2b"> <span class="_ _2"></span>After initiating therapy<span class="_ _1"></span>, most patients are fol<span class="ws0">-</span></div><div class="t m0 x18 h5 y5a ff4 fs2 fc1 sc0 ls0 ws2c">lowed within 4 to 6 weeks to evaluate the clinical and </div><div class="t m0 x18 h5 y5b ff4 fs2 fc1 sc0 ls0 ws2d">hemodynamic response. Patients with refractory P<span class="_ _3"></span>AH may </div><div class="t m0 x18 h5 y5c ff4 fs2 fc1 sc0 ls0 ws0">require alternate or combination therapy<span class="_ _2"></span>.</div><div class="t m0 x1b h5 y5d ff4 fs2 fc1 sc0 ls4 ws2e">Until recently<span class="_ _2"></span>, prostacyclin pathway agonists have </div><div class="t m0 x18 h5 y5e ff4 fs2 fc1 sc0 ls4 ws2f">included parenteral and inhaled analogs of prostacyclin, </div><div class="t m0 x18 h5 y5f ff4 fs2 fc1 sc0 ls4 ws30">including epoprostenol, iloprost, and treprostinil. The bur<span class="_ _1"></span><span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y60 ff4 fs2 fc1 sc0 ls4 ws31">den and risks associated with parenteral prostacyclin ago<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y61 ff4 fs2 fc1 sc0 ls4 ws32">nist therapy are the following: need for parenteral </div><div class="t m0 x18 h5 y62 ff4 fs2 fc1 sc0 ls4 ws33">administration, use of continuous infusion pumps, throm<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y63 ff4 fs2 fc1 sc0 ls4 ws33">botic and infectious complications, possible life-threaten<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y64 ff4 fs2 fc1 sc0 ls4 ws34">ing situation with interruption of infusion, and severe pain </div><div class="t m0 x18 h5 y65 ff4 fs2 fc1 sc0 ls4 ws35">with subcutaneous injections.</div><div class="t m0 x1c h6 y66 ff4 fs4 fc1 sc0 ls5 ws36">4,5</div><div class="t m0 x1d h5 y65 ff4 fs2 fc1 sc0 ls4 ws35"> Inhaled prostacyclin ana<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y67 ff4 fs2 fc1 sc0 ls4 ws37">logues can also be cumbersome and difficult for certain<span class="_ _1"></span> </div><div class="t m0 x18 h5 y68 ff4 fs2 fc1 sc0 ls4 ws38">patient populations to administer<span class="_ _2"></span>. <span class="_ _1"></span>Also, inhaled therapies </div><div class="t m0 x18 h5 y69 ff4 fs2 fc1 sc0 ls4 ws39">leave patients without any doses of medication during </div><div class="t m0 x18 h5 y6a ff4 fs2 fc1 sc0 ls4 ws3a">their hours of sleep. T<span class="_ _3"></span>o that end, the new oral nonpros<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y6b ff4 fs2 fc1 sc0 ls4 ws23">tanoid prostacyclin receptor agonist selexipag is a reason<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y6c ff4 fs2 fc1 sc0 ls4 ws3b">able alternative for certain P<span class="_ _3"></span>AH patient populations. This </div><div class="t m0 x18 h5 y6d ff4 fs2 fc1 sc0 ls4 ws3c">review discusses the data supporting its approval and </div><div class="t m0 x18 h5 y6e ff4 fs2 fc1 sc0 ls4 ws0">potential place in therapy<span class="_ _2"></span>.</div><div class="t m0 x18 h4 y6f ff3 fs3 fc1 sc0 ls0 ws0">Data Selection</div><div class="t m0 x18 h5 y70 ff4 fs2 fc1 sc0 ls0 wsc">A<span class="_ _2"></span> systematic review of the literature for all relevant articles </div><div class="t m0 x18 h5 y71 ff4 fs2 fc1 sc0 ls0 ws3d">was performed through January 16, 2017, using MEDLINE </div><div class="t m0 x18 h5 y72 ff4 fs2 fc1 sc0 ls0 ws3e">(n = 62) and SCOPUS (n = 162), beginning January 1950. </div><div class="t m0 x18 h5 y73 ff4 fs2 fc1 sc0 ls0 ws3f">The search strategy was developed using the keywords and </div><div class="t m0 x18 h5 y74 ff4 fs2 fc1 sc0 ls0 ws40">medical subject headings (MeSH) <span class="ff6 ws0">selexipag<span class="ff4">, <span class="_ _4"></span></span>ACT<span class="_ _1"></span>-293987<span class="ff4">, </span></span></div><div class="t m0 x18 h5 y75 ff6 fs2 fc1 sc0 ls0 ws0">NS-304<span class="ff4 ws41">, and </span>MRE-269<span class="ff4 ws41">. Citations were limited to those pub<span class="ws0">-</span></span></div><div class="t m0 x18 h5 y76 ff4 fs2 fc1 sc0 ls0 ws42">lished in the English language. <span class="_ _2"></span>A<span class="_ _1"></span> manual search of refer<span class="ws0">-</span></div><div class="t m0 x18 h5 y77 ff4 fs2 fc1 sc0 ls0 ws43">ences from reports of clinical trials or review articles was </div><div class="t m0 x18 h5 y78 ff4 fs2 fc1 sc0 ls0 ws44">performed to identify additional relevant studies. </div><div class="t m0 x18 h5 y79 ff4 fs2 fc1 sc0 ls0 ws1b">Conference abstracts from the <span class="_ _2"></span>American College of Clinical </div><div class="t m0 x18 h5 y7a ff4 fs2 fc1 sc0 ls0 ws45">Pharmacology<span class="_ _2"></span>, <span class="_ _1"></span>American College of Cardiology<span class="_ _2"></span>, <span class="_ _1"></span>American </div><div class="t m0 x18 h5 y7b ff4 fs2 fc1 sc0 ls0 ws46">Heart <span class="_ _2"></span>Association, and European Society of Cardiology </div><div class="t m0 x18 h5 y7c ff4 fs2 fc1 sc0 ls0 ws47">were searched for the past 5 years. Citations were eligible </div><div class="t m0 x18 h5 y7d ff4 fs2 fc1 sc0 ls0 ws48">for inclusion in this review if they were in vitro or in vivo </div><div class="t m0 x18 h5 y7e ff4 fs2 fc1 sc0 ls0 ws49">evaluations of selexipag. <span class="_ _2"></span>A<span class="_ _1"></span> total of 20 investigations were </div><div class="t m0 x18 h5 y7f ff4 fs2 fc1 sc0 ls0 ws4a">found and included in this review<span class="_ _2"></span>.</div><div class="t m0 x1e h6 y80 ff4 fs4 fc1 sc0 ls0 ws0">6-25</div><div class="t m0 x1f h5 y7f ff4 fs2 fc1 sc0 ls0 ws4a"> Three citations were </div><div class="t m0 x18 h5 y81 ff4 fs2 fc1 sc0 ls0 ws4b">only in abstract form,</div><div class="t m0 x20 h6 y82 ff4 fs4 fc1 sc0 ls0 ws0">9,10,24</div><div class="t m0 x21 h5 y81 ff4 fs2 fc1 sc0 ls0 ws4b"> with the remainder being full-</div><div class="t m0 x18 h5 y83 ff4 fs2 fc1 sc0 ls0 ws4c">text articles. <span class="_ _2"></span>A<span class="_ _1"></span> search of ClinicalT<span class="_ _1"></span>rials.gov (http://www<span class="_ _2"></span>.</div><div class="t m0 x18 h5 y84 ff4 fs2 fc1 sc0 ls0 ws4d">clinicaltrials.gov) was also conducted to identify additional </div><div class="t m0 x18 h5 y85 ff4 fs2 fc1 sc0 ls0 ws0">recently completed or ongoing studies of relevance.</div><div class="t m0 x18 h4 y86 ff3 fs3 fc1 sc0 ls0 ws0">Chemistry and Pharmacology</div><div class="t m0 x18 h5 y87 ff4 fs2 fc1 sc0 ls6 ws4e">Selexipag [2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)</div><div class="t m0 x18 h5 y88 ff4 fs2 fc1 sc0 ls7 ws16">amino]butoxyl}-<span class="ff6 ls0 ws0">N</span><span class="ws4f">-(methylsulfonyl)acetamide] is an </span></div><div class="t m0 x18 h5 y89 ff4 fs2 fc1 sc0 ls7 ws50">orally available prodrug that is <span class="_ _1"></span>ra<span class="_ _1"></span>pi<span class="_ _1"></span>d<span class="_ _1"></span>ly<span class="_ _1"></span> h<span class="_ _1"></span>yd<span class="_ _1"></span>ro<span class="_ _1"></span>ly<span class="_ _1"></span>ze<span class="_ _1"></span>d <span class="_ _1"></span>by<span class="_ _1"></span> </div><div class="t m0 x18 h5 y8a ff4 fs2 fc1 sc0 ls8 ws51">hepatic microsomes to its active metabolite, {4-[(5,6-<span class="ls0 ws0"> </span></div><div class="t m0 x18 h5 y8b ff4 fs2 fc1 sc0 ls8 ws52">diphenylpyrazin-2-yl)(isopropyl)amino]butoxyl}acetic acid </div><div class="t m0 x18 h5 y8c ff4 fs2 fc1 sc0 ls8 ws53">(ACT<span class="_ _3"></span>-333679, previously known as MRE-269).</div><div class="t m0 x7 h6 y8d ff4 fs4 fc1 sc0 ls9 ws54">6,7</div><div class="t m0 x22 h5 y8c ff4 fs2 fc1 sc0 ls8 ws55"> ACT<span class="_ _3"></span>-</div><div class="t m0 x18 h5 y8e ff4 fs2 fc1 sc0 ls8 ws56">333679 has been shown to be a potent and selective agonist </div><div class="t m0 x23 h5 y58 ff4 fs2 fc1 sc0 ls8 ws57">of the prostaglandin I</div><div class="t m0 x24 h6 y8f ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x25 h5 y58 ff4 fs2 fc1 sc0 ls8 ws57"> (PGI2), also known as the IP<span class="_ _3"></span>, recep<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y5a ff4 fs2 fc1 sc0 ls8 ws3f">tor<span class="_ _2"></span>.</div><div class="t m0 x26 h6 y90 ff4 fs4 fc1 sc0 ls0 ws0">7</div><div class="t m0 x27 h5 y5a ff4 fs2 fc1 sc0 ls8 ws30"> Selexipag differs from the currently available PGI</div><div class="t m0 x28 h6 y91 ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x29 h5 y5a ff4 fs2 fc1 sc0 ls8 ws30"> ana<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y5b ff4 fs2 fc1 sc0 ls8 ws8">logues in that it is a nonprostanoid IP<span class="_ _1"></span> agonist. The binding </div><div class="t m0 x23 h5 y5c ff4 fs2 fc1 sc0 ls8 ws58">affinity of <span class="_ _2"></span>ACT<span class="_ _3"></span>-333679 for the human IP <span class="_ _1"></span>receptor is also </div><div class="t m0 x23 h5 y5d ff4 fs2 fc1 sc0 ls8 ws59">&gt;130 times higher than its affinity for other human pros<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y5e ff4 fs2 fc1 sc0 ls8 ws5a">tanoid receptors.</div><div class="t m0 x2a h6 y92 ff4 fs4 fc1 sc0 ls0 ws0">7</div><div class="t m0 x2b h5 y5e ff4 fs2 fc1 sc0 ls8 ws5a"> It has lower affinity for the prostaglandin </div><div class="t m0 x23 h5 y5f ff4 fs2 fc1 sc0 ls8 ws5b">E receptor subtypes than other PGI</div><div class="t m0 x2c h6 y93 ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x2d h5 y5f ff4 fs2 fc1 sc0 ls8 ws5b"> analogues, such as ilo<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y60 ff4 fs2 fc1 sc0 ls8 ws5c">prost and beraprost. It has been proposed that the nonpros<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y61 ff4 fs2 fc1 sc0 ls8 ws5d">tenoid structure of selexipag in concert with its receptor </div><div class="t m0 x23 h5 y62 ff4 fs2 fc1 sc0 ls8 ws1a">specificity could diminish some of the known adverse events </div><div class="t m0 x23 h5 y63 ff4 fs2 fc1 sc0 ls8 ws5e">of PGI</div><div class="t m0 x17 h6 y94 ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x2e h5 y63 ff4 fs2 fc1 sc0 ls8 ws5e"> analogues, including gastrointestinal adverse </div><div class="t m0 x23 h5 y64 ff4 fs2 fc1 sc0 ls8 ws3f">events.</div><div class="t m0 x2f h6 y95 ff4 fs4 fc1 sc0 ls0 ws0">8</div><div class="t m0 x30 h5 y64 ff4 fs2 fc1 sc0 ls8 ws5f"> The beneficial vasodilatory properties persist </div><div class="t m0 x23 h5 y65 ff4 fs2 fc1 sc0 ls8 ws3">despite repeated treatment, suggesting that severe desensiti<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y67 ff4 fs2 fc1 sc0 ls8 wsa">zation of the IP<span class="_ _1"></span> receptor in rats is unlikely to occur<span class="_ _2"></span>.</div><div class="t m0 x31 h6 y96 ff4 fs4 fc1 sc0 ls9 ws54">9,10</div><div class="t m0 x32 h5 y67 ff4 fs2 fc1 sc0 ls8 wsa"> Rat </div><div class="t m0 x23 h5 y68 ff4 fs2 fc1 sc0 ls8 ws60">studies also have shown selexipag to attenuate vascular </div><div class="t m0 x23 h5 y69 ff4 fs2 fc1 sc0 ls8 ws61">endothelial dysfunction, and pulmonary arterial wall and </div><div class="t m0 x23 h5 y6a ff4 fs2 fc1 sc0 ls8 ws62">right ventricular hypertrophy; increase right ventricular sys<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y6b ff4 fs2 fc1 sc0 ls8 ws38">tolic pressure; and prolong life.</div><div class="t m0 x33 h6 y97 ff4 fs4 fc1 sc0 lsa ws63">11</div><div class="t m0 x34 h5 y6b ff4 fs2 fc1 sc0 ls8 ws38"> More specifically<span class="_ _2"></span>, selexi<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y6c ff4 fs2 fc1 sc0 ls8 ws3d">pag and <span class="_ _2"></span>ACT<span class="_ _2"></span>-333679 relax the pulmonary artery under P<span class="_ _3"></span>AH<span class="_ _4"></span> </div><div class="t m0 x23 h5 y6d ff4 fs2 fc1 sc0 ls8 ws64">conditions in a concentration-dependent manner<span class="_ _1"></span>, a property </div><div class="t m0 x23 h5 y6e ff4 fs2 fc1 sc0 ls8 ws65">not replicated with treprostinil.</div><div class="t m0 x35 h6 y98 ff4 fs4 fc1 sc0 ls9 ws54">12</div><div class="t m0 x33 h5 y6e ff4 fs2 fc1 sc0 ls8 ws65"> Selexipag and <span class="_ _2"></span>ACT<span class="_ _2"></span>-333679 </div><div class="t m0 x23 h5 y99 ff4 fs2 fc1 sc0 ls8 ws66">do not appear to have any effect of cardiac repolarization, </div><div class="t m0 x23 h5 y9a ff4 fs2 fc1 sc0 ls8 ws67">with little prolongation of the QT<span class="_ _2"></span>c interval shown at doses of </div><div class="t m0 x23 h5 y9b ff4 fs2 fc1 sc0 ls8 ws0">800 and 1600 µg.</div><div class="t m0 x2b h6 y9c ff4 fs4 fc1 sc0 ls9 ws54">13</div><div class="t m0 x23 h4 y9d ff3 fs3 fc1 sc0 ls0 ws0">Pharmacokinetics</div><div class="t m0 x23 h5 y73 ff4 fs2 fc1 sc0 ls0 ws20">Selexipag demonstrates dose-proportional pharmacokinet<span class="ws0">-</span></div><div class="t m0 x23 h5 y74 ff4 fs2 fc1 sc0 ls0 ws6">ics with no accumulation seen following multiple doses.</div><div class="t m0 xd h6 y9e ff4 fs4 fc1 sc0 ls0 ws0">14,26</div><div class="t m0 x36 h5 y74 ff4 fs2 fc1 sc0 ls0 ws0"> </div><div class="t m0 x23 h5 y75 ff4 fs2 fc1 sc0 ls0 ws68">It has an oral bioavailability of around 50% (range 42.6%-</div><div class="t m0 x23 h5 y76 ff4 fs2 fc1 sc0 ls0 ws23">57.2%), which can be delayed if given with a high-fat meal </div><div class="t m0 x23 h5 y77 ff4 fs2 fc1 sc0 ls0 ws45">(although the extent of absorption remains unchanged).</div><div class="t m0 xd h6 y9f ff4 fs4 fc1 sc0 ls0 ws0">15,16</div><div class="t m0 x36 h5 y77 ff4 fs2 fc1 sc0 ls0 ws0"> </div><div class="t m0 x23 h5 y78 ff4 fs2 fc1 sc0 ls0 ws69">Following absorption, it is hydrolyzed by carboxylester<span class="ws0">-</span></div><div class="t m0 x23 h5 y79 ff4 fs2 fc1 sc0 ls0 ws6a">ase-1 to its active metabolite <span class="_ _2"></span>ACT<span class="_ _2"></span>-333679. Both com<span class="ws0">-</span></div><div class="t m0 x23 h5 y7a ff4 fs2 fc1 sc0 ls0 ws6b">pounds are ~99% protein bound.</div><div class="t m0 x37 h6 ya0 ff4 fs4 fc1 sc0 ls0 ws0">17</div><div class="t m0 x38 h5 y7a ff4 fs2 fc1 sc0 ls0 ws6b"> Selexipag is also </div><div class="t m0 x23 h5 y7b ff4 fs2 fc1 sc0 ls0 ws6c">metabolized by CYP3A4 and CYP2C8 to less active metab<span class="ws0">-</span></div><div class="t m0 x23 h5 y7c ff4 fs2 fc1 sc0 ls0 ws6d">olites, whereas <span class="_ _2"></span>ACT<span class="_ _2"></span>-333679 is metabolized by UGT1A3 </div><div class="t m0 x23 h5 y7d ff4 fs2 fc1 sc0 ls0 wse">and UGT2B7.</div><div class="t m0 x39 h6 ya1 ff4 fs4 fc1 sc0 ls0 ws0">26,27</div><div class="t m0 x3a h5 y7d ff4 fs2 fc1 sc0 ls0 wse"> Maximal plasma concentrations of selex<span class="ws0">-</span></div><div class="t m0 x23 h5 y7e ff4 fs2 fc1 sc0 ls0 ws5c">ipag and <span class="_ _2"></span>ACT<span class="_ _2"></span>-333679 are reached within 2.5 and 4 hours, </div><div class="t m0 x23 h5 y7f ff4 fs2 fc1 sc0 ls0 ws6e">respectively<span class="_ _2"></span>, whereas steady-state concentrations are </div><div class="t m0 x23 h5 y81 ff4 fs2 fc1 sc0 ls0 ws68">reached within 3 days.</div><div class="t m0 x3b h6 y82 ff4 fs4 fc1 sc0 ls0 ws0">14,15</div><div class="t m0 x3c h5 y81 ff4 fs2 fc1 sc0 ls0 ws68"> The terminal half-life of each is </div><div class="t m0 x23 h5 y83 ff4 fs2 fc1 sc0 ls0 ws6f">1.4 (selexipag) and 8.7 hours (ACT<span class="_ _3"></span>-333679).</div><div class="t m0 x3d h6 ya2 ff4 fs4 fc1 sc0 ls0 ws0">14</div><div class="t m0 xb h5 y83 ff4 fs2 fc1 sc0 ls0 ws6f"> Elimination </div><div class="t m0 x23 h5 y84 ff4 fs2 fc1 sc0 ls0 ws70">of both compounds is almost exclusively through the liver<span class="_ _2"></span>.</div><div class="t m0 x3e h6 ya3 ff4 fs4 fc1 sc0 ls0 ws0">18</div><div class="t m0 x36 h5 y84 ff4 fs2 fc1 sc0 ls0 ws0"> </div><div class="t m0 x23 h5 y85 ff4 fs2 fc1 sc0 ls0 ws5a">Not surprisingly<span class="_ _2"></span>, recent data show that area under the con<span class="ws0">-</span></div><div class="t m0 x23 h5 ya4 ff4 fs2 fc1 sc0 ls0 ws71">centration-time curve from zero to infinity (AUC</div><div class="t m0 x3f h6 ya5 ff4 fs4 fc1 sc0 ls0 ws0">0-<span class="ff5">∝</span></div><div class="t m0 x40 h5 ya4 ff4 fs2 fc1 sc0 ls0 ws0">) </div><div class="t m0 x23 h5 ya6 ff4 fs2 fc1 sc0 ls0 ws6c">increases by 1- to 2-fold in mild and 2- to 4.5-fold in moder<span class="ws0">-</span></div><div class="t m0 x23 h5 ya7 ff4 fs2 fc1 sc0 ls0 ws72">ate hepatic impairment.</div><div class="t m0 x41 h6 ya8 ff4 fs4 fc1 sc0 ls0 ws0">19</div><div class="t m0 x42 h5 ya7 ff4 fs2 fc1 sc0 ls0 ws72"> In those with severe renal impair<span class="ws0">-</span></div><div class="t m0 x23 h5 y87 ff4 fs2 fc1 sc0 ls0 ws16">ment (estimated glomerular filtration rate &lt; 30 mL/min/m</div><div class="t m0 x3e h6 ya9 ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x40 h5 y87 ff4 fs2 fc1 sc0 ls0 ws0">) </div><div class="t m0 x23 h5 y88 ff4 fs2 fc1 sc0 ls0 ws73">also, <span class="_ _5"></span>the AUC</div><div class="t m0 x39 h6 yaa ff4 fs4 fc1 sc0 ls0 ws0">0-<span class="ff5">∝</span></div><div class="t m0 x2a h5 y88 ff4 fs2 fc1 sc0 ls0 ws74"> increased by 1.7-fold when compared with </div><div class="t m0 x23 h5 y89 ff4 fs2 fc1 sc0 ls0 ws0">that in healthy individuals.</div><div class="t m0 x43 h6 yab ff4 fs4 fc1 sc0 ls0 ws0">19</div><div class="t m0 x44 h5 y8a ff4 fs2 fc1 sc0 ls8 ws75">Information regarding potential drug-drug interactions </div><div class="t m0 x23 h5 y8b ff4 fs2 fc1 sc0 ls8 ws76">with selexipag remains somewhat limited. No significant </div><div class="t m0 x23 h5 y8c ff4 fs2 fc1 sc0 ls8 ws77">interaction was found between warfarin and selexipag, </div><div class="t m0 x23 h5 y8e ff4 fs2 fc1 sc0 ls8 ws78">including no impact on the international normalized ratio.</div><div class="t m0 x3e h6 yac ff4 fs4 fc1 sc0 ls9 ws54">20</div><div class="t m0 x36 h5 y8e ff4 fs2 fc1 sc0 ls0 ws0"> </div><a class="l" href="http://www.clinicaltrials.gov) was also conducted to identify additional recently completed or ongoing studies of relevance"><div class="d m1" style="border-style:none;position:absolute;left:303.108000px;bottom:255.492000px;width:47.410000px;height:11.070000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="http://www.clinicaltrials.gov) was also conducted to identify additional recently completed or ongoing studies of relevance"><div class="d m1" style="border-style:none;position:absolute;left:75.600000px;bottom:241.092000px;width:237.000000px;height:11.070000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="http://www.clinicaltrials.gov) was also conducted to identify additional recently completed or ongoing studies of relevance"><div class="d m1" style="border-style:none;position:absolute;left:75.600000px;bottom:226.692000px;width:204.398000px;height:11.070000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf3" class="pf w0 h0" data-page-no="3"><div class="pc pc3 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x2 he y57 ff1 fs2 fc1 sc0 ls0 ws0">490 <span class="_ _7"> </span><span class="ff2">Annals of Pharmacotherapy 51(6)</span></div><div class="t m0 x2 h5 y58 ff4 fs2 fc1 sc0 ls8 ws79">In an attempt to evaluate the impact of inhibitors of organic </div><div class="t m0 x2 h5 y5a ff4 fs2 fc1 sc0 ls8 ws7a">anion-transporting polypeptides (OA<span class="_ _3"></span>TP), p-glycoprotein </div><div class="t m0 x2 h5 y5b ff4 fs2 fc1 sc0 ls8 ws7b">(P-gp), and CYP3A4, multiple doses of the combination </div><div class="t m0 x2 h5 y5c ff4 fs2 fc1 sc0 ls8 ws7c">drug lopinavir/ritonavir were given to healthy individuals in </div><div class="t m0 x2 h5 y5d ff4 fs2 fc1 sc0 ls8 ws59">combination with a single dose of selexipag.</div><div class="t m0 x45 h6 yad ff4 fs4 fc1 sc0 ls9 ws54">21</div><div class="t m0 x46 h5 y5d ff4 fs2 fc1 sc0 ls8 ws59"> Lopinavir/</div><div class="t m0 x2 h5 y5e ff4 fs2 fc1 sc0 ls8 ws7d">ritonavir increased the <span class="_ _2"></span>AUC</div><div class="t m0 x47 h6 yae ff4 fs4 fc1 sc0 ls9 ws54">0-<span class="ff5 ls0 ws0">∝</span></div><div class="t m0 x48 h5 y5e ff4 fs2 fc1 sc0 ls8 ws7d"> and <span class="ff6 ls0 ws0">C</span></div><div class="t m0 x49 h6 yae ff4 fs4 fc1 sc0 ls9 ws54">max</div><div class="t m0 x4a h5 y5e ff4 fs2 fc1 sc0 ls8 ws7d"> of selexipag by 2.2- </div><div class="t m0 x2 h5 y5f ff4 fs2 fc1 sc0 ls8 ws48">and 2.1-fold, although concentrations of <span class="_ _2"></span>ACT<span class="_ _2"></span>-333679 were </div><div class="t m0 x2 h5 y60 ff4 fs2 fc1 sc0 ls8 ws7e">not appreciably affected and no adverse events occurred. </div><div class="t m0 x2 h5 y61 ff4 fs2 fc1 sc0 ls8 ws7f">The authors concluded that selexipag can be safely coad<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y62 ff4 fs2 fc1 sc0 ls8 ws0">ministered with inhibitors of OA<span class="_ _3"></span>TP<span class="_ _3"></span>, P-gp, and CYP3A4.</div><div class="t m0 x2 h4 yaf ff3 fs3 fc1 sc0 ls0 ws0">Clinical Trials</div><div class="t m0 x2 h4 yb0 ff2 fs3 fc1 sc0 ls0 ws0">Phase I Trials</div><div class="t m0 x2 h5 yb1 ff4 fs2 fc1 sc0 ls1 ws80">A<span class="_ _2"></span> placebo-controlled, multiple-dose, uptitration study was<span class="_ _4"></span> </div><div class="t m0 x2 h5 yb2 ff4 fs2 fc1 sc0 ls1 ws81">conducted in 16 healthy individuals.</div><div class="t m0 x4b h6 yb3 ff4 fs4 fc1 sc0 lsb ws82">14</div><div class="t m0 x4a h5 yb4 ff4 fs2 fc1 sc0 ls1 ws81"> Participants in the </div><div class="t m0 x2 h5 yb5 ff4 fs2 fc1 sc0 ls1 ws23">selexipag arm were started at a dose of 400 µg twice daily for </div><div class="t m0 x2 h5 yb6 ff4 fs2 fc1 sc0 ls1 ws83">3 days, then increased by 200 µg twice daily every third day to </div><div class="t m0 x2 h5 yb7 ff4 fs2 fc1 sc0 ls1 ws84">a maximum of 1800 µg twice daily<span class="_ _2"></span>. The maximum dose was </div><div class="t m0 x2 h5 yb8 ff4 fs2 fc1 sc0 ls1 ws7d">continued for 2.5 days. Of the 12 patients who received selex<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 yb9 ff4 fs2 fc1 sc0 ls1 ws85">ipag, 5 (41.7%) prematurely withdrew from the study as a </div><div class="t m0 x2 h5 yba ff4 fs2 fc1 sc0 ls1 ws86">result of adverse events. Of the 9 participants, 7 who reached </div><div class="t m0 x2 h5 ybb ff4 fs2 fc1 sc0 ls1 ws64">the 1800 µg twice-daily level reported moderate drug-related </div><div class="t m0 x2 h5 ybc ff4 fs2 fc1 sc0 ls1 ws87">adverse events that required treatment. Based on these results, </div><div class="t m0 x2 h5 ybd ff4 fs2 fc1 sc0 ls1 ws88">it was concluded that an uptitration scheme starting at 400 µg </div><div class="t m0 x2 h5 ybe ff4 fs2 fc1 sc0 ls1 ws89">twice daily<span class="_ _2"></span>, in 200-µg increments, to a maximum dose of<span class="_ _4"></span> </div><div class="t m0 x2 h5 ybf ff4 fs2 fc1 sc0 ls1 ws8a">1600 µg twice daily should be the target dosing strategy mov<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 yc0 ff4 fs2 fc1 sc0 ls1 ws0">ing forward and used in future clinical trials.</div><div class="t m0 x2 h4 yc1 ff2 fs3 fc1 sc0 ls0 ws0">Phase II Trial</div><div class="t m0 x2 h5 yc2 ff4 fs2 fc1 sc0 ls8 ws38">Simonneau et al</div><div class="t m0 x4c h6 yc3 ff4 fs4 fc1 sc0 ls9 ws54">22</div><div class="t m0 x4d h5 yc2 ff4 fs2 fc1 sc0 ls8 ws38"> conducted a phase 2, multicenter<span class="_ _1"></span>, proof-</div><div class="t m0 x2 h5 yc4 ff4 fs2 fc1 sc0 ls8 ws8b">of-concept, parallel-group trial lasting 17 weeks. Patients </div><div class="t m0 x2 h5 yc5 ff4 fs2 fc1 sc0 ls8 ws8c">were eligible for inclusion if they were <span class="ff5 ls0 ws0">≥</span>18 years of age with </div><div class="t m0 x2 h5 yc6 ff4 fs2 fc1 sc0 ls8 ws8d">symptomatic idiopathic or hereditary P<span class="_ _3"></span>AH associated with </div><div class="t m0 x2 h5 yc7 ff4 fs2 fc1 sc0 ls8 ws8a">either a connective tissue disease, corrected congenital heart </div><div class="t m0 x2 h5 yc8 ff4 fs2 fc1 sc0 ls8 ws7d">disease, or anorexigen use. Patients had to have been receiv<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 yc9 ff4 fs2 fc1 sc0 ls8 ws8e">ing either an ERA<span class="_ _2"></span> and/or a PDE-5 inhibitor at a stable dose<span class="_ _4"></span> </div><div class="t m0 x2 h5 y7f ff4 fs2 fc1 sc0 ls8 ws3a">for at least 12 weeks at the time of screening. Mandatory </div><div class="t m0 x2 h5 y81 ff4 fs2 fc1 sc0 ls8 ws8f">baseline hemodynamics included a pulmonary vascular </div><div class="t m0 x2 h5 y83 ff4 fs2 fc1 sc0 ls8 ws90">resistance (PVR) &gt;400 dyn s cm</div><div class="t m0 x4e h6 ya2 ff4 fs4 fc1 sc0 ls9 ws54">-5</div><div class="t m0 x4f h5 y83 ff4 fs2 fc1 sc0 ls8 ws90">, and two 6-minute walk </div><div class="t m0 x2 h5 y84 ff4 fs2 fc1 sc0 ls8 ws1">tests of 150 to 500 m inclusive and within ±15% of each </div><div class="t m0 x2 h5 y85 ff4 fs2 fc1 sc0 ls8 ws91">other<span class="_ _2"></span>. Exclusion criteria included patients with clinically </div><div class="t m0 x2 h5 ya4 ff4 fs2 fc1 sc0 ls8 ws92">unstable right heart failure (WHO FC IV), those who had </div><div class="t m0 x2 h5 ya6 ff4 fs2 fc1 sc0 ls8 ws93">received epoprostenol within 3 months of trial screening, </div><div class="t m0 x2 h5 ya7 ff4 fs2 fc1 sc0 ls8 ws94">patients with thromboembolic disease, or anyone who had </div><div class="t m0 x2 h5 y87 ff4 fs2 fc1 sc0 ls8 ws0">received an investigational drug within the prior 30 days.</div><div class="t m0 x8 h5 y88 ff4 fs2 fc1 sc0 ls0 ws87">A<span class="_ _2"></span> total of 43 patients were enrolled and randomized, in a </div><div class="t m0 x2 h5 y89 ff4 fs2 fc1 sc0 ls0 ws95">3:1 ratio, to receive either selexipag or placebo. Those in </div><div class="t m0 x2 h5 y8a ff4 fs2 fc1 sc0 ls0 ws48">the selexipag arm (n = 33) were initiated on a dose of 200 </div><div class="t m0 x2 h5 y8b ff4 fs2 fc1 sc0 ls0 ws96">µg twice daily for 2 days, 400 µg twice daily for 4 days, 600 </div><div class="t m0 x2 h5 y8c ff4 fs2 fc1 sc0 ls0 ws97">µg twice daily for 14 days, and 800 µg twice daily thereaf<span class="ws0">-</span></div><div class="t m0 x2 h5 y8e ff4 fs2 fc1 sc0 ls0 ws98">ter<span class="_ _2"></span>. Patients were uptitrated to the maximally tolerated dose </div><div class="t m0 x9 h5 yca ff4 fs2 fc1 sc0 ls0 ws79">(MTD) was achieved. The protocol allowed for the dose to </div><div class="t m0 x9 h5 ycb ff4 fs2 fc1 sc0 ls0 ws99">be temporarily decreased to allow for alleviation of the </div><div class="t m0 x9 h5 ycc ff4 fs2 fc1 sc0 ls0 ws3f">adverse event. The final dose had to have been stable for at </div><div class="t m0 x9 h5 ycd ff4 fs2 fc1 sc0 ls0 ws9a">least 4 weeks prior to the final evaluation at week 17. The </div><div class="t m0 x9 h5 yce ff4 fs2 fc1 sc0 ls0 ws9b">primary efficacy end point was the percentage change in </div><div class="t m0 x9 h5 ycf ff4 fs2 fc1 sc0 ls0 ws95">PVR from baseline to week 17. <span class="_ _2"></span>Additional hemodynamic </div><div class="t m0 x9 h5 yd0 ff4 fs2 fc1 sc0 ls0 ws9c">outcomes, 6-minute walk distance, and worsening of P<span class="_ _3"></span>AH </div><div class="t m0 x9 h5 yd1 ff4 fs2 fc1 sc0 ls0 ws23">were also collected. Main analyses were conducted accord<span class="ws0">-</span></div><div class="t m0 x9 h5 yd2 ff4 fs2 fc1 sc0 ls0 ws9d">ing to the per-protocol population (all treated patients with<span class="ws0">-</span></div><div class="t m0 x9 h5 yd3 ff4 fs2 fc1 sc0 ls0 ws0">out a protocol violation).</div><div class="t m0 x50 h5 yd4 ff4 fs2 fc1 sc0 lsc ws9e">Of the 43 patients enrolled, 35 (selexipag = 29, placebo = 6) </div><div class="t m0 x9 h5 yd5 ff4 fs2 fc1 sc0 lsc ws9f">were analyzed in the per-protocol <span class="_ _1"></span>group. Background therapy<span class="_ _4"></span> </div><div class="t m0 x9 h5 yd6 ff4 fs2 fc1 sc0 lsc ws66">included ERA<span class="_ _2"></span> monotherapy in 37%, PDE-5 inhibitor mono<span class="ls0 ws0">-</span></div><div class="t m0 x9 h5 yd7 ff4 fs2 fc1 sc0 lsc ws2c">therapy in 28%, and combination ERA<span class="_ _2"></span> + PDE-5 inhibitor<span class="_ _4"></span> </div><div class="t m0 x9 h5 yd8 ff4 fs2 fc1 sc0 lsc ws8a">therapy in 35% of patients. It was found that 14 (42.4%) of the </div><div class="t m0 x9 h5 yd9 ff4 fs2 fc1 sc0 lsc wsc">selexipag patients reached a final dose of 800 µg twice daily<span class="_ _2"></span>, 7<span class="_ _4"></span> </div><div class="t m0 x9 h5 yda ff4 fs2 fc1 sc0 lsc wsa0">(21.2%) reached a dose of 600 µg twice daily<span class="_ _2"></span>, 6 (18.2%)<span class="_ _4"></span> </div><div class="t m0 x9 h5 ydb ff4 fs2 fc1 sc0 lsc ws1e">reached a dose of 400 µg twice daily<span class="_ _2"></span>, and 4 (12.1%) reached a<span class="_ _4"></span> </div><div class="t m0 x9 h5 ydc ff4 fs2 fc1 sc0 lsc wsa1">dose of 200 µg twice daily<span class="_ _2"></span>. The mean dose achieved was not </div><div class="t m0 x9 h5 ydd ff4 fs2 fc1 sc0 lsc wsa2">provided, nor were the adverse events that prevented uptitra<span class="ls0 ws0">-</span></div><div class="t m0 x9 h5 yde ff4 fs2 fc1 sc0 lsc ws9f">tion of the doses. Selexipag significantly reduced the PVR by </div><div class="t m0 x9 h5 ydf ff4 fs2 fc1 sc0 lsc wsa3">30.3% by week 17 compared with placebo (−44.7% vs </div><div class="t m0 x9 h5 ye0 ff4 fs2 fc1 sc0 lsc wsa4">−12.2%; <span class="_ _5"></span><span class="ff6 ls0 ws0">P</span><span class="wsa5"> = 0.0045; Figure 1A). <span class="_ _2"></span>Analysis of all 43 patients<span class="_ _4"></span> </span></div><div class="t m0 x9 hf ye1 ff3 fsb fc1 sc0 ls0 ws0">Figure 1.<span class="ff1"> <span class="_ _8"> </span>Change in pulmonary vascular resistance (A) and </span></div><div class="t m0 x9 hf ye2 ff1 fsb fc1 sc0 ls0 ws0">6-minute walk distance (B) from baseline to week 17 with </div><div class="t m0 x9 hf ye3 ff1 fsb fc1 sc0 ls0 ws0">selexipag versus placebo. Reproduced with permission from </div><div class="t m0 x9 hf ye4 ff1 fsb fc1 sc0 ls0 ws0">Simonneau et al.</div><div class="t m0 x51 h10 ye5 ff1 fsc fc1 sc0 ls0 ws0">22</div><div class="t m0 x9 ha ye6 ff1 fs8 fc1 sc0 ls0 ws0">Abbreviations: 6MWD, 6-minute walk distance; CL, confidence limits; </div><div class="t m0 x9 ha ye7 ff1 fs8 fc1 sc0 ls0 ws0">PVR, pulmonary vascular resistance; TE, treatment effect.</div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf4" class="pf w0 h0" data-page-no="4"><div class="pc pc4 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x18 he y57 ff2 fs2 fc1 sc0 ls0 ws0">Baker et al <span class="_ _6"> </span><span class="ff1">491</span></div><div class="t m0 x23 hf ye8 ff3 fsb fc1 sc0 ls0 ws0">Figure 2.<span class="ff1"> <span class="_ _8"> </span>Primary results of the GRIPHON trial: Selexipag </span></div><div class="t m0 x23 hf ye9 ff1 fsb fc1 sc0 ls0 ws0">reduced the primary composite end point of all-cause death </div><div class="t m0 x23 hf yea ff1 fsb fc1 sc0 ls0 ws0">or pulmonary arterial hypertension–related complication (<span class="ff2">P</span> &lt; </div><div class="t m0 x23 hf yeb ff1 fsb fc1 sc0 ls0 ws0">0.001). Reproduced with permission from Sitbon et al.</div><div class="t m0 x52 h10 yec ff1 fsc fc1 sc0 ls0 ws0">23</div><div class="t m0 x18 h5 y58 ff4 fs2 fc1 sc0 lsc wsa6">included in the study showed similar findings. <span class="_ _2"></span>A<span class="_ _1"></span> significant<span class="_ _4"></span> </div><div class="t m0 x18 h5 y5a ff4 fs2 fc1 sc0 lsc ws76">increase in the 6-minute walk distance was also seen with </div><div class="t m0 x18 h5 y5b ff4 fs2 fc1 sc0 lsc wsa7">selexipag versus placebo (+24.7 vs +0.4 m, respectively; </div><div class="t m0 x18 h5 y5c ff4 fs2 fc1 sc0 lsc wsa8">Figure 1B). Selexipag patients also had improvements in car<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y5d ff4 fs2 fc1 sc0 lsc wsa9">diac index (+0.5 L/min/m</div><div class="t m0 x53 h6 yad ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x54 h5 y5d ff4 fs2 fc1 sc0 lsc wsa4">, <span class="_ _9"> </span><span class="ff6 ls0 ws0">P</span><span class="wsa9"> = 0.01), right atrial pressure </span></div><div class="t m0 x18 h5 y5e ff4 fs2 fc1 sc0 lsc ws7e">(+3.2 mm Hg, <span class="ff6 ls0 ws0">P</span> = 0.02), and systemic vascular resistance </div><div class="t m0 x18 h5 y5f ff4 fs2 fc1 sc0 lsc wsaa">(−407.8 dyn/s/cm</div><div class="t m0 x55 h6 yed ff4 fs4 fc1 sc0 lsd wsab">-5</div><div class="t m0 x56 h5 y5f ff4 fs2 fc1 sc0 lsc wsa4">, <span class="_ _8"> </span><span class="ff6 ls0 ws0">P</span><span class="wsaa"> = 0.01) versus placebo. Despite the </span></div><div class="t m0 x18 h5 y60 ff4 fs2 fc1 sc0 lsc ws31">reductions in systemic vascular resistance with selexipag, sys<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y61 ff4 fs2 fc1 sc0 lsc wsa1">temic hypotension was not appreciated. The small number of </div><div class="t m0 x18 h5 y62 ff4 fs2 fc1 sc0 lsc wsac">patients included in the study resulted in various imbalances in </div><div class="t m0 x18 h5 y63 ff4 fs2 fc1 sc0 lsc wsa8">baseline characteristics and limited the ability to evaluate sta<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y64 ff4 fs2 fc1 sc0 lsc ws84">tistical significance for some secondary outcomes. The proof-</div><div class="t m0 x18 h5 y65 ff4 fs2 fc1 sc0 lsc ws6">of-concept study did, however<span class="_ _1"></span>, support further evaluation in an </div><div class="t m0 x18 h5 y67 ff4 fs2 fc1 sc0 lsc ws0">adequately powered clinical trial.</div><div class="t m0 x18 h4 yee ff2 fs3 fc1 sc0 ls0 ws0">Phase III Trial</div><div class="t m0 x18 h5 y6b ff4 fs2 fc1 sc0 lse wsad">Selexipag received its regulatory approval based on the </div><div class="t m0 x18 h5 y6c ff4 fs2 fc1 sc0 lse wsae">results of the multicenter<span class="_ _1"></span>, double-blind, randomized, paral<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y6d ff4 fs2 fc1 sc0 lse wsaf">lel-group, placebo-controlled, event-driven phase 3 </div><div class="t m0 x18 h5 y6e ff4 fs2 fc1 sc0 lse wsb0">GRIPHON (Prostacyclin [PGI</div><div class="t m0 x57 h6 yef ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x4b h5 y6e ff4 fs2 fc1 sc0 lse wsb0">] Receptor <span class="_ _2"></span>Agonist in </div><div class="t m0 x18 h5 y99 ff4 fs2 fc1 sc0 lse wsb1">Pulmonary <span class="_ _2"></span>Arterial Hypertension) study<span class="_ _1"></span>.</div><div class="t m0 x58 h6 yf0 ff4 fs4 fc1 sc0 lsf wsb2">23</div><div class="t m0 x59 h5 y99 ff4 fs2 fc1 sc0 lse wsb1"> Patients 18 to </div><div class="t m0 x18 h5 y9a ff4 fs2 fc1 sc0 lse ws12">75 years of age with either idiopathic or heritable P<span class="_ _3"></span>AH or </div><div class="t m0 x18 h5 y9b ff4 fs2 fc1 sc0 lse wsb3">those with P<span class="_ _3"></span>AH associated with human immunodeficiency </div><div class="t m0 x18 h5 y70 ff4 fs2 fc1 sc0 lse wsb4">virus infection, drug abuse, connective tissue disease, or </div><div class="t m0 x18 h5 y71 ff4 fs2 fc1 sc0 lse wsb5">repaired congenital systemic-to-pulmonary shunts were </div><div class="t m0 x18 h5 y72 ff4 fs2 fc1 sc0 lse wsb6">included. Similar to the study by Simonneau et al,</div><div class="t m0 x5a h6 yf1 ff4 fs4 fc1 sc0 lsf wsb2">22</div><div class="t m0 x5b h5 y72 ff4 fs2 fc1 sc0 lse wsb6"> patients </div><div class="t m0 x18 h5 y73 ff4 fs2 fc1 sc0 lse ws5a">were required to have a PVR of at least 400 dyn s cm</div><div class="t m0 x5c h6 yf2 ff4 fs4 fc1 sc0 lsf wsb2">-5</div><div class="t m0 x5d h5 y73 ff4 fs2 fc1 sc0 ls0 ws3e"> (5 </div><div class="t m0 x18 h5 y74 ff4 fs2 fc1 sc0 lse ws3f">W<span class="_ _2"></span>ood units) and a 6-minute walk distance between 50 and </div><div class="t m0 x18 h5 y75 ff4 fs2 fc1 sc0 lse ws76">450 m. The mean baseline 6-minute walk distance was </div><div class="t m0 x18 h5 y76 ff4 fs2 fc1 sc0 lse ws22">353.2 ± 80.01 m at baseline. Participants were allowed to </div><div class="t m0 x18 h5 y77 ff4 fs2 fc1 sc0 lse ws83">receive concomitant ERA<span class="_ _2"></span> therapy<span class="_ _1"></span>, PDE-5 inhibitor<span class="_ _1"></span>, or both </div><div class="t m0 x18 h5 y78 ff4 fs2 fc1 sc0 lse ws9d">as long as it was at a stable dose for at least 3 months prior </div><div class="t m0 x18 h5 y79 ff4 fs2 fc1 sc0 lse wsa1">to enrollment. Those who had received other prostacyclin </div><div class="t m0 x18 h5 y7a ff4 fs2 fc1 sc0 lse ws0">analogues were excluded.</div><div class="t m0 x1b h5 y7b ff4 fs2 fc1 sc0 ls0 wsb5">Eligible patients were randomized in a 1:1 ratio to </div><div class="t m0 x18 h5 y7c ff4 fs2 fc1 sc0 ls0 wsb7">receive either dose-adjusted selexipag or a matching pla<span class="ws0">-</span></div><div class="t m0 x18 h5 y7d ff4 fs2 fc1 sc0 ls0 wsb8">cebo. Selexipag was initiated at a dose of 200 µg twice daily </div><div class="t m0 x18 h5 y7e ff4 fs2 fc1 sc0 ls0 wsb9">and was increased in 200-µg increments over a 12-week </div><div class="t m0 x18 h5 y7f ff4 fs2 fc1 sc0 ls0 ws34">period until intolerable adverse effects (eg, headache or jaw </div><div class="t m0 x18 h5 y81 ff4 fs2 fc1 sc0 ls0 wsba">pain) were experienced. The dose was then decreased in </div><div class="t m0 x18 h5 y83 ff4 fs2 fc1 sc0 ls0 ws3d">200-µg increments until the MTD was reached. The highest </div><div class="t m0 x18 h5 y84 ff4 fs2 fc1 sc0 ls0 wsd">dose allowed was 1600 µg twice daily<span class="_ _2"></span>. Patients continued </div><div class="t m0 x18 h5 y85 ff4 fs2 fc1 sc0 ls0 wsbb">therapy until they either dropped out, experienced a primary </div><div class="t m0 x18 h5 ya4 ff4 fs2 fc1 sc0 ls0 wsbc">end point event, or the study ended. The study was designed </div><div class="t m0 x18 h5 ya6 ff4 fs2 fc1 sc0 ls0 wsbd">to continue until at least 331 primary end point events had </div><div class="t m0 x18 h5 ya7 ff4 fs2 fc1 sc0 ls0 ws21">occurred (median duration of 70.7 weeks in the selexipag </div><div class="t m0 x18 h5 y87 ff4 fs2 fc1 sc0 ls0 ws26">and 63.7 weeks in the placebo group). <span class="_ _1"></span>Those who prema<span class="ws0">-</span></div><div class="t m0 x18 h5 y88 ff4 fs2 fc1 sc0 ls0 wsbe">turely discontinued their treatment were given the option to </div><div class="t m0 x18 h5 y89 ff4 fs2 fc1 sc0 ls0 ws33">continue in the study in a posttreatment observation period </div><div class="t m0 x18 h5 y8a ff4 fs2 fc1 sc0 ls0 wsbf">until the end of the study<span class="_ _2"></span>. Participants were seen at screen<span class="ws0">-</span></div><div class="t m0 x18 h5 y8b ff4 fs2 fc1 sc0 ls0 wsa9">ing, baseline, and at 8, 16, and 26 weeks, then every 6 </div><div class="t m0 x18 h5 y8c ff4 fs2 fc1 sc0 ls0 wsc0">months thereafter<span class="_ _2"></span>. Clinical and laboratory data were col<span class="ws0">-</span></div><div class="t m0 x18 h5 y8e ff4 fs2 fc1 sc0 ls0 ws0">lected at each appointment.</div><div class="t m0 x44 h5 yf3 ff4 fs2 fc1 sc0 ls0 wsc">The primary outcome was a composite of death or P<span class="_ _3"></span>AH-</div><div class="t m0 x23 h5 yf4 ff4 fs2 fc1 sc0 ls0 wsc1">related complication and was analyzed in a time-to-event, </div><div class="t m0 x23 h5 yf5 ff4 fs2 fc1 sc0 ls0 wsbe">on-treatment fashion with data censored at the time therapy </div><div class="t m0 x23 h5 yf6 ff4 fs2 fc1 sc0 ls0 wsc2">was discontinued. This end point matches that which <span class="_ _1"></span>was </div><div class="t m0 x23 h5 yf7 ff4 fs2 fc1 sc0 ls0 ws84">recommended by a task force in 2009.</div><div class="t m0 x38 h6 yf8 ff4 fs4 fc1 sc0 ls0 ws0">28</div><div class="t m0 x5e h5 yf9 ff4 fs2 fc1 sc0 ls0 ws84"> P<span class="_ _3"></span>AH-related com<span class="ws0">-</span></div><div class="t m0 x23 h5 yfa ff4 fs2 fc1 sc0 ls0 wsc3">plications included worsening of disease requiring hospital<span class="ws0">-</span></div><div class="t m0 x23 h5 yfb ff4 fs2 fc1 sc0 ls0 wsc4">ization or disease progression, initiation of a parenteral </div><div class="t m0 x23 h5 yfc ff4 fs2 fc1 sc0 ls0 wsc5">prostanoid agent, initiation of long-term oxygen therapy<span class="_ _2"></span>, or </div><div class="t m0 x23 h5 yfd ff4 fs2 fc1 sc0 ls0 ws99">requiring a lung transplant or balloon atrial septostomy<span class="_ _2"></span>. </div><div class="t m0 x23 h5 yfe ff4 fs2 fc1 sc0 ls0 wsc6">Secondary end points included change in 6-minute walk </div><div class="t m0 x23 h5 yff ff4 fs2 fc1 sc0 ls0 ws67">test from baseline to week 26, lack of WHO functional class </div><div class="t m0 x23 h5 y100 ff4 fs2 fc1 sc0 ls0 ws43">worsening, P<span class="_ _3"></span>AH-related death or hospitalization for wors<span class="ws0">-</span></div><div class="t m0 x23 h5 y101 ff4 fs2 fc1 sc0 ls0 wsc7">ening disease, change in N-terminal probrain natriuretic </div><div class="t m0 x23 h5 y102 ff4 fs2 fc1 sc0 ls0 ws78">peptide (NT<span class="_ _3"></span>-proBNP) from baseline to week 26, and death </div><div class="t m0 x23 h5 y103 ff4 fs2 fc1 sc0 ls0 wsc8">from any cause. Initial power calculations in this event-</div><div class="t m0 x23 h5 y104 ff4 fs2 fc1 sc0 ls0 wsa2">driven study estimated that 670 patients would need to be </div><div class="t m0 x23 h5 y105 ff4 fs2 fc1 sc0 ls0 ws89">enrolled over a 2-year period for 202 primary events to </div><div class="t m0 x23 h5 y106 ff4 fs2 fc1 sc0 ls0 wsc9">occur<span class="_ _2"></span>. <span class="_ _1"></span>An interim analysis showed that a higher-than-</div><div class="t m0 x23 h5 y107 ff4 fs2 fc1 sc0 ls0 ws1a">expected number of participants were receiving background </div><div class="t m0 x23 h5 y108 ff4 fs2 fc1 sc0 ls0 wsca">therapy and that the event rate was lower than expected. </div><div class="t m0 x23 h5 y109 ff4 fs2 fc1 sc0 ls0 wscb">The required number of primary end points was then </div><div class="t m0 x23 h5 y10a ff4 fs2 fc1 sc0 ls0 ws2e">increased to 331, increasing the estimated number of </div><div class="t m0 x23 h5 y10b ff4 fs2 fc1 sc0 ls0 ws0">patients to 1<span class="_ _1"></span>150.</div><div class="t m0 x44 h5 y10c ff4 fs2 fc1 sc0 ls8 ws5a">In total, 1<span class="_ _1"></span>156 patients were enrolled from 181 centers in </div><div class="t m0 x23 h5 y10d ff4 fs2 fc1 sc0 ls8 ws3">39 countries. Whereas 20.4% of patients were not receiving </div><div class="t m0 x23 h5 y10e ff4 fs2 fc1 sc0 ls8 wscc">P<span class="_ _3"></span>AH-related therapies at baseline, 14.7% were receiving </div><div class="t m0 x23 h5 y10f ff4 fs2 fc1 sc0 ls8 wscd">ERA<span class="_ _2"></span> monotherapy<span class="_ _1"></span>, 32.4% were receiving PDE-5 inhibitor </div><div class="t m0 x23 h5 y110 ff4 fs2 fc1 sc0 ls8 wsce">monotherapy<span class="_ _2"></span>, and 32.5% were receiving ERA<span class="_ _1"></span> + PDE-5 </div><div class="t m0 x23 h5 y111 ff4 fs2 fc1 sc0 ls8 wsac">inhibitor combination therapy<span class="_ _2"></span>. The median duration of treat<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y112 ff4 fs2 fc1 sc0 ls8 ws98">ment was 70.7 weeks in the selexipag group and 63.7 weeks </div><div class="t m0 x23 h5 y113 ff4 fs2 fc1 sc0 ls8 wscf">in the placebo group. The primary end point occurred in </div><div class="t m0 x23 h5 y114 ff4 fs2 fc1 sc0 ls8 wsa2">41.6% of the placebo group versus 27.0% of the selexipag </div><div class="t m0 x23 h5 y115 ff4 fs2 fc1 sc0 ls8 ws88">group, representing a 40% risk reduction (hazard ratio [HR] </div><div class="t m0 x23 h5 y116 ff4 fs2 fc1 sc0 ls8 wsd0">= 0.60, 99% CI = 0.46 to 0.78, <span class="ff6 ls0 ws0">P</span> &lt; 0.001; Figure 2). </div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf5" class="pf w0 h0" data-page-no="5"><div class="pc pc5 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x2 he y57 ff1 fs2 fc1 sc0 ls0 ws0">492 <span class="_ _7"> </span><span class="ff2">Annals of Pharmacotherapy 51(6)</span></div><div class="t m0 x2 h5 y58 ff4 fs2 fc1 sc0 ls8 wsbd">Sensitivity analysis showed similar results when those who </div><div class="t m0 x2 h5 y5a ff4 fs2 fc1 sc0 ls8 ws94">prematurely discontinued therapy were included. <span class="_ _2"></span>Also, the<span class="_ _4"></span> </div><div class="t m0 x2 h5 y5b ff4 fs2 fc1 sc0 ls8 wsc3">beneficial effects of selexipag on the primary end point were </div><div class="t m0 x2 h5 y5c ff4 fs2 fc1 sc0 ls8 ws9d">consistent across prespecified dose strata as well as all other </div><div class="t m0 x2 h5 y5d ff4 fs2 fc1 sc0 ls8 wsd1">evaluated subgroups of patients. The treatment ef<span class="_ _1"></span>fect of </div><div class="t m0 x2 h5 y5e ff4 fs2 fc1 sc0 ls8 ws68">selexipag was also consistent whether patients were receiv<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y5f ff4 fs2 fc1 sc0 ls8 ws64">ing no P<span class="_ _3"></span>AH therapy at baseline (HR = 0.57; 99% CI = 0.32 </div><div class="t m0 x2 h5 y60 ff4 fs2 fc1 sc0 ls8 ws0">to 1.03), ERA<span class="_ _2"></span> monotherapy at baseline (HR = 0.66; 99% CI<span class="_ _4"></span> </div><div class="t m0 x2 h5 y61 ff4 fs2 fc1 sc0 ls8 wsd2">= 0.32 to 1.35), PDE-5 inhibitor monotherapy at baseline </div><div class="t m0 x2 h5 y62 ff4 fs2 fc1 sc0 ls8 ws3f">(HR = 0.58; 99% CI = 0.37 to 0.91), or combination ERA<span class="_ _2"></span> +<span class="_ _4"></span> </div><div class="t m0 x2 h5 y63 ff4 fs2 fc1 sc0 ls8 wsa2">PDE-5 inhibitor at baseline (HR = 0.63; 99% CI = 0.39 to </div><div class="t m0 x2 h5 y64 ff4 fs2 fc1 sc0 ls8 ws3f">1.01).</div><div class="t m0 x5f h6 y95 ff4 fs4 fc1 sc0 ls9 ws54">24</div><div class="t m0 x8 h5 y65 ff4 fs2 fc1 sc0 ls0 wsd3">Unfortunately<span class="_ _2"></span>, statistical analysis evaluating the indi<span class="ws0">-</span></div><div class="t m0 x2 h5 y67 ff4 fs2 fc1 sc0 ls0 ws3e">vidual components of the primary composite outcome was </div><div class="t m0 x2 h5 y68 ff4 fs2 fc1 sc0 ls0 wsbb">not reported. The incidence of hospitalization for worsening </div><div class="t m0 x2 h5 y69 ff4 fs2 fc1 sc0 ls0 ws96">of P<span class="_ _3"></span>AH (13.6% vs 18.7%) and disease progression (6.6% vs </div><div class="t m0 x2 h5 y6a ff4 fs2 fc1 sc0 ls0 wsd4">17.2%) were lower in the selexipag versus the placebo </div><div class="t m0 x2 h5 y6b ff4 fs2 fc1 sc0 ls0 wsd5">group. Conversely<span class="_ _2"></span>, death from any cause was higher with </div><div class="t m0 x2 h5 y6c ff4 fs2 fc1 sc0 ls0 wsd6">selexipag compared with placebo (4.9% vs 3.1%). However<span class="_ _1"></span>, </div><div class="t m0 x2 h5 y6d ff4 fs2 fc1 sc0 ls0 wsd7">when all-cause mortality was analyzed through the end of </div><div class="t m0 x2 h5 y6e ff4 fs2 fc1 sc0 ls0 wsca">the study (rather than at the end of the treatment period, </div><div class="t m0 x2 h5 y99 ff4 fs2 fc1 sc0 ls0 ws29">which was the primary analysis), no difference between the </div><div class="t m0 x2 h5 y9a ff4 fs2 fc1 sc0 ls0 wsd8">selexipag and placebo groups was seen (HR = 0.97; 95% CI </div><div class="t m0 x2 h5 y9b ff4 fs2 fc1 sc0 ls0 ws9">= 0.74 to 1.28; <span class="ff6 ws0">P</span> = 0.42). Other components of the primary </div><div class="t m0 x2 h5 y70 ff4 fs2 fc1 sc0 ls0 wsa4">composite outcome, including initiation of parenteral pros<span class="ws0">-</span></div><div class="t m0 x2 h5 y71 ff4 fs2 fc1 sc0 ls0 wsf">tanoid therapy or long-term oxygen therapy for worsening </div><div class="t m0 x2 h5 y72 ff4 fs2 fc1 sc0 ls0 wsc3">of P<span class="_ _3"></span>AH (1.7% vs 2.2%) and need for lung transplantation or </div><div class="t m0 x2 h5 y73 ff4 fs2 fc1 sc0 ls0 wsd5">balloon atrial septostomy for worsening of P<span class="_ _3"></span>AH (0.2% vs </div><div class="t m0 x2 h5 y74 ff4 fs2 fc1 sc0 ls0 wsd9">0.3%), were similar between the selexipag and placebo </div><div class="t m0 x2 h5 y75 ff4 fs2 fc1 sc0 ls0 wsc6">groups. <span class="_ _2"></span>Again, no statistical comparisons were made for </div><div class="t m0 x2 h5 y76 ff4 fs2 fc1 sc0 ls0 ws28">these outcomes, so statements regarding their significance </div><div class="t m0 x2 h5 y77 ff4 fs2 fc1 sc0 ls0 ws0">cannot be definitively made.</div><div class="t m0 x8 h5 y78 ff4 fs2 fc1 sc0 ls0 ws93">The 6-minute walk distance improved by 4.0 m from </div><div class="t m0 x2 h5 y79 ff4 fs2 fc1 sc0 ls0 ws5c">baseline with selexipag compared with a 9.0-m worsening </div><div class="t m0 x2 h5 y7a ff4 fs2 fc1 sc0 ls0 ws2">with placebo (treatment effect = 12.0 m, 99% CI = 1 to 24; </div><div class="t m0 x2 h5 y7b ff6 fs2 fc1 sc0 ls0 ws0">P<span class="ff4 ws9f"> = 0.003). <span class="_ _2"></span>As a reminder, the baseline 6-minute walk dis<span class="ws0">-</span></span></div><div class="t m0 x2 h5 y7c ff4 fs2 fc1 sc0 ls0 ws12">tance was 353.2 ± 80.01 m in the overall population; thus, </div><div class="t m0 x2 h5 y7d ff4 fs2 fc1 sc0 ls0 wsda">the difference between groups is approximately 3%. <span class="_ _1"></span>The </div><div class="t m0 x2 h5 y7e ff4 fs2 fc1 sc0 ls0 wsdb">secondary end point of death from P<span class="_ _3"></span>AH or hospitalization </div><div class="t m0 x2 h5 y7f ff4 fs2 fc1 sc0 ls0 ws39">for worsening P<span class="_ _3"></span>AH was also significantly reduced with </div><div class="t m0 x2 h5 y81 ff4 fs2 fc1 sc0 ls0 ws1e">selexipag (17.8%) versus placebo (23.5%; HR = 0.70, 95% </div><div class="t m0 x2 h5 y83 ff4 fs2 fc1 sc0 ls0 wsdc">CI = 0.54 to 0.91; <span class="ff6 ws0">P</span> = 0.003). Of note, a majority of these </div><div class="t m0 x2 h5 y84 ff4 fs2 fc1 sc0 ls0 ws88">events (87.4%) were hospitalizations. The NT<span class="_ _3"></span>-proBNP<span class="_ _1"></span> was </div><div class="t m0 x2 h5 y85 ff4 fs2 fc1 sc0 ls0 ws33">also significantly lowered with selexipag versus placebo at </div><div class="t m0 x2 h5 ya4 ff4 fs2 fc1 sc0 ls0 ws0">week 26 (<span class="ff6">P</span> &lt; 0.001).</div><div class="t m0 x2 h4 y117 ff2 fs3 fc1 sc0 ls0 ws0">Special Populations</div><div class="t m0 x2 h5 y88 ff4 fs2 fc1 sc0 ls7 ws4b">T<span class="_ _2"></span>o date, little information on the safety and efficacy of </div><div class="t m0 x2 h5 y89 ff4 fs2 fc1 sc0 ls7 wsdd">selexipag in special populations is available. The pre<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y8a ff4 fs2 fc1 sc0 ls7 wsde">scribing information for selexipag cites animal studies </div><div class="t m0 x2 h5 y8b ff4 fs2 fc1 sc0 ls7 ws27">suggesting no appreciable effects on embryofetal devel<span class="ls0 ws0">-</span></div><div class="t m0 x2 h5 y8c ff4 fs2 fc1 sc0 ls7 wsb4">opment or survival.</div><div class="t m0 x60 h6 y8d ff4 fs4 fc1 sc0 ls10 wsdf">26</div><div class="t m0 x56 h5 y8c ff4 fs2 fc1 sc0 ls7 wsb4"> Selexipag or its metabolites were </div><div class="t m0 x2 h5 y8e ff4 fs2 fc1 sc0 ls7 wse0">also detected in the milk of rats; thus, it is recommended </div><div class="t m0 x9 h5 y58 ff4 fs2 fc1 sc0 ls7 wse1">to either discontinue nursing or selexipag to minimize </div><div class="t m0 x9 h5 y5a ff4 fs2 fc1 sc0 ls7 ws8a">infant risk. No information on its use in pediatric patients </div><div class="t m0 x9 h5 y5b ff4 fs2 fc1 sc0 ls7 wse2">is currently available. The GRIPHON study enrolled<span class="_ _1"></span> </div><div class="t m0 x9 h5 y5c ff4 fs2 fc1 sc0 ls7 ws83">nearly 250 patients older than 65 years, with a small num<span class="ls0 ws0">-</span></div><div class="t m0 x9 h5 y5d ff4 fs2 fc1 sc0 ls7 ws9e">ber (n = 19) being older than 75 years.</div><div class="t m0 x61 h6 yad ff4 fs4 fc1 sc0 ls10 wsdf">23,26</div><div class="t m0 x62 h5 y5d ff4 fs2 fc1 sc0 ls7 ws9e"> Subgroup anal<span class="ls0 ws0">-</span></div><div class="t m0 x9 h5 y5e ff4 fs2 fc1 sc0 ls7 ws51">yses showed similar efficacy with selexipag versus<span class="_ _1"></span> </div><div class="t m0 x9 h5 y5f ff4 fs2 fc1 sc0 ls7 wse3">placebo in patients younger than compared with older </div><div class="t m0 x9 h5 y60 ff4 fs2 fc1 sc0 ls7 ws62">than 65 years (<span class="ff6 ls0 ws0">P</span> value for interaction = 0.6783). No dose </div><div class="t m0 x9 h5 y61 ff4 fs2 fc1 sc0 ls7 wse4">adjustments are required for selexipag in patients with </div><div class="t m0 x9 h5 y62 ff4 fs2 fc1 sc0 ls7 wsc2">mild, moderate, or severe renal insufficiency (estimated<span class="_ _1"></span> </div><div class="t m0 x9 h5 y63 ff4 fs2 fc1 sc0 ls7 wsbc">glomerular filtration rate &gt; 15 mL/min/1.73 m</div><div class="t m0 x63 h6 y118 ff4 fs4 fc1 sc0 ls0 ws0">2</div><div class="t m0 x64 h5 y63 ff4 fs2 fc1 sc0 ls7 wsbc">), although </div><div class="t m0 x9 h5 y64 ff4 fs2 fc1 sc0 ls7 ws22">experience in those receiving dialysis is not available. <span class="_ _2"></span>A<span class="_ _1"></span> </div><div class="t m0 x9 h5 y65 ff4 fs2 fc1 sc0 ls7 wsd7">once-daily regimen of selexipag is suggested in patients </div><div class="t m0 x9 h5 y67 ff4 fs2 fc1 sc0 ls7 ws2d">with moderate hepatic impairment (Child-Pugh class B), </div><div class="t m0 x9 h5 y68 ff4 fs2 fc1 sc0 ls7 wse5">whereas no dose adjustments are needed for those with </div><div class="t m0 x9 h5 y69 ff4 fs2 fc1 sc0 ls7 ws0">mild impairment (Child-Pugh class <span class="_ _2"></span>A).</div><div class="t m0 x9 h4 y119 ff3 fs3 fc1 sc0 ls0 ws0">Dosage and Administration</div><div class="t m0 x9 h5 y6d ff4 fs2 fc1 sc0 lse wse6">Based on the dosing scheme used in the GRIPHON study<span class="_ _2"></span>,</div><div class="t m0 x65 h6 y11a ff4 fs4 fc1 sc0 lsf wsb2">23</div><div class="t m0 xd h5 y6d ff4 fs2 fc1 sc0 ls0 ws0"> </div><div class="t m0 x9 h5 y6e ff4 fs2 fc1 sc0 lse wse7">selexipag should be initiated at a dose of 200 µg by mouth </div><div class="t m0 x9 h5 y99 ff4 fs2 fc1 sc0 lse ws94">twice daily<span class="_ _2"></span>. The dose can be taken with food to improve </div><div class="t m0 x9 h5 y9a ff4 fs2 fc1 sc0 lse wse8">tolerability without altering selexipag or <span class="_ _2"></span>ACT<span class="_ _2"></span>-333679 </div><div class="t m0 x9 h5 y9b ff4 fs2 fc1 sc0 lse wsc5">exposure.</div><div class="t m0 x66 h6 y9c ff4 fs4 fc1 sc0 lsf wsb2">26</div><div class="t m0 x30 h5 y9b ff4 fs2 fc1 sc0 lse ws96"> The dose can be increased in increments of 200 </div><div class="t m0 x9 h5 y70 ff4 fs2 fc1 sc0 lse wsd2">µg at weekly intervals until the MTD has been reached. </div><div class="t m0 x9 h5 y71 ff4 fs2 fc1 sc0 lse wse9">The maximum recommended daily dose is 1600 µg twice </div><div class="t m0 x9 h5 y72 ff4 fs2 fc1 sc0 lse wsea">daily<span class="_ _2"></span>. Selexipag is available in the following tablet </div><div class="t m0 x9 h5 y73 ff4 fs2 fc1 sc0 lse ws6f">strengths: 200, 400, 600, 800, 1000, 1200, 1400, and 1600 </div><div class="t m0 x9 h5 y74 ff4 fs2 fc1 sc0 lse wsc5">µg.</div><div class="t m0 x67 h6 y9e ff4 fs4 fc1 sc0 lsf wsb2">26</div><div class="t m0 x11 h5 y74 ff4 fs2 fc1 sc0 lse wseb"> Bioequivalence between taking eight 200-µg tablets </div><div class="t m0 x9 h5 y75 ff4 fs2 fc1 sc0 lse wsbb">or a single 1600-µg tablet has been demonstrated in healthy </div><div class="t m0 x9 h5 y76 ff4 fs2 fc1 sc0 lse wsc5">volunteers.</div><div class="t m0 x68 h6 y11b ff4 fs4 fc1 sc0 lsf wsb2">25</div><div class="t m0 x50 h5 y77 ff4 fs2 fc1 sc0 ls0 wsec">The tablets should not be split, crushed, or chewed </div><div class="t m0 x9 h5 y78 ff4 fs2 fc1 sc0 ls0 ws42">because they are film-coated. This could complicate drug </div><div class="t m0 x9 h5 y79 ff4 fs2 fc1 sc0 ls0 wsed">administration in patients requiring feeding tubes or </div><div class="t m0 x9 h5 y7a ff4 fs2 fc1 sc0 ls0 wsee">mechanical ventilation. Before initiating selexipag, a patient </div><div class="t m0 x9 h5 y7b ff4 fs2 fc1 sc0 ls0 wsf">enrollment form must be completed and sent to the manu<span class="ws0">-</span></div><div class="t m0 x9 h5 y7c ff4 fs2 fc1 sc0 ls0 ws92">facturer<span class="_ _2"></span>. Patients will pick up their selexipag from a spe<span class="ws0">-</span></div><div class="t m0 x9 h5 y7d ff4 fs2 fc1 sc0 ls0 wsef">cialty pharmacy<span class="_ _2"></span>, similar to other prostacyclins and ERAs. </div><div class="t m0 x9 h5 y7e ff4 fs2 fc1 sc0 ls0 wsc6">The wholesale acquisition cost of selexipag ranges from </div><div class="t m0 x9 h5 y7f ff4 fs2 fc1 sc0 ls0 ws1c">$130.68 to $290.40 per tablet, depending on the strength. </div><div class="t m0 x9 h5 y81 ff4 fs2 fc1 sc0 ls0 ws3">This could result in costs of $160 <span class="_ _a"></span>000 to $170 <span class="_ _a"></span>000 per year<span class="_ _2"></span>. </div><div class="t m0 x9 h5 y83 ff4 fs2 fc1 sc0 ls0 wsb7">This is to be compared with annual costs of ~$30 <span class="_ _b"></span>000 to </div><div class="t m0 x9 h5 y84 ff4 fs2 fc1 sc0 ls0 wsf0">$40 <span class="_ _b"></span>000 for bosentan or ambrisentan, $8000 to $9000 for </div><div class="t m0 x9 h5 y85 ff4 fs2 fc1 sc0 ls0 wsf1">tadalafil, or ~$60 <span class="_ _c"></span>000 to 70 <span class="_ _c"></span>000 for inhaled iloprost. </div><div class="t m0 x9 h5 ya4 ff4 fs2 fc1 sc0 ls0 wsf2">Subcutaneous treprostinil is also ~$100 <span class="_ _d"></span>000 per year<span class="_ _2"></span>. <span class="_ _1"></span>A<span class="_ _1"></span> </div><div class="t m0 x9 h5 ya6 ff4 fs2 fc1 sc0 ls0 wsf3">cost-effectiveness analysis for selexipag is not currently </div><div class="t m0 x9 h5 ya7 ff4 fs2 fc1 sc0 ls0 wsf4">available, but given the high price compared with other </div><div class="t m0 x9 h5 y87 ff4 fs2 fc1 sc0 ls0 wsf5">available therapies, it would be of great interest to P<span class="_ _3"></span>AH </div><div class="t m0 x9 h5 y88 ff4 fs2 fc1 sc0 ls0 ws0">practitioners.</div><div class="t m0 x9 h4 y11c ff3 fs3 fc1 sc0 ls0 ws0">Safety</div><div class="t m0 x9 h5 y8c ff4 fs2 fc1 sc0 ls0 ws1b">The most commonly reported adverse events with selexipag </div><div class="t m0 x9 h5 y8e ff4 fs2 fc1 sc0 ls0 wsac">versus placebo in the GRIPHON study</div><div class="t m0 x69 h6 yac ff4 fs4 fc1 sc0 ls0 ws0">23</div><div class="t m0 x6a h5 y8e ff4 fs2 fc1 sc0 ls0 wsac"> included headache </div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf6" class="pf w0 h0" data-page-no="6"><div class="pc pc6 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x18 he y57 ff2 fs2 fc1 sc0 ls0 ws0">Baker et al <span class="_ _6"> </span><span class="ff1">493</span></div><div class="t m0 x18 h5 y58 ff4 fs2 fc1 sc0 ls0 ws88">(65.2% vs 32.8%, <span class="ff6 ws0">P</span> &lt; 0.001), diarrhea (42.4% vs 19.1%, <span class="ff6 ws0">P<span class="ff4"> </span></span></div><div class="t m0 x18 h5 y5a ff4 fs2 fc1 sc0 ls0 ws74">&lt; 0.001), nausea (33.6% vs 18.5%, <span class="ff6 ws0">P</span> &lt; 0.001), and jaw pain </div><div class="t m0 x18 h5 y5b ff4 fs2 fc1 sc0 ls0 ws68">(25.7% vs 6.2%, <span class="ff6 ws0">P</span> &lt; 0.001). These are adverse events that </div><div class="t m0 x18 h5 y5c ff4 fs2 fc1 sc0 ls0 wsf6">occur most frequently during the dose titration phase and </div><div class="t m0 x18 h5 y5d ff4 fs2 fc1 sc0 ls0 ws15">are commonly associated with prostacyclin agonists; these </div><div class="t m0 x18 h5 y5e ff4 fs2 fc1 sc0 ls0 wsd">are also the adverse events most likely to limit a patient’<span class="_ _2"></span>s </div><div class="t m0 x18 h5 y5f ff4 fs2 fc1 sc0 ls0 wsf7">ability to uptitrate their dose. Other adverse events that </div><div class="t m0 x18 h5 y60 ff4 fs2 fc1 sc0 ls0 wsf8">occurred more frequently with selexipag than placebo </div><div class="t m0 x18 h5 y61 ff4 fs2 fc1 sc0 ls0 ws24">included vomiting (18.1% vs 8.5%, <span class="ff6 ws0">P</span> &lt; 0.001), extremity </div><div class="t m0 x18 h5 y62 ff4 fs2 fc1 sc0 ls0 wsf9">pain (16.9% vs 8.0%, <span class="ff6 ws0">P</span> &lt; 0.001), myalgia (16.0% vs 5.9%, </div><div class="t m0 x18 h5 y63 ff6 fs2 fc1 sc0 ls0 ws0">P<span class="ff4 ws48"> &lt; 0.001), and flushing (12.2% vs 5.0%, </span>P<span class="ff4 ws48"> &lt; 0.001). The </span></div><div class="t m0 x18 h5 y64 ff4 fs2 fc1 sc0 ls0 wsc7">overall incidence of at least 1 treatment-related adverse </div><div class="t m0 x18 h5 y65 ff4 fs2 fc1 sc0 ls0 ws48">event did not differ between those receiving selexipag and </div><div class="t m0 x18 h5 y67 ff4 fs2 fc1 sc0 ls0 wsfa">placebo (98.3 vs 96.9%, respectively). Hyperthyroidism </div><div class="t m0 x18 h5 y68 ff4 fs2 fc1 sc0 ls0 wsfb">occurred in 1.4% of the selexipag group versus 0% in the </div><div class="t m0 x18 h5 y69 ff4 fs2 fc1 sc0 ls0 wsfc">placebo group (<span class="ff6 ws0">P</span> = 0.004); however<span class="_ _1"></span>, only 1 selexipag </div><div class="t m0 x18 h5 y6a ff4 fs2 fc1 sc0 ls0 wse6">patient had to discontinue therapy because of the thyroid lab </div><div class="t m0 x18 h5 y6b ff4 fs2 fc1 sc0 ls0 wsd7">changes. The incidence of at least 1 serious adverse event </div><div class="t m0 x18 h5 y6c ff4 fs2 fc1 sc0 ls0 wsfd">did not differ between groups (<span class="ff6 ws0">P</span> = 0.26), although overall </div><div class="t m0 x18 h5 y6d ff4 fs2 fc1 sc0 ls0 ws94">discontinuations resulting from adverse events were more </div><div class="t m0 x18 h5 y6e ff4 fs2 fc1 sc0 ls0 wsfe">common in the selexipag (14.3%) than placebo groups </div><div class="t m0 x18 h5 y99 ff4 fs2 fc1 sc0 ls0 ws0">(7.1%; <span class="ff6">P</span><span class="ws3f"> &lt; 0.001). The rate of all-cause death from the pri</span>-</div><div class="t m0 x18 h5 y9a ff4 fs2 fc1 sc0 ls0 wscc">mary composite end point was nominally higher in the </div><div class="t m0 x18 h5 y9b ff4 fs2 fc1 sc0 ls0 ws45">selexipag group, but statistical analysis was not conducted. </div><div class="t m0 x18 h5 y70 ff4 fs2 fc1 sc0 ls0 wsc4">However<span class="_ _1"></span>, no difference in all-cause mortality was seen </div><div class="t m0 x18 h5 y71 ff4 fs2 fc1 sc0 ls0 wsff">when the data were analyzed through the end of the study <span class="_ _e"></span><span class="ws0"> </span></div><div class="t m0 x18 h5 y72 ff4 fs2 fc1 sc0 ls0 ws0">(<span class="ff6">P</span><span class="ws62"> = 0.42). <span class="_ _2"></span>As previously mentioned, thorough QT<span class="_ _1"></span>c studies </span></div><div class="t m0 x18 h5 y73 ff4 fs2 fc1 sc0 ls0 wsf9">did not reveal any dose-related changes in QT<span class="_ _2"></span>c with selexi<span class="ws0">-</span></div><div class="t m0 x18 h5 y74 ff4 fs2 fc1 sc0 ls0 ws100">pag <span class="_ _5"></span>or ACT<span class="_ _3"></span>-333679.</div><div class="t m0 x6b h6 y9e ff4 fs4 fc1 sc0 ls0 ws0">13</div><div class="t m0 x18 h4 y11d ff3 fs3 fc1 sc0 ls0 ws0">Summary</div><div class="t m0 x18 h5 y78 ff4 fs2 fc1 sc0 ls0 ws1c">Current guidelines recommend prostacyclin pathway ago<span class="ws0">-</span></div><div class="t m0 x18 h5 y79 ff4 fs2 fc1 sc0 ls0 wsdb">nists for patients who are WHO FC IV/III with rapid pro<span class="ws0">-</span></div><div class="t m0 x18 h5 y7a ff4 fs2 fc1 sc0 ls0 ws66">gression or other markers of poor clinical prognosis.</div><div class="t m0 x6c h6 ya0 ff4 fs4 fc1 sc0 ls0 ws0">29</div><div class="t m0 x6d h5 y7a ff4 fs2 fc1 sc0 ls0 ws66"> Of </div><div class="t m0 x18 h5 y7b ff4 fs2 fc1 sc0 ls0 ws72">these, continuous IV epoprostenol is recommended as first-</div><div class="t m0 x18 h5 y7c ff4 fs2 fc1 sc0 ls0 wse">line therapy in P<span class="_ _3"></span>AH patients with WHO FC IV<span class="_ _1"></span> symptoms.</div><div class="t m0 x6e h6 y11e ff4 fs4 fc1 sc0 ls0 ws0">29</div><div class="t m0 x6f h5 y7c ff4 fs2 fc1 sc0 ls0 ws0"> </div><div class="t m0 x18 h5 y7d ff4 fs2 fc1 sc0 ls0 ws7f">Other prostacyclin agonists have been shown to improve </div><div class="t m0 x18 h5 y7e ff4 fs2 fc1 sc0 ls0 ws101">hemodynamic parameters, symptoms, and functional capac<span class="ws0">-</span></div><div class="t m0 x18 h5 y7f ff4 fs2 fc1 sc0 ls0 ws96">ity in patients with WHO FC III.</div><div class="t m0 x70 h6 y80 ff4 fs4 fc1 sc0 ls0 ws0">30-33</div><div class="t m0 x71 h5 y7f ff4 fs2 fc1 sc0 ls0 ws96"> Other oral agents, such </div><div class="t m0 x18 h5 y81 ff4 fs2 fc1 sc0 ls0 ws69">as the ERAs and PDE-5 inhibitors are recommended in </div><div class="t m0 x18 h5 y83 ff4 fs2 fc1 sc0 ls0 ws67">WHO FC II or III patients.</div><div class="t m0 x48 h6 ya2 ff4 fs4 fc1 sc0 ls0 ws0">5</div><div class="t m0 x21 h5 y83 ff4 fs2 fc1 sc0 ls0 ws67"> The guidelines similarly recom<span class="ws0">-</span></div><div class="t m0 x18 h5 y84 ff4 fs2 fc1 sc0 ls0 ws30">mend selexipag for patients with WHO FC II or III P<span class="_ _3"></span>AH.</div><div class="t m0 x5d h6 ya3 ff4 fs4 fc1 sc0 ls0 ws0">5</div><div class="t m0 x72 h5 y84 ff4 fs2 fc1 sc0 ls11 ws30"> A </div><div class="t m0 x18 h5 y85 ff4 fs2 fc1 sc0 ls0 wse5">vast majority of the patients included in GRIPHON were </div><div class="t m0 x18 h5 ya4 ff4 fs2 fc1 sc0 ls0 ws0">either FC II (45.8%) or III (52.5%) at baseline.</div><div class="t m0 x1b h5 ya6 ff4 fs2 fc1 sc0 ls12 wsd">Although the primary composite end point of death or a </div><div class="t m0 x18 h5 ya7 ff4 fs2 fc1 sc0 ls12 ws102">complication related to P<span class="_ _3"></span>AH was significantly lowered with </div><div class="t m0 x18 h5 y87 ff4 fs2 fc1 sc0 ls12 ws6">selexipag compared with placebo (HR = 0.60; <span class="ff6 ls0 ws0">P</span> &lt; 0.001), the </div><div class="t m0 x18 h5 y88 ff4 fs2 fc1 sc0 ls12 ws103">difference appears to be driven primarily by lower rates of </div><div class="t m0 x18 h5 y89 ff4 fs2 fc1 sc0 ls12 ws104">disease progression and hospitalization for worsening of </div><div class="t m0 x18 h5 y8a ff4 fs2 fc1 sc0 ls12 wsb1">P<span class="_ _3"></span>AH. Disease progression was defined as a decrease from </div><div class="t m0 x18 h5 y8b ff4 fs2 fc1 sc0 ls12 wsbb">baseline of at least 15% in the 6-minute walk distance accom<span class="ls0 ws0">-</span></div><div class="t m0 x18 h5 y8c ff4 fs2 fc1 sc0 ls12 ws30">panied by a worsening of WHO FC or the need for additional </div><div class="t m0 x18 h5 y8e ff4 fs2 fc1 sc0 ls12 ws16">P<span class="_ _3"></span>AH treatment (for those in WHO FC III/IV). The dif<span class="_ _1"></span>ference </div><div class="t m0 x23 h5 y58 ff4 fs2 fc1 sc0 ls12 ws83">in 6-minute walk distance between groups was 12 m (99% CI </div><div class="t m0 x23 h5 y5a ff4 fs2 fc1 sc0 ls12 ws68">= 1 to 24; <span class="ff6 ls0 ws0">P</span> = 0.003), representing a 3% improvement from </div><div class="t m0 x23 h5 y5b ff4 fs2 fc1 sc0 ls12 ws1f">baseline. Consensus groups have reported</div><div class="t m0 x73 h6 y11f ff4 fs4 fc1 sc0 ls13 ws105">3,34</div><div class="t m0 x3d h5 y5b ff4 fs2 fc1 sc0 ls12 ws1f"> that the esti<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y5c ff4 fs2 fc1 sc0 ls12 wsd">mated minimally important distance for 6-minute walk dis<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y5d ff4 fs2 fc1 sc0 ls12 ws106">tance is approximately 33 m; the improvement seen in </div><div class="t m0 x23 h5 y5e ff4 fs2 fc1 sc0 ls12 ws72">GRIPHON with selexipag is well below this threshold. <span class="_ _2"></span>Also,<span class="_ _4"></span> </div><div class="t m0 x23 h5 y5f ff4 fs2 fc1 sc0 ls12 wsfa">the 2015 European Society of Cardiology and European </div><div class="t m0 x23 h5 y60 ff4 fs2 fc1 sc0 ls12 ws107">Respiratory Society guidelines for P<span class="_ _3"></span>AH</div><div class="t m0 x38 h6 y120 ff4 fs4 fc1 sc0 ls0 ws0">5</div><div class="t m0 x74 h5 y60 ff4 fs2 fc1 sc0 ls12 ws107"> recommend a treat<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y61 ff4 fs2 fc1 sc0 ls12 ws4d">ment goal of &gt;440 m; this means that the average participant </div><div class="t m0 x23 h5 y62 ff4 fs2 fc1 sc0 ls12 ws4">in GRIPHON would be unlikely to reach this goal given the </div><div class="t m0 x23 h5 y63 ff4 fs2 fc1 sc0 ls12 ws0">therapies administered.</div><div class="t m0 x44 h5 y64 ff4 fs2 fc1 sc0 ls0 ws2b">These efficacy findings, in concert with the reasonable </div><div class="t m0 x23 h5 y65 ff4 fs2 fc1 sc0 ls0 ws108">safety profile of selexipag, must be taken into context with </div><div class="t m0 x23 h5 y67 ff4 fs2 fc1 sc0 ls0 ws40">its high cost. Current market estimates suggest that annual </div><div class="t m0 x23 h5 y68 ff4 fs2 fc1 sc0 ls0 ws9f">costs of selexipag are appreciably higher than that of other </div><div class="t m0 x23 h5 y69 ff4 fs2 fc1 sc0 ls0 ws9">orally available P<span class="_ _3"></span>AH therapies and are similar to the paren<span class="ws0">-</span></div><div class="t m0 x23 h5 y6a ff4 fs2 fc1 sc0 ls0 ws109">teral prostacyclin agonists. <span class="_ _2"></span>A<span class="_ _1"></span> cost-effectiveness analysis </div><div class="t m0 x23 h5 y6b ff4 fs2 fc1 sc0 ls0 ws72">would be beneficial to patients, clinicians, and payers. If its </div><div class="t m0 x23 h5 y6c ff4 fs2 fc1 sc0 ls0 ws98">use is either not met by the improvements in 6-minute walk </div><div class="t m0 x23 h5 y6d ff4 fs2 fc1 sc0 ls0 ws25">distance seen in GRIPHON or improvement in functional </div><div class="t m0 x23 h5 y6e ff4 fs2 fc1 sc0 ls0 ws3b">class (or have disease progression), therapy could be esca<span class="ws0">-</span></div><div class="t m0 x23 h5 y99 ff4 fs2 fc1 sc0 ls0 ws104">lated to parenteral therapy with a prostacyclin agonist. </div><div class="t m0 x23 h5 y9a ff4 fs2 fc1 sc0 ls0 ws90">Additionally<span class="_ _2"></span>, referral for listing for lung transplant should </div><div class="t m0 x23 h5 y9b ff4 fs2 fc1 sc0 ls0 ws0">also be considered.</div><div class="t m0 x44 h5 y70 ff4 fs2 fc1 sc0 ls4 wse">There is ongoing research with selexipag, including the </div><div class="t m0 x23 h5 y71 ff4 fs2 fc1 sc0 ls4 ws10a">Efficacy and Safety of Initial <span class="_ _1"></span>T<span class="_ _1"></span>riple Dual Oral Combination </div><div class="t m0 x23 h5 y72 ff4 fs2 fc1 sc0 ls4 ws10b">Therapy in Patients with Newly Diagnosed Pulmonary </div><div class="t m0 x23 h5 y73 ff4 fs2 fc1 sc0 ls4 ws10c">Arterial Hypertension (TRITON) trial (NCT02558231).<span class="_ _1"></span> </div><div class="t m0 x23 h5 y74 ff4 fs2 fc1 sc0 ls4 ws10d">Additional trials are also needed to assess its use in patients </div><div class="t m0 x23 h5 y75 ff4 fs2 fc1 sc0 ls4 ws10e">with WHO FC IV<span class="_ _1"></span> and other PH groups. Similarly<span class="_ _2"></span>, data on </div><div class="t m0 x23 h5 y76 ff4 fs2 fc1 sc0 ls4 wsc0">the impact of selexipag on PH-related quality of life is </div><div class="t m0 x23 h5 y77 ff4 fs2 fc1 sc0 ls4 ws9c">only available in the Food and Drug <span class="_ _2"></span>Administration sub<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y78 ff4 fs2 fc1 sc0 ls4 ws10f">mission information, where they state that no differences<span class="_ _1"></span> </div><div class="t m0 x23 h5 y79 ff4 fs2 fc1 sc0 ls4 ws49">versus placebo were seen</div><div class="t m0 x3c h6 y121 ff4 fs4 fc1 sc0 ls5 ws36">35</div><div class="t m0 x75 h5 y79 ff4 fs2 fc1 sc0 ls4 ws49">; however<span class="_ _1"></span>, specific details are </div><div class="t m0 x23 h5 y7a ff4 fs2 fc1 sc0 ls4 ws110">not provided. This aspect of PH care <span class="_ _1"></span>also requires addi<span class="ls0 ws0">-</span></div><div class="t m0 x23 h5 y7b ff4 fs2 fc1 sc0 ls4 wsbe">tional study<span class="_ _2"></span>. Until this information becomes available, the </div><div class="t m0 x23 h5 y7c ff4 fs2 fc1 sc0 ls4 ws111">specific role of selexipag in managing P<span class="_ _3"></span>AH patients is </div><div class="t m0 x23 h5 y7d ff4 fs2 fc1 sc0 ls4 ws29">unclear<span class="_ _2"></span>.</div><div class="t m0 x23 h3 y7f ff3 fs2 fc1 sc0 ls0 ws0">Declaration of Conflicting Interests</div><div class="t m0 x23 h11 y122 ff4 fsb fc1 sc0 ls0 ws112">The authors declared no potential conflicts of interest with respect </div><div class="t m0 x23 h11 y123 ff4 fsb fc1 sc0 ls0 ws0">to the research, authorship, and/or publication of this article.</div><div class="t m0 x23 h3 y124 ff3 fs2 fc1 sc0 ls0 ws0">Funding</div><div class="t m0 x23 h11 y125 ff4 fsb fc1 sc0 ls0 ws113">The authors received no financial support for the research, author<span class="ws0">-</span></div><div class="t m0 x23 h11 y126 ff4 fsb fc1 sc0 ls0 ws0">ship, and/or publication of this article.</div><div class="t m0 x23 h3 y127 ff3 fs2 fc1 sc0 ls0 ws0">References</div><div class="t m0 x23 h11 y128 ff4 fsb fc1 sc0 ls0 ws114"> <span class="_ _8"> </span>1. <span class="_"> </span>Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and </div><div class="t m0 x27 h11 y129 ff4 fsb fc1 sc0 ls0 ws115">diagnosis of pulmonary hypertension. <span class="ff6">J Am Coll Cardiol</span><span class="ws0">. </span></div><div class="t m0 x27 h11 y12a ff4 fsb fc1 sc0 ls0 ws0">2013;62(25, suppl):D42-D50.</div><div class="t m0 x23 h11 y12b ff4 fsb fc1 sc0 ls0 ws112"> <span class="_ _f"> </span>2. <span class="_ _10"> </span>Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical </div><div class="t m0 x27 h11 y12c ff4 fsb fc1 sc0 ls0 ws116">classification of pulmonary hypertension. <span class="ff6">J Am Coll Cardiol</span><span class="ws0">. </span></div><div class="t m0 x27 h11 y12d ff4 fsb fc1 sc0 ls0 ws0">2009;54(1, suppl):S43-S54.</div></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf7" class="pf w0 h0" data-page-no="7"><div class="pc pc7 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x2 he y57 ff1 fs2 fc1 sc0 ls0 ws0">494 <span class="_ _7"> </span><span class="ff2">Annals of Pharmacotherapy 51(6)</span></div><div class="t m0 x2 h11 y12e ff4 fsb fc1 sc0 ls0 ws117"> <span class="_ _4"></span>3. <span class="_ _5"></span>McLaughlin VV, Gaine SP, Howard LS, et al. Treatment </div><div class="t m0 x5 h11 y12f ff4 fsb fc1 sc0 ls0 ws118">goals for pulmonary hypertension. <span class="ff6">J Am Coll Cardiol</span><span class="ws0">. </span></div><div class="t m0 x5 h11 y130 ff4 fsb fc1 sc0 ls0 ws0">2013;62:D73-D81.</div><div class="t m0 x2 h11 y131 ff4 fsb fc1 sc0 ls14 ws119"> <span class="_ _9"> </span>4. <span class="_ _9"> </span>Taichman DB, Ornelas J, Chung GL, et al. Pharmacologic<span class="_ _1"></span> </div><div class="t m0 x5 h11 y132 ff4 fsb fc1 sc0 ls14 ws11a">therapy for pulmonary arterial hypertension in adults: </div><div class="t m0 x5 h11 y133 ff4 fsb fc1 sc0 ls14 ws11b">CHEST guideline and expert panel report. <span class="ff6 ws112">Chest</span>. 2014;146:<span class="ls0 ws0"> </span></div><div class="t m0 x5 h11 y134 ff4 fsb fc1 sc0 ls14 ws112">449-475.</div><div class="t m0 x2 h11 y135 ff4 fsb fc1 sc0 ls0 ws11c"> <span class="_ _4"></span>5. <span class="_ _5"></span>Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS </div><div class="t m0 x5 h11 y136 ff4 fsb fc1 sc0 ls0 ws11d">guidelines for the diagnosis and treatment of pulmonary </div><div class="t m0 x5 h11 y137 ff4 fsb fc1 sc0 ls0 ws11e">hypertension: the Joint Task Force for the Diagnosis and </div><div class="t m0 x5 h11 y138 ff4 fsb fc1 sc0 ls0 ws11f">Treatment of Pulmonary Hypertension of the European </div><div class="t m0 x5 h11 y139 ff4 fsb fc1 sc0 ls0 ws120">Society of Cardiology (ESC) and the European Respiratory </div><div class="t m0 x5 h11 y13a ff4 fsb fc1 sc0 ls0 ws121">Society (ERS). Endorsed by: Association for European </div><div class="t m0 x5 h11 y13b ff4 fsb fc1 sc0 ls0 ws122">Paediatric and Congenital Cardiology (AEPC), International </div><div class="t m0 x5 h11 y13c ff4 fsb fc1 sc0 ls0 ws123">Society for Heart and Lung Transplantation (ISHLT). <span class="ff6 ws0">Eur </span></div><div class="t m0 x5 h11 y13d ff6 fsb fc1 sc0 ls0 ws0">Heart J<span class="ff4">. 2016;37:67-119.</span></div><div class="t m0 x2 h11 y13e ff4 fsb fc1 sc0 ls0 ws124"> <span class="_ _1"></span>6. Nakamura A, Yamada T, Asaki T. Synthesis and evalu<span class="ws0">-</span></div><div class="t m0 x5 h11 y13f ff4 fsb fc1 sc0 ls0 ws125">ation of <span class="ff6 ws0">N</span>-acylsulfonamide and <span class="ff6 ws0">N</span>-acylsulfonylurea pro<span class="ws0">-</span></div><div class="t m0 x5 h11 y140 ff4 fsb fc1 sc0 ls0 ws126">drugs of a prostacyclin receptor agonist. <span class="ff6">Bioorg Med Chem</span><span class="ws0">. </span></div><div class="t m0 x5 h11 y141 ff4 fsb fc1 sc0 ls0 ws0">2007;15:7720-7725.</div><div class="t m0 x2 h11 y142 ff4 fsb fc1 sc0 ls0 ws127"> <span class="_ _11"> </span>7. <span class="_ _9"> </span>Kuwano K, Hashino A, Asaki T, et al. 2-{4-[(5,6-diphenyl<span class="ws0">-</span></div><div class="t m0 x5 h11 y143 ff4 fsb fc1 sc0 ls15 ws128">pyrazin-2-yl)(isopropyl)amino]butoxyl}-<span class="ff6 ls0 ws0">N</span>-(methylsulfonyl)</div><div class="t m0 x5 h11 y144 ff4 fsb fc1 sc0 ls0 ws129">acetamide (NS-304), an orally available and long-active pros<span class="ws0">-</span></div><div class="t m0 x5 h11 y145 ff4 fsb fc1 sc0 ls0 ws12a">tacyclin receptor agonist prodrug. <span class="ff6">J Pharmacol Exp Ther</span><span class="ws0">. </span></div><div class="t m0 x5 h11 y146 ff4 fsb fc1 sc0 ls0 ws0">2007;322:1181-1188.</div><div class="t m0 x2 h11 y147 ff4 fsb fc1 sc0 ls0 ws12b"> <span class="_"> </span>8. <span class="_"> </span>Morrison K, Ernst R, Hess P, Studer R, Clozel M. Selexipag: </div><div class="t m0 x5 h11 y148 ff4 fsb fc1 sc0 ls0 ws12c">a selective prostacyclin agonist that does not affect rat gastric </div><div class="t m0 x5 h11 y149 ff4 fsb fc1 sc0 ls0 ws0">function. <span class="ff6">J Pharmacol Exp Ther</span>. 2010;335:249-255.</div><div class="t m0 x2 h11 y14a ff4 fsb fc1 sc0 ls14 ws12d"> <span class="_ _12"></span>9. <span class="_ _11"> </span>Gatfield J, Menyhart K, Morrison K, Nayler O. The non-</div><div class="t m0 x5 h11 y14b ff4 fsb fc1 sc0 ls14 ws12e">prostanoid prostacyclin receptor agonist ACT-333679, </div><div class="t m0 x5 h11 y14c ff4 fsb fc1 sc0 ls14 ws12f">the active metabolite of selexipag, is characterized by low </div><div class="t m0 x5 h11 y14d ff4 fsb fc1 sc0 ls14 ws130">beta-arrestin recruitment and receptor internalization activ<span class="ls0 ws0">-</span></div><div class="t m0 x5 h11 y14e ff4 fsb fc1 sc0 ls14 ws131">ity [abstract 1110-174]. <span class="ff6">J Am Coll Cardiol</span>. 2015;65(suppl):<span class="ls0 ws0"> </span></div><div class="t m0 x5 h11 y14f ff4 fsb fc1 sc0 ls14 ws112">A1542.</div><div class="t m0 x2 h11 y150 ff4 fsb fc1 sc0 ls0 ws132"> <span class="_ _b"></span>10. <span class="_"> </span>Morrison K, Wanner D, Gatfield J, Gnerre C, Hess P, Clozel </div><div class="t m0 x5 h11 y151 ff4 fsb fc1 sc0 ls0 ws133">M. Repeated oral administration of the selective prostacyclin </div><div class="t m0 x5 h11 y152 ff4 fsb fc1 sc0 ls0 ws134">receptor agonist selexipag does not cause tachyphylaxis in </div><div class="t m0 x5 h11 y153 ff4 fsb fc1 sc0 ls0 ws123">spontaneously hypertensive rats [abstract 1214-172]. <span class="ff6">J Am </span></div><div class="t m0 x5 h11 y154 ff6 fsb fc1 sc0 ls0 ws0">Coll Cardiol<span class="ff4">. 2015;65(suppl):A1558.</span></div><div class="t m0 x2 h11 y155 ff4 fsb fc1 sc0 ls16 ws135"> <span class="_ _0"></span>11. <span class="_"> </span>Kuwano K, Hashino A, Noda K, Kosugi K, Kuwabara K. A </div><div class="t m0 x5 h11 y156 ff4 fsb fc1 sc0 ls16 ws136">long-acting and highly selective prostacyclin receptor ago<span class="ls0 ws0">-</span></div><div class="t m0 x5 h11 y157 ff4 fsb fc1 sc0 ls16 ws5d">nist prodrug, 2-{4-[(5,6-diphenylpyrazin-2-yl)(isopropyl)</div><div class="t m0 x5 h11 y158 ff4 fsb fc1 sc0 ls16 ws5">amino]butoxyl}-<span class="ff6 ls0 ws0">N</span><span class="ws137">-(methylsulfonyl)acetamide (NS-304), </span></div><div class="t m0 x5 h11 y159 ff4 fsb fc1 sc0 ls16 wsbe">ameliorates rat pulmonary hypertension with unique relax<span class="ls0 ws0">-</span></div><div class="t m0 x5 h11 y15a ff4 fsb fc1 sc0 ls16 ws130">ant responses of its active form, {4-[(5,6-diphenylpyrazin-</div><div class="t m0 x5 h11 y15b ff4 fsb fc1 sc0 ls16 ws138">2-yl)(isopropyl)amino]butoxyl}acetic acid (MRE-269), on </div><div class="t m0 x5 h11 y15c ff4 fsb fc1 sc0 ls16 ws139">rat pulmonary artery. <span class="ff6">J Pharmacol Exp Ther</span>. 2008;326:<span class="ls0 ws0"> </span></div><div class="t m0 x5 h11 y15d ff4 fsb fc1 sc0 ls16 ws5">691-699.</div><div class="t m0 x2 h11 y15e ff4 fsb fc1 sc0 ls0 ws13a"> <span class="_ _d"></span>12. <span class="_ _11"> </span>Morrison K, Studer R, Ernst R, Haag F, Kauser K, Clozel </div><div class="t m0 x5 h11 y15f ff4 fsb fc1 sc0 ls0 ws13b">M. Differential effects of selexipag and prostacyclin analogs </div><div class="t m0 x5 h11 y160 ff4 fsb fc1 sc0 ls0 ws13c">in rat pulmonary artery. <span class="ff6">J Pharmacol Exp Ther</span>. 2012;343:<span class="ws0"> </span></div><div class="t m0 x5 h11 y161 ff4 fsb fc1 sc0 ls0 ws0">547-555.</div><div class="t m0 x2 h11 y162 ff4 fsb fc1 sc0 ls0 ws13d"> <span class="_ _b"></span>13. <span class="_ _8"> </span>Hoch M, Darpo B, Remenova T, et al. A thorough QT study </div><div class="t m0 x5 h11 y163 ff4 fsb fc1 sc0 ls0 ws13e">in the context of an uptitration regiment with selexipag, a </div><div class="t m0 x5 h11 y164 ff4 fsb fc1 sc0 ls0 ws13f">selective oral prostacyclin receptor agonist. <span class="ff6">Drug Des Devel </span></div><div class="t m0 x5 h11 y165 ff6 fsb fc1 sc0 ls0 ws0">Ther<span class="ff4">. 2015;9:175-185.</span></div><div class="t m0 x2 h11 y166 ff4 fsb fc1 sc0 ls0 ws8"> <span class="_ _b"></span>14. <span class="_ _11"> </span>Bruderer S, Hurst N, Kaufmann P, Dingemanse J. Multiple-</div><div class="t m0 x5 h11 y167 ff4 fsb fc1 sc0 ls0 ws140">dose up-titration study to evaluate the safety, tolerability, </div><div class="t m0 x5 h11 y168 ff4 fsb fc1 sc0 ls0 ws141">pharmacokinetics, and pharmacodynamics of selexipag, an </div><div class="t m0 x76 h11 y169 ff4 fsb fc1 sc0 ls0 ws142">orally available selective prostacyclin receptor agonist, in </div><div class="t m0 x76 h11 y16a ff4 fsb fc1 sc0 ls0 ws0">healthy subjects. <span class="ff6">Pharmacology</span>. 2014;94:145-156.</div><div class="t m0 x9 h11 y16b ff4 fsb fc1 sc0 ls0 ws143"> <span class="_ _e"></span>15. <span class="_ _9"> </span>Kaufmann P, Okubo K, Bruderer S, et al. Pharmacokinetics </div><div class="t m0 x76 h11 y16c ff4 fsb fc1 sc0 ls0 ws144">and tolerability of the novel oral prostacyclin IP receptor ago<span class="ws0">-</span></div><div class="t m0 x76 h11 y16d ff4 fsb fc1 sc0 ls0 ws0">nist selexipag. <span class="ff6">Am J Cardiovasc Drugs</span>. 2015;15:195-203.</div><div class="t m0 x9 h11 y16e ff4 fsb fc1 sc0 ls0 ws145"> <span class="_ _d"></span>16. <span class="_ _5"></span>Kaufmann P, Hurst N, Astrue B, Dingemanse J. Absolute </div><div class="t m0 x76 h11 y16f ff4 fsb fc1 sc0 ls0 ws146">oral bioavailability of selexipag, a novel oral prostacyclin IP </div><div class="t m0 x76 h11 y170 ff4 fsb fc1 sc0 ls0 ws0">receptor agonist. <span class="ff6">Eur J Clin Pharmacol</span>. 2017;73:151-156.</div><div class="t m0 x9 h11 y171 ff4 fsb fc1 sc0 ls0 ws147"> <span class="_ _13"></span>17. <span class="_ _1"></span>Sardana M, Moll M, Farber HW. Pharmacokinetic drug </div><div class="t m0 x76 h11 y172 ff4 fsb fc1 sc0 ls0 ws148">evaluation of selexipag for the treatment of pulmonary </div><div class="t m0 x76 h11 y173 ff4 fsb fc1 sc0 ls0 ws149">arterial hypertension. <span class="ff6">Expert Opin Drug Metab Toxicol</span><span class="ws0">. </span></div><div class="t m0 x76 h11 y174 ff4 fsb fc1 sc0 ls0 ws0">2016;12:1513-1520.</div><div class="t m0 x9 h11 y175 ff4 fsb fc1 sc0 ls0 ws14a"> <span class="_ _0"></span>18. <span class="_ _10"> </span>Kaufmann P, Okubo K, Sidharta PN, Yamada T, Dingemanse </div><div class="t m0 x76 h11 y176 ff4 fsb fc1 sc0 ls0 ws14b">J, Mukai H. Investigation of the absorption, metabolism, and </div><div class="t m0 x76 h11 y177 ff4 fsb fc1 sc0 ls0 ws7f">excretion of 14</div><div class="t m0 x77 h12 y178 ff4 fsc fc1 sc0 ls0 ws0">C</div><div class="t m0 x78 h11 y179 ff4 fsb fc1 sc0 ls0 ws7f">-selexipag following oral administration to </div><div class="t m0 x76 h11 y17a ff4 fsb fc1 sc0 ls0 ws14a">healthy male subjects. <span class="ff6">Clin Pharmacol Ther</span>. 2012;92(supple<span class="ws0">-</span></div><div class="t m0 x76 h11 y17b ff4 fsb fc1 sc0 ls0 ws0">ment S1):S85.</div><div class="t m0 x9 h11 y17c ff4 fsb fc1 sc0 ls0 ws14c"> <span class="_ _14"></span>19. <span class="_ _15"></span>Kaufmann P, Cruz HG, Krause A, Ulc I, Halabi A, </div><div class="t m0 x76 h11 y17d ff4 fsb fc1 sc0 ls0 ws14d">Dingemanse J. Pharmacokinetics of the novel oral prosta<span class="ws0">-</span></div><div class="t m0 x76 h11 y17e ff4 fsb fc1 sc0 ls0 ws143">cyclin receptor agonist selexipag in subjects with hepatic or </div><div class="t m0 x76 h11 y17f ff4 fsb fc1 sc0 ls0 ws0">renal impairment. <span class="ff6">Br J Clin Pharmacol</span>. 2016;82:369-379.</div><div class="t m0 x9 h11 y180 ff4 fsb fc1 sc0 ls0 ws14e"> <span class="_ _16"></span>20. <span class="_ _4"></span>Bruderer S, Okubo K, Mukai H, Mant T, Dingemanse J. </div><div class="t m0 x76 h11 y181 ff4 fsb fc1 sc0 ls0 ws14f">Investigation of potential pharmacodynamics and pharmaco<span class="ws0">-</span></div><div class="t m0 x76 h11 y182 ff4 fsb fc1 sc0 ls0 ws150">kinetic interactions between selexipag and warfarin in healthy </div><div class="t m0 x76 h11 y183 ff4 fsb fc1 sc0 ls0 ws0">male subjects. <span class="ff6">Clin Ther</span>. 2016;38:1228-1236.</div><div class="t m0 x9 h11 y184 ff4 fsb fc1 sc0 ls0 ws151"> <span class="_ _b"></span>21. <span class="_ _9"> </span>Kaufmann P, Niglis S, Bruderer S, et al. Effect of lopinavir/</div><div class="t m0 x76 h11 y185 ff4 fsb fc1 sc0 ls0 ws143">ritonavir on the pharmacokinetics of selexipag an oral pros<span class="ws0">-</span></div><div class="t m0 x76 h11 y186 ff4 fsb fc1 sc0 ls0 ws152">tacyclin receptor agonist and its active metabolite in healthy </div><div class="t m0 x76 h11 y187 ff4 fsb fc1 sc0 ls0 ws0">subjects. <span class="ff6">Br J Clin Pharmacol</span>. 2015;80:670-677.</div><div class="t m0 x9 h11 y188 ff4 fsb fc1 sc0 ls0 ws153"> <span class="_ _16"></span>22. <span class="_ _5"></span>Simonneau G, Torbicki A, Hoeper MM, et al. Selexipag: </div><div class="t m0 x76 h11 y189 ff4 fsb fc1 sc0 ls0 ws154">an oral, selective prostacyclin receptor agonist for the treat<span class="ws0">-</span></div><div class="t m0 x76 h11 y18a ff4 fsb fc1 sc0 ls0 ws155">ment of pulmonary arterial hypertension. <span class="ff6">Eur Respir J</span><span class="ws0">. </span></div><div class="t m0 x76 h11 y18b ff4 fsb fc1 sc0 ls0 ws0">2012;40:874-880.</div><div class="t m0 x9 h11 y18c ff4 fsb fc1 sc0 ls0 ws156"> <span class="_ _d"></span>23. <span class="_ _5"></span>Sitbon O, Channick R, Chin KM, et al. Selexipag for the </div><div class="t m0 x76 h11 y18d ff4 fsb fc1 sc0 ls0 ws157">treatment of pulmonary arterial hypertension. <span class="ff6">N Engl J Med</span><span class="ws0">. </span></div><div class="t m0 x76 h11 y18e ff4 fsb fc1 sc0 ls0 ws0">2015;373:2522-2533.</div><div class="t m0 x9 h11 y18f ff4 fsb fc1 sc0 ls0 ws158"> <span class="_ _b"></span>24. <span class="_ _9"> </span>Lang I, Gaine S, Galie N, et al. Effect of selexipag on long-</div><div class="t m0 x76 h11 y190 ff4 fsb fc1 sc0 ls0 ws159">term outcomes in patients with pulmonary arterial hyper<span class="ws0">-</span></div><div class="t m0 x76 h11 y191 ff4 fsb fc1 sc0 ls0 ws15a">tension (PAH) receiving one, two or no PAH therapies at </div><div class="t m0 x76 h11 y192 ff4 fsb fc1 sc0 ls0 ws95">baseline: results from the GRIPHON study [abstract 2365]. </div><div class="t m0 x76 h11 y193 ff6 fsb fc1 sc0 ls0 ws0">Eur Heart J<span class="ff4">. 2015;36(suppl 1):381-382.</span></div><div class="t m0 x9 h11 y194 ff4 fsb fc1 sc0 ls0 ws15b"> <span class="_ _17"></span>25. <span class="_ _e"></span>Baldoni D, Bruderer S, Muhsen N, Dingemanse J. </div><div class="t m0 x76 h11 y195 ff4 fsb fc1 sc0 ls0 ws15c">Bioequivalence of different dose-strength tablets of selexi<span class="ws0">-</span></div><div class="t m0 x76 h11 y196 ff4 fsb fc1 sc0 ls0 ws15d">pag, a selective prostacyclin receptor agonist, in a multiple-</div><div class="t m0 x76 h11 y197 ff4 fsb fc1 sc0 ls0 ws13b">dose up-titration study. <span class="ff6">Int J Clin Pharmacol Ther</span>. 2015;53:<span class="ws0"> </span></div><div class="t m0 x76 h11 y198 ff4 fsb fc1 sc0 ls0 ws0">788-798.</div><div class="t m0 x9 h11 y199 ff4 fsb fc1 sc0 ls0 ws15e"> <span class="_ _14"></span>26. <span class="_ _a"></span>Uptravi [package insert and label information]. https://</div><div class="t m0 x76 h11 y19a ff4 fsb fc1 sc0 ls17 ws15f">uptravi.com/pdf/UPTRAVI-Full-Prescribing-Information.</div><div class="t m0 x76 h11 y19b ff4 fsb fc1 sc0 ls0 ws0">pdf. Accessed December 19, 2016.</div><div class="t m0 x9 h11 y19c ff4 fsb fc1 sc0 ls0 ws160"> <span class="_ _a"></span>27. <span class="_ _18"> </span>Scott LJ. Selexipag: first global approval. <span class="ff6 ws0">Drugs</span>. 2016;76:413-</div><div class="t m0 x76 h11 y19d ff4 fsb fc1 sc0 ls0 ws0">418.</div><div class="t m0 x9 h11 y19e ff4 fsb fc1 sc0 ls0 ws14b"> <span class="_ _b"></span>28. <span class="_"> </span>McLaughlin VV, Badesch DB, Delcroix M, et al. End points </div><div class="t m0 x76 h11 y19f ff4 fsb fc1 sc0 ls0 ws138">and clinical trial design in pulmonary arterial hypertension. <span class="ff6 ws0">J </span></div><div class="t m0 x76 h11 y1a0 ff6 fsb fc1 sc0 ls0 ws0">Am Coll Cardiol<span class="ff4">. 2009;54(suppl):S97-S107.</span></div><div class="t m0 x9 h11 y1a1 ff4 fsb fc1 sc0 ls0 ws154"> <span class="_ _e"></span>29. <span class="_ _9"> </span>Galiè N, Corris PA, Frost A, et al. Updated treatment algo<span class="ws0">-</span></div><div class="t m0 x76 h11 y1a2 ff4 fsb fc1 sc0 ls0 ws161">rithm of pulmonary arterial hypertension. <span class="ff6">J Am Coll Cardiol</span><span class="ws0">. </span></div><div class="t m0 x76 h11 y1a3 ff4 fsb fc1 sc0 ls0 ws0">2013;62(25, suppl):D60-D72.</div><div class="t m0 x9 h11 y1a4 ff4 fsb fc1 sc0 ls18 ws162"> <span class="_ _19"></span>30. Barst RJ, Rubin LJ, Long WA, et al. A comparison of </div><div class="t m0 x76 h11 y1a5 ff4 fsb fc1 sc0 ls18 ws163">continuous intravenous epoprostenol (prostacyclin) with <span class="_ _c"></span><span class="ls0 ws0"> </span></div><a class="l" href="https://uptravi.com/pdf/UPTRAVI-Full-Prescribing-Information.pdf"><div class="d m1" style="border-style:none;position:absolute;left:617.986800px;bottom:239.782800px;width:25.011000px;height:9.963000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="https://uptravi.com/pdf/UPTRAVI-Full-Prescribing-Information.pdf"><div class="d m1" style="border-style:none;position:absolute;left:382.800000px;bottom:226.582800px;width:221.000000px;height:9.963000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="https://uptravi.com/pdf/UPTRAVI-Full-Prescribing-Information.pdf"><div class="d m1" style="border-style:none;position:absolute;left:382.800000px;bottom:213.382800px;width:11.997000px;height:9.963000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
<div id="pf8" class="pf w0 h0" data-page-no="8"><div class="pc pc8 w0 h0"><img class="bi x0 y0 w0 h0" alt="" src="data:image/png;base64,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"/><div class="t m0 x18 he y57 ff2 fs2 fc1 sc0 ls0 ws0">Baker et al <span class="_ _6"> </span><span class="ff1">495</span></div><div class="t m0 x4 h11 y12e ff4 fsb fc1 sc0 ls18 ws164">conventional therapy for primary pulmonary hypertension. </div><div class="t m0 x4 h11 y12f ff6 fsb fc1 sc0 ls18 ws0">N Engl J Med<span class="ff4">. 1996;334:296-301.</span></div><div class="t m0 x18 h11 y130 ff4 fsb fc1 sc0 ls0 ws165"> <span class="_ _e"></span>31. <span class="_ _11"> </span>Simonneau G, Barst RJ, Gailie N, et al. Continuous subcu<span class="ws0">-</span></div><div class="t m0 x4 h11 y131 ff4 fsb fc1 sc0 ls0 ws166">taneous infusion of treprostinil, a prostacyclin analogue, in </div><div class="t m0 x4 h11 y132 ff4 fsb fc1 sc0 ls0 ws167">patients with pulmonary arterial hypertension: a double-blind, </div><div class="t m0 x4 h11 y133 ff4 fsb fc1 sc0 ls0 ws168">randomized, placebo-controlled trial. <span class="ff6">Am J Respir Crit Care </span></div><div class="t m0 x4 h11 y134 ff6 fsb fc1 sc0 ls0 ws0">Med<span class="ff4">. 2002;165:800-804.</span></div><div class="t m0 x18 h11 y135 ff4 fsb fc1 sc0 ls0 ws169"> <span class="_ _d"></span>32. <span class="_ _12"> </span>Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. </div><div class="t m0 x4 h11 y136 ff4 fsb fc1 sc0 ls0 ws15d">Safety and efficacy of IV treprostinil for pulmonary arterial </div><div class="t m0 x4 h11 y137 ff4 fsb fc1 sc0 ls0 ws16a">hypertension: a prospective, multicenter, open-label, 12-week </div><div class="t m0 x4 h11 y138 ff4 fsb fc1 sc0 ls0 ws0">trial. <span class="ff6">Chest</span>. 2006;129:683-688.</div><div class="t m0 x23 h11 y1a6 ff4 fsb fc1 sc0 ls0 ws156"> <span class="_ _d"></span>33. <span class="_ _5"></span>Olschewski H, Simonneau G, Gailie N, et al. Inhaled ilo<span class="ws0">-</span></div><div class="t m0 x27 h11 y1a7 ff4 fsb fc1 sc0 ls0 ws16b">prost for severe pulmonary hypertension. <span class="ff6">N Engl J Med</span><span class="ws0">. </span></div><div class="t m0 x27 h11 y1a8 ff4 fsb fc1 sc0 ls0 ws0">2002;347:322-329.</div><div class="t m0 x23 h11 y1a9 ff4 fsb fc1 sc0 ls0 ws162"> <span class="_ _19"></span>34. <span class="_ _4"></span>Mathai SC, Puhan MA, Lam D, Wise RA. The minimal </div><div class="t m0 x27 h11 y1aa ff4 fsb fc1 sc0 ls0 ws16c">important difference in the 6-minute walk test for patients </div><div class="t m0 x27 h11 y1ab ff4 fsb fc1 sc0 ls0 ws16d">with pulmonary arterial hypertension. <span class="ff6">Am J Respir Crit Care </span></div><div class="t m0 x27 h11 y1ac ff6 fsb fc1 sc0 ls0 ws0">Med<span class="ff4">. 2012;186:428-433.</span></div><div class="t m0 x23 h11 y1ad ff4 fsb fc1 sc0 ls0 ws16e"> <span class="_ _0"></span>35. <span class="_ _10"> </span>Center for Drug Evaluation and Research; Gordon M, Garnett </div><div class="t m0 x27 h11 y1ae ff4 fsb fc1 sc0 ls0 ws16f">C. Clinical review: selexipag. http://www.accessdata.fda.</div><div class="t m0 x27 h11 y1af ff4 fsb fc1 sc0 ls19 ws170">gov/drugsatfda_docs/nda/2015/2079<span class="_ _1"></span>47Orig1s000MedR.pdf. </div><div class="t m0 x27 h11 y1b0 ff4 fsb fc1 sc0 ls0 ws0">Accessed February 9, 2017.</div><a class="l" href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf"><div class="d m1" style="border-style:none;position:absolute;left:549.330000px;bottom:741.382800px;width:97.225000px;height:9.963000px;background-color:rgba(255,255,255,0.000001);"></div></a><a class="l" href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/207947Orig1s000MedR.pdf"><div class="d m1" style="border-style:none;position:absolute;left:400.800000px;bottom:728.182800px;width:218.750000px;height:9.963000px;background-color:rgba(255,255,255,0.000001);"></div></a></div><div class="pi" data-data='{"ctm":[1.200000,0.000000,0.000000,1.200000,0.000000,0.000000]}'></div></div>
</div>
<div class="loading-indicator">
<img alt="" src="data:image/png;base64,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"/>
</div>
</body>
</html>
